Cardiac sarcomedo inhibitor

By developing ectopic inhibitors of cardiac myosin, the problem of insufficient selectivity of existing cardiac sarcosal regulators has been solved, effective regulation of cardiac sarcosal agents has been achieved, improving cardiac function and reducing side effects, and providing safer and effective treatment options.

CN118955409APending Publication Date: 2024-11-15CYTOKINETICS INC
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202410976837.3
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Priority Date
2018-08-31
Filing Date
2019-08-30
Publication Date
2024-11-15

AI Technical Summary

Technical Problem

Existing cardiac sarcosal regulators have poor selectivity for cardiac sarcosals, leading to adverse effects such as cell damage, abnormal flaccidity and potential arrhythmic side effects, limiting their combined retention in the treatment of hypertrophic cardiomyopathy and heart failure Application of injection fractions.

Method used

An ectopic inhibitor of cardiac myosin was developed as a cardiac sarcosal inhibitor, which regulates cardiac sarcosal function by targeting cardiac myosin, providing a more selective and safe treatment plan.

Benefits of technology

The agent has a wider therapeutic index, weaker cardiac flaccid effects, better pharmacokinetics and better safety, which can effectively improve cardiac function, reduce symptoms and reduce patient mortality.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118955409A_ABST
    Figure CN118955409A_ABST
Patent Text Reader

Abstract

The present invention provides compounds of Formula (I): or a pharmaceutically acceptable salt thereof, wherein R1, R2A, R2B, R3, R4 and R5 are as defined herein. Also provided are pharmaceutically acceptable compositions comprising a compound of Formula (I) or a pharmaceutically acceptable salt thereof. Also provided are methods of using a compound of Formula (I) or a pharmaceutically acceptable salt thereof. # imgabs0 #
Need to check novelty before this filing date? Find Prior Art

Description

[0001] This application is a divisional application of the Chinese invention patent application (application date: August 30, 2019; application number: 201980068999.4; invention name: cardiac sarcomere inhibitor).

[0002] Cross-reference to related applications

[0003] This application claims priority to U.S. Provisional Application No. 62 / 726,162, filed on August 31, 2018, entitled “CARDIAC SARCOMERE INHIBITORS,” the contents of which are incorporated herein by reference in their entirety for all purposes. Technical Field

[0004] Provided herein are heterocyclic compounds, pharmaceutical compositions comprising the compounds, and methods of using the compounds to treat various cardiac diseases and disorders. Background of the Invention

[0006] The present invention relates to certain chemical entities that selectively modulate cardiac sarcomeres, and in particular to certain chemical entities, pharmaceutical compositions and methods for treating various cardiac diseases and disorders.

[0007] The cardiac sarcomere is composed of a network of contractile structural proteins that regulate myocardial function. The components of the cardiac sarcomere offer therapeutic targets for a variety of cardiac diseases and disorders, such as modulating contraction and relaxation by increasing contractility or promoting complete relaxation, respectively. The force and speed of cardiac contraction are major determinants of organ function and are regulated by the cyclical interaction of actin and myosin. Regulation of actin-myosin binding is regulated by the myofilament regulatory protein network and intracellular Ca 2+ The troponin complex and tropomyosin are thin filament proteins that control actin-binding sites and the availability of essential and regulatory light chains, while myosin-binding protein C regulates the position and mechanical properties of myosin.

[0008] Abnormalities in the cardiac sarcomere have been identified as drivers of numerous cardiac diseases and disorders, such as hypertrophic cardiomyopathy (HCM) and heart failure with preserved ejection fraction (HFpEF). Mutations in sarcomeric proteins cause disease by conferring either 'hyper' or 'hypo' contractility to the heart muscle. Regulators of cardiac sarcomeres can be used to rebalance contractility and halt or reverse the disease process.

[0009] Existing agents that target cardiac sarcomeres, such as inotropic agents (drugs that increase the heart's ability to contract), have poor selectivity for cardiac tissue, resulting in well-recognized adverse effects that limit their use. These adverse effects include cellular damage due to increased rates of energy expenditure, increased relaxation abnormalities, and increased cytosolic Ca in the myocardium, which may be stimulated by inotropic agents. 2+ Given the limitations of currently available agents, new approaches are needed to improve cardiac function in the setting of HCM and HFpEF.

[0010] There is still a great need for agents that utilize new mechanisms of action and may have better results in terms of short-term and long-term symptom relief, safety and patient mortality. New agents with improved therapeutic indexes relative to existing agents will provide a means to achieve these clinical results. The selectivity of agents for cardiac sarcomeres (e.g., by targeting cardiac myosin) has been identified as an important means to achieve this improved therapeutic index. The present invention provides such agents (particularly cardiac sarcomere inhibitors) and methods of use thereof. These agents are allosteric inhibitors of cardiac myosin. The benefits of these compounds include a wider therapeutic index, a weaker cardiac relaxation effect, better pharmacokinetics and better safety.

[0011] The present invention provides chemical entities, pharmaceutical compositions and methods for treating heart failure, including HCM and HFpEF. The composition is a cardiac sarcomere inhibitor, such as a cardiac myosin inhibitor. Summary of the Invention

[0012] In one aspect, there is provided a compound of formula (I) or a pharmaceutically acceptable salt thereof:

[0013]

[0014] in:

[0015] R 1 selected from the group consisting of substituted or unsubstituted phenyl and substituted or unsubstituted pyridyl;

[0016] R 2A 、R 2B and R 3 Defined by any of (i) to (iii):

[0017] (i)R 2A is H or substituted or unsubstituted alkyl;

[0018] R 2Bis selected from the group consisting of H, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted cycloalkenyl, substituted or unsubstituted cycloalkynyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl, and substituted or unsubstituted heteroaryl; and

[0019] R 3 is substituted or unsubstituted phenyl or substituted or unsubstituted pyridyl;

[0020] or

[0021] (ii)R 2A is H or substituted or unsubstituted alkyl;

[0022] R 2B is substituted or unsubstituted phenyl or substituted or unsubstituted pyridyl; and

[0023] R 3 is a substituted or unsubstituted alkyl group;

[0024] or

[0025] (iii)R 2A and R 2B Together with the carbon atom to which they are attached, they form G 1 , where G 1 is a substituted or unsubstituted cycloalkyl, substituted or unsubstituted cycloalkenyl, substituted or unsubstituted cycloalkynyl, or substituted or unsubstituted heterocyclyl ring, each of which is optionally fused to a phenyl ring; and

[0026] R 3 selected from the group consisting of substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted cycloalkenyl, substituted or unsubstituted cycloalkynyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl, and substituted or unsubstituted heteroaryl;

[0027] R 4 is H or substituted or unsubstituted alkyl; and

[0028] R 5 is H or substituted or unsubstituted alkyl;

[0029] Where one or more of the provisions (a) to (c) apply, then R 1 is substituted or unsubstituted pyridyl or phenyl substituted with at least one substituent other than methyl or methoxy:

[0030] (a)R 2A and R 2B As defined in (i), and R3 is a substituted or unsubstituted phenyl group;

[0031] (b)R 2A and R 3 As defined in (ii), and R 2B is 4-methoxyphenyl;

[0032] (c)R 2A and R 2B As defined in (iii), and R 3 It is 4-methoxyphenylmethyl.

[0033] In another aspect, a compound of formula (Ia) or a pharmaceutically acceptable salt thereof is provided:

[0034]

[0035] in:

[0036] R 1 selected from the group consisting of substituted or unsubstituted phenyl and substituted or unsubstituted pyridyl;

[0037] R 2A is H or substituted or unsubstituted alkyl;

[0038] R 2B selected from the group consisting of H, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted cycloalkenyl, substituted or unsubstituted cycloalkynyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl, and substituted or unsubstituted heteroaryl;

[0039] R 3 is substituted or unsubstituted phenyl or substituted or unsubstituted pyridyl;

[0040] R 4 is H or substituted or unsubstituted alkyl; and

[0041] R 5 is H or substituted or unsubstituted alkyl;

[0042] Among them, when R 3 When R is a substituted or unsubstituted phenyl group, 1 It is a substituted or unsubstituted pyridyl group or a phenyl group substituted with at least one substituent other than a methyl group or a methoxy group.

[0043] In another aspect, a compound of formula (Ib) or a pharmaceutically acceptable salt thereof is provided:

[0044]

[0045] in:

[0046] R 1 selected from the group consisting of substituted or unsubstituted phenyl and substituted or unsubstituted pyridyl;

[0047] R 2A is H or substituted or unsubstituted alkyl;

[0048] R 2B is substituted or unsubstituted phenyl or substituted or unsubstituted pyridyl;

[0049] R 3 is a substituted or unsubstituted alkyl group;

[0050] R 4 is H or substituted or unsubstituted alkyl; and

[0051] R 5 is H or substituted or unsubstituted alkyl;

[0052] Among them, when R 2B When it is 4-methoxyphenyl, R 1 It is a substituted or unsubstituted pyridyl group or a phenyl group substituted with at least one substituent other than a methyl group or a methoxy group.

[0053] In another aspect, a compound of formula (Ic) or a pharmaceutically acceptable salt thereof is provided:

[0054]

[0055] in:

[0056] R 1 selected from the group consisting of: substituted or unsubstituted pyridyl and substituted or unsubstituted pyridyl;

[0057] R 2A and R 2B Together with the carbon atom to which they are attached, they form G 1 , where G 1 is a substituted or unsubstituted cycloalkyl, substituted or unsubstituted cycloalkenyl, substituted or unsubstituted cycloalkynyl, or substituted or unsubstituted heterocyclyl ring, each of which is optionally fused to a phenyl ring;

[0058] R 3 selected from the group consisting of substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted cycloalkenyl, substituted or unsubstituted cycloalkynyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl, and substituted or unsubstituted heteroaryl;

[0059] R 4 is H or substituted or unsubstituted alkyl; and

[0060] R 5 is H or substituted or unsubstituted alkyl;

[0061] Among them, when R 3 When it is 4-methoxyphenylmethyl, R 1 It is a substituted or unsubstituted pyridyl group or a phenyl group substituted with at least one substituent other than a methyl group or a methoxy group.

[0062] In another aspect, a compound of formula (Id) or a pharmaceutically acceptable salt thereof is provided:

[0063]

[0064] in:

[0065] R 2A is H or substituted or unsubstituted alkyl;

[0066] R 2B selected from the group consisting of H, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted cycloalkenyl, substituted or unsubstituted cycloalkynyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl, and substituted or unsubstituted heteroaryl;

[0067] n is 0, 1, or 2;

[0068] R 3a is selected from the group consisting of: halo and cyano; and

[0069] R 4 It’s H.

[0070] In another aspect, a compound of formula (Ie) or a pharmaceutically acceptable salt thereof is provided:

[0071]

[0072] in:

[0073] R 1 selected from the group consisting of substituted or unsubstituted phenyl and substituted or unsubstituted pyridyl;

[0074] R 2A is H or substituted or unsubstituted alkyl;

[0075] R 2B is substituted or unsubstituted phenyl or substituted or unsubstituted pyridyl; and

[0076] R4 It is H;

[0077] Among them, when R 2B When it is 4-methoxyphenyl, R 1 It is a substituted or unsubstituted pyridyl group or a phenyl group substituted with at least one substituent other than a methyl group or a methoxy group.

[0078] In another aspect, a compound of formula (If) or a pharmaceutically acceptable salt thereof is provided:

[0079]

[0080] in:

[0081] G 1 selected from the group consisting of a substituted or unsubstituted cycloalkyl, a substituted or unsubstituted cycloalkenyl, a substituted or unsubstituted cycloalkynyl, and a substituted or unsubstituted heterocyclyl ring, each of which is optionally fused to a phenyl ring;

[0082] R 1a selected from the group consisting of cyano, halo, substituted or unsubstituted alkoxy, substituted or unsubstituted alkyl, and substituted or unsubstituted heterocyclyl;

[0083] R 2a selected from the group consisting of substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted alkoxycarbonyl, substituted or unsubstituted aminoacyl, substituted or unsubstituted acyl, substituted or unsubstituted aminosulfonyl, substituted or unsubstituted aminocarbonylamino, and substituted or unsubstituted alkyl;

[0084] n is 0, 1, 2, or 3;

[0085] R 3 is selected from the group consisting of: substituted or unsubstituted alkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocyclyl, and substituted or unsubstituted aryl; and

[0086] R 4 It is H;

[0087] Among them, when R 3 When it is 4-methoxyphenylmethyl, R 1a Not methyl or methoxy.

[0088] In another aspect, a compound of formula (Ig) or a pharmaceutically acceptable salt thereof is provided:

[0089]

[0090] in:

[0091] R1a selected from the group consisting of cyano, halo, substituted or unsubstituted alkoxy, substituted or unsubstituted alkyl, and substituted or unsubstituted heterocyclyl;

[0092] R 2a selected from the group consisting of substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted alkoxycarbonyl, substituted or unsubstituted aminoacyl, substituted or unsubstituted acyl, substituted or unsubstituted aminosulfonyl, substituted or unsubstituted aminocarbonylamino, and substituted or unsubstituted alkyl;

[0093] n is 0, 1, 2, or 3;

[0094] R 3a is selected from the group consisting of: halo and cyano; and

[0095] R 4 It’s H.

[0096] In another aspect, a compound of formula (Ih) or a pharmaceutically acceptable salt thereof is provided:

[0097]

[0098] in:

[0099] R 1a selected from the group consisting of cyano, halo, substituted or unsubstituted alkoxy, substituted or unsubstituted alkyl, and substituted or unsubstituted heterocyclyl;

[0100] R 2a selected from the group consisting of substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted alkoxycarbonyl, substituted or unsubstituted aminoacyl, substituted or unsubstituted acyl, substituted or unsubstituted aminosulfonyl, substituted or unsubstituted aminocarbonylamino, and substituted or unsubstituted alkyl;

[0101] R 3 is selected from the group consisting of: substituted or unsubstituted alkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocyclyl, and substituted or unsubstituted aryl; and

[0102] R 4 It is H;

[0103] Among them, when R 3 When it is 4-methoxyphenylmethyl, R 1a Not methyl or methoxy.

[0104] In another aspect, a compound of formula (Ii) or a pharmaceutically acceptable salt thereof is provided:

[0105]

[0106] in:

[0107] R 1a selected from the group consisting of cyano, halo, substituted or unsubstituted alkoxy, substituted or unsubstituted alkyl, and substituted or unsubstituted heterocyclyl;

[0108] R 2a selected from the group consisting of substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted alkoxycarbonyl, substituted or unsubstituted aminoacyl, substituted or unsubstituted acyl, substituted or unsubstituted aminosulfonyl, substituted or unsubstituted aminocarbonylamino, and substituted or unsubstituted alkyl;

[0109] R 3 selected from the group consisting of substituted or unsubstituted alkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocyclyl, and substituted or unsubstituted aryl;

[0110] R 4 It is H;

[0111] R 5 is H or substituted or unsubstituted alkyl; and

[0112] X is -CH2- or -C(O)-;

[0113] Among them, when R 3 When it is 4-methoxyphenylmethyl, R 1a Not methyl or methoxy.

[0114] In another aspect, a compound of formula (Ij) or a pharmaceutically acceptable salt thereof is provided:

[0115]

[0116] in:

[0117] R 1 is a substituted or unsubstituted phenyl group;

[0118] Each R 2b are independently substituted or unsubstituted alkyl;

[0119] R 3 is substituted or unsubstituted phenyl or substituted or unsubstituted pyridyl;

[0120] R 4 It is H;

[0121] R 5 is H or substituted or unsubstituted alkyl;

[0122] n is 0, 1, or 2; and

[0123] q is 0 or 1,

[0124] When R 3 When it is a substituted or unsubstituted phenyl group, R 1 It is a phenyl group substituted with at least one substituent other than a methyl group or a methoxy group.

[0125] In another aspect, a compound of formula (Ik-1) or a pharmaceutically acceptable salt thereof is provided:

[0126]

[0127] in:

[0128] R 2A is H or substituted or unsubstituted alkyl;

[0129] R 2B selected from the group consisting of substituted or unsubstituted alkyl, substituted or unsubstituted cycloalkyl, and substituted or unsubstituted heterocyclyl;

[0130] m is 0, 1, or 2;

[0131] p is 0, 1, or 2;

[0132] Each R 1a independently selected from the group consisting of: halogenated and substituted or unsubstituted alkyl;

[0133] Each R 3a are independently selected from the group consisting of halo, cyano, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, and substituted or unsubstituted alkoxy; and

[0134] R 4 It’s H.

[0135] In another aspect, a compound of formula (Ik-2) or a pharmaceutically acceptable salt thereof is provided:

[0136]

[0137] in:

[0138] G 1 selected from the group consisting of substituted or unsubstituted cycloalkyl and substituted or unsubstituted heterocyclyl;

[0139] Each R 1a independently selected from the group consisting of: halogenated and substituted or unsubstituted alkyl;

[0140] Each R 2aindependently selected from the group consisting of substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted alkoxycarbonyl, substituted or unsubstituted aminoacyl, substituted or unsubstituted acyl, substituted or unsubstituted aminosulfinyl, substituted or unsubstituted aminocarbonylamino, and substituted or unsubstituted alkyl;

[0141] Each R 3a independently selected from the group consisting of halo, cyano, and substituted or unsubstituted alkyl;

[0142] R 4 It is H;

[0143] R 5 is H or substituted or unsubstituted alkyl;

[0144] m is 0, 1, or 2;

[0145] n is 0, 1, or 2; and

[0146] p is 0, 1, or 2.

[0147] In another aspect, a compound of formula (I1) or a pharmaceutically acceptable salt thereof is provided:

[0148]

[0149] in:

[0150] R 2A is H or substituted or unsubstituted alkyl;

[0151] R 2b selected from the group consisting of H, substituted or unsubstituted alkyl, substituted or unsubstituted alkoxycarbonyl, substituted or unsubstituted aminoacyl, and hydroxy;

[0152] m is 0, 1, or 2;

[0153] p is 0, 1, or 2;

[0154] Each R 1a independently selected from the group consisting of: halogenated and substituted or unsubstituted alkyl;

[0155] Each R 3a are independently halo; and

[0156] R 4 It’s H.

[0157] In another aspect, a compound of formula (Im) or a pharmaceutically acceptable salt thereof is provided:

[0158]

[0159] in:

[0160] Q is -O- or -N(R 2b )-;

[0161] R 2b selected from the group consisting of: H and substituted or unsubstituted acyl;

[0162] m is 0, 1, or 2;

[0163] p is 0, 1, or 2;

[0164] Each R 1a independently selected from the group consisting of: halogenated and substituted or unsubstituted alkyl;

[0165] Each R 3a are independently halo; and

[0166] R 4 It’s H.

[0167] In another aspect, a compound of formula (In-1) or a pharmaceutically acceptable salt thereof is provided:

[0168]

[0169] in:

[0170] R 1 selected from the group consisting of substituted or unsubstituted phenyl and substituted or unsubstituted pyridyl;

[0171] R 2A 、R 2B and R 3 Defined by any of (i) to (iii):

[0172] (i)R 2A is H or substituted or unsubstituted alkyl;

[0173] R 2B is selected from the group consisting of H, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted cycloalkenyl, substituted or unsubstituted cycloalkynyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl, and substituted or unsubstituted heteroaryl; and

[0174] R 3 is substituted or unsubstituted phenyl or substituted or unsubstituted pyridyl;

[0175] or

[0176] (ii)R 2Ais H or substituted or unsubstituted alkyl;

[0177] R 2B is substituted or unsubstituted phenyl or substituted or unsubstituted pyridyl; and

[0178] R 3 is a substituted or unsubstituted alkyl group;

[0179] or

[0180] (iii)R 2A and R 2B Together with the carbon atom to which they are attached, they form G 1 , where G 1 is a substituted or unsubstituted cycloalkyl, substituted or unsubstituted cycloalkenyl, substituted or unsubstituted cycloalkynyl, or substituted or unsubstituted heterocyclyl ring, each of which is optionally fused to a phenyl ring; and

[0181] R 3 selected from the group consisting of substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted cycloalkenyl, substituted or unsubstituted cycloalkynyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl, and substituted or unsubstituted heteroaryl;

[0182] R 4 is H or substituted or unsubstituted alkyl; and

[0183] R 5 is H or substituted or unsubstituted alkyl;

[0184] Where one or more of the provisions (a) to (c) apply, then R 1 is substituted or unsubstituted pyridyl or phenyl substituted with at least one substituent other than methyl or methoxy:

[0185] (a)R 2A and R 2B As defined in (i), and R 3 is a substituted or unsubstituted phenyl group;

[0186] (b)R 2A and R 3 As defined in (ii), and R 2B is 4-methoxyphenyl;

[0187] (c)R 2A and R 2B As defined in (iii), and R 3 It is 4-methoxyphenylmethyl.

[0188] In another aspect, a compound of formula (In-2) ​​or a pharmaceutically acceptable salt thereof is provided:

[0189]

[0190] in:

[0191] R 1 selected from the group consisting of substituted or unsubstituted phenyl and substituted or unsubstituted pyridyl;

[0192] R 2A 、R 2B and R 3 Defined by any of (i) to (iii):

[0193] (i)R 2A is H or substituted or unsubstituted alkyl;

[0194] R 2B is selected from the group consisting of H, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted cycloalkenyl, substituted or unsubstituted cycloalkynyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl, and substituted or unsubstituted heteroaryl; and

[0195] R 3 is substituted or unsubstituted phenyl or substituted or unsubstituted pyridyl;

[0196] or

[0197] (ii)R 2A is H or substituted or unsubstituted alkyl;

[0198] R 2B is substituted or unsubstituted phenyl or substituted or unsubstituted pyridyl; and

[0199] R 3 is a substituted or unsubstituted alkyl group;

[0200] or

[0201] (iii)R 2A and R 2B Together with the carbon atom to which they are attached, they form G 1 , where G 1 is a substituted or unsubstituted cycloalkyl, substituted or unsubstituted cycloalkenyl, substituted or unsubstituted cycloalkynyl, or substituted or unsubstituted heterocyclyl ring, each of which is optionally fused to a phenyl ring; and

[0202] R 3selected from the group consisting of substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted cycloalkenyl, substituted or unsubstituted cycloalkynyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl, and substituted or unsubstituted heteroaryl;

[0203] R 4 is H or substituted or unsubstituted alkyl; and

[0204] R 5 is H or substituted or unsubstituted alkyl;

[0205] Where one or more of the provisions (a) to (c) apply, then R 1 is substituted or unsubstituted pyridyl or phenyl substituted with at least one substituent other than methyl or methoxy:

[0206] (a)R 2A and R 2B As defined in (i), and R 3 is a substituted or unsubstituted phenyl group;

[0207] (b)R 2A and R 3 As defined in (ii), and R 2B is 4-methoxyphenyl;

[0208] (c)R 2A and R 2B As defined in (iii), and R 3 It is 4-methoxyphenylmethyl.

[0209] In some embodiments, provided is a compound selected from the group consisting of the compounds of Table 1 or pharmaceutically acceptable salts thereof.

[0210] Some aspects provide a pharmaceutical composition comprising a compound of formula (I) or any variation thereof, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient.

[0211] Some aspects provide methods for treating heart disease in a subject in need thereof, the methods comprising administering to the subject a compound of formula (I) or any variation thereof, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition containing a compound of formula (I) or any variation thereof, or a pharmaceutically acceptable salt thereof. In some embodiments, the heart disease is hypertrophic cardiomyopathy (HCM). In some embodiments, the HCM is obstructive or non-obstructive, or is caused by sarcomere and / or non-sarcomere mutations. In some embodiments, the heart disease is heart failure with preserved ejection fraction (HFpEF). In some embodiments, the heart disease is selected from the group consisting of: diastolic dysfunction, primary or secondary restrictive cardiomyopathy, myocardial infarction, angina pectoris, and left ventricular outflow tract obstruction. In some embodiments, the heart disease is hypertensive heart disease, congenital heart disease, cardiac ischemia, coronary heart disease, diabetic heart disease, congestive heart failure, right heart failure, cardiorenal syndrome, or infiltrative cardiomyopathy. In some embodiments, the heart disease is heart aging and / or diastolic dysfunction due to aging or a condition related thereto. In some embodiments, the heart disease is left ventricular hypertrophy and / or concentric left ventricular remodeling or a condition related thereto.

[0212] Other aspects provide methods of treating a disease or condition associated with HCM in a subject in need thereof, wherein the method comprises administering to the subject a compound of formula (I) or any variation thereof, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition containing a compound of formula (I) or any variation thereof, or a pharmaceutically acceptable salt thereof. In some embodiments, the disease or condition is selected from the group consisting of Fabry's disease, Danon disease, mitochondrial cardiomyopathy, and Noonan syndrome.

[0213] Some aspects provide methods for treating a disease or condition associated with secondary left ventricular wall thickening in a subject in need thereof, wherein the method comprises administering to the subject a compound of formula (I) or any variation thereof, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition containing a compound of formula (I) or any variation thereof, or a pharmaceutically acceptable salt thereof. In some embodiments, the disease or condition is selected from the group consisting of: hypertension, valvular heart disease (such as aortic stenosis and mitral insufficiency), metabolic syndrome (such as diabetes and obesity), end-stage renal disease, scleroderma, sleep apnea, amyloidosis, Fabry disease, Friedreich Ataxia, Danon disease, Noonan syndrome, and Pompe disease.

[0214] Other aspects provide methods for treating diseases or conditions associated with left ventricular chamber stenosis and chamber occlusion, hyperdynamic left ventricular contraction, myocardial ischemia, or cardiac fibrosis. Methods for treating muscular dystrophy (e.g., Duchenne muscular dystrophy) or glycogen storage disease are also provided.

[0215] Also provided is a method for inhibiting cardiac sarcomeres, wherein the method comprises contacting the cardiac sarcomere with a compound having formula (I) or any variation thereof, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition containing a compound having formula (I) or any variation thereof, or a pharmaceutically acceptable salt thereof. DETAILED DESCRIPTION

[0216] definition

[0217] As used in this specification, the following words and phrases are generally intended to have the meanings as set forth below, unless otherwise indicated by the context in which they are used.

[0218] Throughout this application, unless the context indicates otherwise, references to compounds of Formula (I) include all subgroups of Formula (I) defined herein, such as Formula (la)-2, Formula (lb)-3, Formula (lc)-4, Formula (Id)-5, Formula (Ie)-6, Formula (Ig)-7, Formula (Ih)-8, Formula (Ii)-9, Formula (Ij)-10, Formula (Ik-2), Formula (ll)-11, Formula (Im)-12, Formula (In-1) and Formula (In-2), including all substructures, subgenera, preferences, embodiments, examples and specific compounds defined and / or described herein. References to compounds of Formula (I) and subgroups thereof, such as Formula (la)-(la), Formula (lb)-(lb), Formula (lc)-(lc), Formula (ld)-(le), Formula (If)-(Ig), Formula (Ih), Formula (Ii), Formula (Ij), Formula (Ik-1), Formula (Ik-2), Formula (ll), Formula (Im), Formula (In-1), and Formula (In-2), include their ionic forms, polymorphs, pseudopolymorphs, amorphous forms, solvates, co-crystals, chelates, isomers, tautomers, oxides (e.g., N-oxides, S-oxides), esters, prodrugs, isotopes, and / or protected forms. In some embodiments, reference is made to compounds of Formula (I) and subgroups thereof, such as Formula (Ia)-(Ib)-(Ic), Formula (Id), Formula (Ie), Formula (If), Formula (Ig)-(Ih), Formula (Ii), Formula (Ij), Formula (Ik-1), Formula (Ik-2), Formula (Il), Formula (Im), Formula (In-1), and Formula (In-2), including their polymorphs, solvates, co-crystals, isomers, tautomers, and / or oxides. In some embodiments, reference is made to compounds of Formula (I) and subgroups thereof, such as Formula (Ia)-(Ib)-(Ic), Formula (Id), Formula (Ie), Formula (If), Formula (Ig)-(Ih), Formula (Ii), Formula (Ij), Formula (Ik-1), Formula (Ik-2), Formula (Il), Formula (Im), Formula (In-1), and Formula (In-2), including their polymorphs, solvates, and / or co-crystals. In some embodiments, reference to compounds of formula (I) and subgroups thereof, such as Formula (Ia)-(Ib)-(Ic), Formula (Id), Formula (Ie), Formula (If), Formula (Ig)-(Ih), Formula (Ii), Formula (Ij), Formula (Ik-1), Formula (Ik-2), Formula (Il), Formula (Im), Formula (In-1), and Formula (In-2), includes isomers, tautomers, and / or oxides thereof. In some embodiments, reference to compounds of formula (I) and subgroups thereof, such as Formula (Ia)-(Ib)-(Ic), Formula (Id), Formula (Ie), Formula (If), Formula (Ig)-(Ih), Formula (Ii), Formula (Ij), Formula (Ik-1), Formula (Ik-2), Formula (Il), Formula (Im), Formula (In-1), and Formula (In-2), includes solvates thereof.

[0219] "Alkyl" encompasses straight and branched carbon chains having the indicated number of carbon atoms, e.g., 1 to 20 carbon atoms, or 1 to 8 carbon atoms, or 1 to 6 carbon atoms. For example, C 1-6 Alkyl encompasses straight and branched chain alkyl groups of 1 to 6 carbon atoms. When naming an alkyl residue having a specific number of carbon atoms, it is intended to encompass all branched and straight chain forms having that number of carbon atoms; thus, for example, "propyl" includes n-propyl and isopropyl; and "butyl" includes n-butyl, sec-butyl, isobutyl, and tert-butyl. Examples of alkyl groups include, but are not limited to, methyl, ethyl, propyl, isopropyl, n-butyl, sec-butyl, tert-butyl, pentyl, 2-pentyl, 3-pentyl, isopentyl, neopentyl, hexyl, 2-hexyl, 3-hexyl, and 3-methylpentyl.

[0220] When a range of values ​​is provided (e.g., C 1-6 alkyl), each value within the stated range and all intermediate ranges are included. For example, “C 1-6 "Alkyl" includes C1, C2, C3, C4, C5, C6, C 1-6 、C 2-6 、C 3-6 、C 4-6 、C 5-6 、C 1-5 、C 2-5 、C 3-5 、C 4-5 、C 1-4 、C 2-4 、C 3-4 、C 1-3 、C 2-3 and C 1-2 alkyl.

[0221] "Alkenyl" refers to an unsaturated branched or straight chain alkyl group having a specified number of carbon atoms (e.g., 2 to 8 or 2 to 6 carbon atoms) and at least one carbon-carbon double bond. The group can be in a cis or trans conformation (Z or E conformation) about the double bond. Alkenyl includes, but is not limited to, vinyl, propenyl (e.g., prop-1-ene-1-yl, prop-1-ene-2-yl, prop-2-ene-1-yl (allyl), prop-2-ene-2-yl) and butenyl (e.g., but-1-ene-1-yl, but-1-ene-2-yl, 2-methyl-prop-1-ene-1-yl, but-2-ene-1-yl, but-2-ene-1-yl, but-2-ene-2-yl, but-1,3-diene-1-yl, but-1,3-diene-2-yl).

[0222] "Alkynyl" refers to an unsaturated, branched or straight chain alkyl group having the indicated number of carbon atoms (e.g., 2 to 8 or 2 to 6 carbon atoms) and at least one carbon-carbon triple bond. Alkynyl groups include, but are not limited to, ethynyl, propynyl (e.g., prop-1-yn-1-yl, prop-2-yn-1-yl), and butynyl (e.g., but-1-yn-1-yl, but-1-yn-3-yl, but-3-yn-1-yl).

[0223] "Cycloalkyl" indicates a non-aromatic fully saturated carbocyclic ring with a specified number of carbon atoms, such as 3 to 10 or 3 to 8 or 3 to 6 ring carbon atoms. Cycloalkyl can be a monocyclic or polycyclic ring (such as a bicyclic or tricyclic ring). Examples of cycloalkyl include cyclopropyl, cyclobutyl, cyclopentyl and cyclohexyl, as well as bridged and caged ring groups (such as norbornane, bicyclo [2.2.2] octane). In addition, one ring of polycyclic cycloalkyl can be aromatic, provided that the polycyclic cycloalkyl is combined with the parent structure via non-aromatic carbon. For example, 1,2,3,4-tetrahydronaphthalene-1-yl (wherein the portion is combined with the parent structure via a non-aromatic carbon atom) is a cycloalkyl, while 1,2,3,4-tetrahydronaphthalene-5-yl (wherein the portion is combined with the parent structure via an aromatic carbon atom) is not a cycloalkyl. The examples of the polycyclic cycloalkyl consisting of the cycloalkyl fused to an aromatic ring are described below.

[0224] " cycloalkenyl " indicates the non-aromatic carbocyclic ring containing the carbon atoms (such as 3 to 10 or 3 to 8 or 3 to 6 ring carbon atoms) of the number indicated and at least one carbon-carbon double bond.Cycloalkenyl can be monocyclic or polycyclic (such as bicyclic, tricyclic).The example of cycloalkenyl includes cyclopropenyl, cyclobutenyl, cyclopentenyl, cyclopentadienyl and cyclohexenyl, and bridge and cage ring group (such as bicyclo [2.2.2] octene).In addition, a ring of polycyclic cycloalkenyl can be aromatic, and condition is that the polycyclic cycloalkenyl is combined with parent structure via non-aromatic carbon atom.For example, it is believed that indene-1-base (wherein said part is combined with parent structure via non-aromatic carbon atom) is cycloalkenyl, and it is believed that indene-4-base (wherein said part is combined with parent structure via aromatic carbon atom) is not cycloalkenyl.Describe the example of the polycyclic cycloalkenyl consisting of the cycloalkenyl fused with aromatic ring below.

[0225] "Cycloalkynyl" refers to an unsaturated hydrocarbon group having at least one site of acetylenic unsaturation within a cycloalkyl group (i.e., having at least one moiety of the formula C≡C). A cycloalkynyl group may consist of one ring (e.g., cyclooctyne) or multiple rings. A cycloalkynyl moiety is an unsaturated cyclic hydrocarbon group having 5 to 10 ring carbon atoms ("C5-C 10 Examples include cyclopentyne, cyclohexyne, cycloheptyne, cyclooctyne, cyclononyne, and the like.

[0226] "Aryl" indicates an aromatic carbocyclic ring with a specified number of carbon atoms, for example, 6 to 12 or 6 to 10 carbon atoms. Aryl can be monocyclic or polycyclic (e.g., bicyclic, tricyclic). In some cases, both rings of a polycyclic aryl are aromatic (e.g., naphthyl). In other cases, a polycyclic aryl can include a non-aromatic ring fused to an aromatic ring, provided that the polycyclic aryl is bound to the parent structure via atoms in the aromatic ring. Therefore, it is believed that 1,2,3,4-tetrahydronaphthalene-5-yl (wherein the moiety is bound to the parent structure via an aromatic carbon atom) is an aryl, while it is believed that 1,2,3,4-tetrahydronaphthalene-1-yl (wherein the moiety is bound to the parent structure via a non-aromatic carbon atom) is not an aryl. Similarly, it is believed that 1,2,3,4-tetrahydroquinolin-8-yl (wherein the portion is bound to the parent structure via an aromatic carbon atom) is an aryl group, while it is believed that 1,2,3,4-tetrahydroquinolin-1-yl (wherein the portion is bound to the parent structure via a non-aromatic nitrogen atom) is not an aryl group. However, the term "aryl" does not encompass "heteroaryl" as defined herein or overlaps with it, regardless of the point of attachment (e.g., quinolin-5-yl and quinolin-2-yl are both heteroaryl groups). In some cases, the aryl group is a phenyl group or a naphthyl group. In some cases, the aryl group is a phenyl group. Other examples of aryl groups comprising aromatic carbocyclic rings fused to non-aromatic rings are described below.

[0227] "Heteroaryl" refers to an aromatic ring containing the indicated number of atoms (e.g., a 5- to 12-membered or a 5- to 10-membered heteroaryl) consisting of one or more heteroatoms (e.g., 1, 2, 3, or 4 heteroatoms) selected from N, O, and S, and the remaining ring atoms are carbon. The heteroaryl group does not contain adjacent S and O atoms. In some embodiments, the total number of S and O atoms in the heteroaryl group is no more than 2. In some embodiments, the total number of S and O atoms in the heteroaryl group is no more than 1. Unless otherwise noted, the heteroaryl group can be combined with the parent structure through a carbon or nitrogen atom when valence permits. For example, "pyridyl" includes 2-pyridyl, 3-pyridyl, and 4-pyridyl, and "pyrrolyl" includes 1-pyrrolyl, 2-pyrrolyl, and 3-pyrrolyl.

[0228] In some cases, the heteroaryl group is a monocyclic ring. Examples include pyrrole, pyrazole, imidazole, triazole (e.g., 1,2,3-triazole, 1,2,4-triazole, 1,2,4-triazole), tetrazole, furan, isoxazole, oxazole, oxadiazole (e.g., 1,2,3-oxadiazole, 1,2,4-oxadiazole, 1,3,4-oxadiazole), thiophene, isothiazole, thiazole, thiadiazole (e.g., 1,2,3-thiadiazole, 1,2,4-thiadiazole, 1,3,4-thiadiazole), pyridine, pyridazine, pyrimidine, pyrazine, triazine (e.g., 1,2,4-triazine, 1,3,5-triazine), and tetrazine.

[0229] In some cases, both rings of the polycyclic heteroaryl group are aromatic. Examples include indole, isoindole, indazole, benzimidazole, benzotriazole, benzofuran, benzoxazole, benzisoxazole, benzoxadiazole, benzothiophene, benzothiazole, benzisothiazole, benzothiadiazole, 1H-pyrrolo[2,3-b]pyridine, 1H-pyrazolo[3,4-b]pyridine, 3H-imidazo[4,5-b]pyridine, 3H-[1,2,3]triazolo[4,5-b]pyridine, 1H-pyrrolo[3,2-b]pyridine, 1H-pyrazolo[4,3-b]pyridine, 1H-imidazo[4,5-b]pyridine, 1H-[1,2,3]triazolo[4,5-b]pyridine, 1H-pyrrolo[2,3-c]pyridine, 1H-pyrazolo[3,4-c]pyridine , 3H-imidazo[4,5-c]pyridine, 3H-[1,2,3]triazolo[4,5-c]pyridine, 1H-pyrrolo[3,2-c]pyridine, 1H-pyrazolo[4,3-c]pyridine, 1H-imidazo[4,5-c]pyridine, 1H-[1,2,3]triazolo[4,5-c]pyridine, furo[2,3-b]pyridine, oxazolo[5,4-b]pyridine, isoxazolo[5,4-b]pyridine, [1,2,3]oxadiazolo[5,4-b]pyridine, furo[3,2-b]pyridine, oxazolo[4,5-b]pyridine, isoxazolo[4,5-b]pyridine, [1,2,3]oxadiazolo[4,5-b]pyridine, furo[2,3-c ]pyridine, oxazolo[5,4-c]pyridine, isoxazolo[5,4-c]pyridine, [1,2,3]oxadiazolo[5,4-c]pyridine, furo[3,2-c]pyridine, oxazolo[4,5-c]pyridine, isoxazolo[4,5-c]pyridine, [1,2,3]oxadiazolo[4,5-c]pyridine, thieno[2,3-b]pyridine, thiazolo[5,4-b]pyridine, isothiazolo[5,4-b]pyridine, [1,2,3]thiadiazolo[5,4-b]pyridine, thieno[3,2-b]pyridine, thiazolo[4,5-b]pyridine, isothiazolo[4,5-b]pyridine, [1,2,3]thiadiazolo[4,5-b]pyridine, thieno[2,3

[0015] Examples of the present invention include thiazoline, thiazolo[5,4-c]pyridine, isothiazolo[5,4-c]pyridine, [1,2,3]thiadiazolo[5,4-c]pyridine, thieno[3,2-c]pyridine, thiazolo[4,5-c]pyridine, isothiazolo[4,5-c]pyridine, [1,2,3]thiadiazolo[4,5-c]pyridine, quinoline, isoquinoline, cinnoline, quinazoline, quinoxaline, pyrazine, naphthyridine (e.g., 1,8-naphthyridine, 1,7-naphthyridine, 1,6-naphthyridine, 1,5-naphthyridine, 2,7-naphthyridine, 2,6-naphthyridine), imidazo[1,2-a]pyridine, 1H-pyrazolo[3,4-d]thiazole, 1H-pyrazolo[4,3-d]thiazole, and imidazo[2,1-b]thiazole.

[0230] In other cases, a polycyclic heteroaryl group may include a non-aromatic ring (e.g., cycloalkyl, cycloalkenyl, heterocycloalkyl, heterocycloalkenyl) fused to a heteroaryl ring, provided that the polycyclic heteroaryl group is attached to the parent structure via an atom in the aromatic ring. For example, 4,5,6,7-tetrahydrobenzo[d]thiazol-2-yl (wherein the moiety is attached to the parent structure via an aromatic carbon atom) is considered a heteroaryl group, while 4,5,6,7-tetrahydrobenzo[d]thiazol-5-yl (wherein the moiety is attached to the parent structure via a non-aromatic carbon atom) is not considered a heteroaryl group. Examples of polycyclic heteroaryl groups consisting of a heteroaryl ring fused to a non-aromatic ring are described below.

[0231] " Heterocycloalkyl " indicates the non-aromatic fully saturated ring (for example, 3 yuan to 10 yuan or 3 yuan to 7 yuan heterocycloalkyl) of the atom with the number indicated, and it is made up of one or more heteroatoms (for example 1,2,3 or 4 heteroatoms) selected from N, O and S, and all the other ring atoms are carbon.Heterocycloalkyl can be monocycle or polycycle (for example bicyclic, tricycle).The example of heterocycloalkyl includes oxiranyl, aziridine, azetidinyl, pyrrolidinyl, imidazolidinyl, pyrazolidinyl, piperidinyl, piperazinyl, morpholinyl and thiomorpholinyl.Example includes thiomorpholine S-oxide and thiomorpholine S, S-dioxide.In addition, a ring of polycyclic heterocycloalkyl can be aromatic (for example aryl or heteroaryl), and condition is that described polycyclic heterocycloalkyl is combined with parent structure via non-aromatic carbon or nitrogen atom. For example, 1,2,3,4-tetrahydroquinolin-1-yl (wherein the moiety is attached to the parent structure via a non-aromatic nitrogen atom) is considered a heterocycloalkyl, whereas 1,2,3,4-tetrahydroquinolin-8-yl (wherein the moiety is attached to the parent structure via an aromatic carbon atom) is not considered a heterocycloalkyl. Examples of polycyclic heterocycloalkyls consisting of a heterocycloalkyl fused to an aromatic ring are described below.

[0232] "Heterocycloalkenyl" refers to a non-aromatic ring having the indicated number of atoms (e.g., 3- to 10-membered or 3- to 7-membered heterocycloalkyl), consisting of one or more heteroatoms (e.g., 1, 2, 3, or 4 heteroatoms) selected from N, O, and S, with the remaining ring atoms being carbon, and at least one double bond being derived by removing one hydrogen molecule from adjacent carbon atoms, adjacent nitrogen atoms, or adjacent carbon and nitrogen atoms of the corresponding heterocycloalkyl. A heterocycloalkenyl group can be monocyclic or polycyclic (e.g., bicyclic, tricyclic). Examples of heterocycloalkenyl groups include dihydrofuranyl (e.g., 2,3-dihydrofuranyl, 2,5-dihydrofuranyl), dihydrothiophenyl (e.g., 2,3-dihydrothiophenyl, 2,5-dihydrothiophenyl), dihydropyrrolyl (e.g., 2,3-dihydro-1H-pyrrolyl, 2,5-dihydro-1H-pyrrolyl), dihydroimidazolyl (e.g., 2,3-dihydro-1H-imidazolyl, 4,5-dihydro-1H-imidazolyl), pyranyl, dihydropyranyl (e.g., 3,4-dihydro-2H-pyranyl, 3,6-dihydro-2H-pyranyl), tetrahydropyridinyl (e.g., 1,2,3,4-tetrahydropyridinyl, 1,2,3,6-tetrahydropyridinyl), and dihydropyridine (e.g., 1,2-dihydropyridine, 1,4-dihydropyridine). In addition, one ring of a polycyclic heterocycloalkenyl group may be aromatic (e.g., aryl or heteroaryl), provided that the polycyclic heterocycloalkenyl group is bound to the parent structure via a non-aromatic carbon or nitrogen atom. For example, 1,2-dihydroquinolin-1-yl (wherein the moiety is bound to the parent structure via a non-aromatic nitrogen atom) is considered a heterocycloalkenyl group, while 1,2-dihydroquinolin-8-yl (wherein the moiety is bound to the parent structure via an aromatic carbon atom) is not considered a heterocycloalkenyl group. Examples of polycyclic heterocycloalkenyl groups consisting of a heterocycloalkenyl group fused to an aromatic ring are described below.

[0233] Examples of polycyclic rings consisting of an aromatic ring (e.g., aryl or heteroaryl) fused to a non-aromatic ring (e.g., cycloalkyl, cycloalkenyl, heterocycloalkyl, heterocycloalkenyl) include indenyl, 2,3-dihydro-1H-indenyl, 1,2,3,4-tetrahydronaphthyl, benzo[1,3]dioxolyl, tetrahydroquinolinyl, 2,3-dihydrobenzo[1,4]dioxinyl, indolinyl, isoindolinyl, 2,3-dihydro-1H-indazolyl, 2,3-dihydro-1H-benzo[d]imidazolyl, 2,3-dihydrobenzofuranyl, 1,3-dihydroisobenzofuranyl, 1,3-dihydrobenzo[c]isoxazolyl, 2,3-dihydrobenzo[d]isoxazolyl, 2,3-dihydrobenzo[ d]oxazolyl, 2,3-dihydrobenzo[b]thienyl, 1,3-dihydrobenzo[c]thienyl, 1,3-dihydrobenzo[c]isothiazolyl, 2,3-dihydrobenzo[d]isothiazolyl, 2,3-dihydrobenzo[d]thiazolyl, 5,6-dihydro-4H-cyclopenta[d]thiazolyl, 4,5,6,7-tetrahydrobenzo[d]thiazolyl, 5,6-dihydro-4H-pyrrolo[3,4-d]thiazolyl, 4,5,6,7-tetrahydrothiazolo[5,4-c]pyridinyl, indolin-2-one, indolin-3-one, isoindolin-1-one, 1,2-dihydroindazol-3-one, 1H-benzo[d]imidazol-2(3H)-one, benzofuran-2(3H)-one, benzofuran -3(2H)-one, isobenzofuran-1(3H)-one, benzo[c]isoxazol-3(1H)-one, benzo[d]isoxazol-3(2H)-one, benzo[d]oxazol-2(3H)-one, benzo[b]thiophen-2(3H)-one, benzo[b]thiophen-3(2H)-one, benzo[c]thiophen-1(3H)-one, benzo[c]isothiazol-3(1H)-one, benzo[d]isothiazol-3(2H)-one, benzo[d]thiazol-2(3H)-one, 4,5-dihydropyrrolo[3,4-d]thiazol-6-one, 1,2-dihydropyrazolo[3,4-d]thiazol-3-one, quinolin-4(3H)-one, quinazolin-4(3H-one, quinazole quinoxaline-2,4(1H,3H)-dione, quinoxaline-2(1H)-one, quinoxaline-2,3(1H,4H)-dione, cinnolin-4(3H)-one, pyridin-2(1H)-one, pyrimidin-2(1H)-one, pyrimidin-4(3H)-one, pyridazin-3(2H)-one, 1H-pyrrolo[3,2-b]pyridin-2(3H)-one, 1H-pyrrolo[3,2-c]pyridin-2(3H)-one, 1H-pyrrolo[2,3-c]pyridin-2(3H)-one, 1H-pyrrolo[2,3-b]pyridin-2(3H)-one, 1,2-dihydropyrazolo[3,4-d]thiazol-3-one and 4,5-dihydropyrrolo[3,4-d]thiazol-6-one.As discussed herein, whether each ring is considered to be aryl, heteroaryl, cycloalkyl, cycloalkenyl, heterocycloalkyl, or heterocycloalkenyl is determined by the atom to which the moiety is attached to the parent structure.

[0234] The terms "heterocycle," "heterocyclyl," or "heterocyclic" refer to a saturated, partially unsaturated, or unsaturated 4- to 12-membered ring containing at least one heteroatom independently selected from nitrogen, oxygen, and sulfur. Unless otherwise specified, the heteroatom may be carbon or nitrogen-linked, the -CH2- group may optionally be replaced with -C(O)-, and the ring sulfur atom may optionally be oxidized to form a sulfinyl or sulfonyl group. The heterocycle may be aromatic (heteroaryl) or non-aromatic. In addition, not all rings of a polycyclic heterocyclyl may be aromatic (e.g., aryl or heteroaryl). For example, 1,2,3,4-tetrahydroquinolin-1-yl and 1,2,3,4-tetrahydroquinolin-8-yl are both considered heterocyclyls.

[0235] "Heterocycle," "heterocyclyl," or "heterocyclic" also includes bicyclic, tricyclic, and tetracyclic groups in which any of the above heterocycles is fused to one or two rings independently selected from aryl, cycloalkyl, and heterocycle. Exemplary heterocycles include acridinyl, benzimidazolyl, benzofuranyl, benzothiazolyl, benzothiophenyl, benzoxazolyl, biotinyl, cinnolinyl, dihydrofuranyl, dihydroindolinyl, dihydropyranyl, dihydrothienyl, dithiazolyl, furanyl, homopiperidinyl, imidazolidinyl, imidazolinyl, imidazolyl, indolyl, isoquinolinyl, isothiazolidinyl, isothiazolidinyl, isoxazolidinyl, isoxazolidinyl, morpholinyl, oxadiazolyl, oxazolidine alkyl, pyridyl, pyridyl, pyrimidinyl, pyrimidinyl, pyrrolidinyl, pyrrolidin-2-onyl, pyrrolinyl, pyrrolyl, quinolinyl, quinoxalinoyl, tetrahydrofuranyl, tetrahydroisoquinolinyl, tetrahydropyranyl, tetrahydroquinolinyl, tetrazolyl, thiadiazolyl, thiazolidinyl, thiazolyl, thiophenyl, thiomorpholinyl, thiopyranyl, and triazolyl.

[0236] "Halogen" or "halo" refers to fluoro, chloro, bromo or iodo.

[0237] Unless otherwise indicated, the compounds disclosed and / or described herein include all possible enantiomers, diastereomers, mesoisomers and other stereoisomeric forms, including racemic mixtures, optically pure forms and intermediate mixtures thereof. Enantiomers, diastereomers, mesoisomers and other stereoisomeric forms can be prepared using chiral synthons or chiral reagents, or resolved using conventional techniques. Unless otherwise specified, when the compounds disclosed and / or described herein contain olefinic double bonds or other centers of geometric asymmetry, it is expected that the compounds include E and Z isomers. When the compounds described herein contain moieties capable of tautomerization, and unless otherwise specified, it is expected that the compounds include all possible tautomers.

[0238] "Protecting group" has the meaning commonly associated with it in organic synthesis, that is, a group that selectively blocks one or more reactive sites in a multifunctional compound so that a chemical reaction can be selectively performed on another unprotected reactive site and the group can be easily removed after the selective reaction is complete. Various protecting groups are disclosed, for example, in TH Greene and PGM Wuts, Protective Groups in Organic Synthesis, 3rd edition, John Wiley & Sons, New York (1999). For example, a "hydroxyl protected form" contains at least one hydroxyl group protected by a hydroxyl protecting group. Similarly, amines and other reactive groups can be similarly protected.

[0239] The term "pharmaceutically acceptable salt" refers to a salt of any of the compounds herein that is known to be non-toxic and commonly used in the medical literature. In some embodiments, a pharmaceutically acceptable salt of a compound retains the biological effects of the compounds described herein and is not biologically or otherwise undesirable. Examples of pharmaceutically acceptable salts can be found in Berge et al., Pharmaceutical Salts, J. Pharmaceutical Sciences, January 1977, 66(1), 1-19. Pharmaceutically acceptable acid addition salts can be formed with inorganic and organic acids. Inorganic acids from which salts can be derived include, for example, hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, and phosphoric acid. Organic acids from which salts can be derived include, for example, acetic acid, propionic acid, glycolic acid, pyruvic acid, lactic acid, oxalic acid, malic acid, maleic acid, malonic acid, succinic acid, fumaric acid, tartaric acid, citric acid, benzoic acid, cinnamic acid, mandelic acid, methanesulfonic acid, ethanesulfonic acid, 2-hydroxyethylsulfonic acid, p-toluenesulfonic acid, stearic acid, and salicylic acid. Pharmaceutically acceptable base addition salts can be formed with inorganic and organic bases. Inorganic bases from which salts can be derived include, for example, sodium, potassium, lithium, ammonium, calcium, magnesium, iron, zinc, copper, manganese, and aluminum. Organic bases from which salts can be derived include, for example, primary, secondary, and tertiary amines; substituted amines, including naturally occurring substituted amines; cyclic amines; and basic ion exchange resins. Examples of organic bases include isopropylamine, trimethylamine, diethylamine, triethylamine, tripropylamine, and ethanolamine. In some embodiments, pharmaceutically acceptable base addition salts are selected from ammonium, potassium, sodium, calcium, and magnesium salts.

[0240] If the compounds described herein are obtained in the form of acid addition salts, the free base can be obtained by alkalizing a solution of the acid salt. Conversely, if the compound is a free base, an addition salt, particularly a pharmaceutically acceptable addition salt, can be produced by dissolving the free base in a suitable organic solvent and treating the solution with an acid according to conventional procedures for preparing acid addition salts from base compounds (see, for example, Berge et al., Pharmaceutical Salts, J. Pharmaceutical Sciences, January 1977, 66(1), 1-19). Those skilled in the art will recognize that a variety of synthetic methods can be used to prepare pharmaceutically acceptable addition salts.

[0241] A "solvate" is formed by the interaction of a solvent with a compound. Suitable solvents include, for example, water and alcohols (eg, ethanol). Solvates include hydrates of the compound and water in any ratio, such as monohydrates, dihydrates, and hemihydrates.

[0242] The term "substituted" means that the specified group or moiety bears one or more substituents, including but not limited to alkoxy, acyl, acyloxy, alkoxycarbonyl, carbonylalkoxy, acylamino, amino, aminoacyl, aminocarbonylamino, aminocarbonyloxy, cycloalkyl, cycloalkenyl, aryl, heteroaryl, aryloxy, cyano, azido, halo, hydroxy, nitro, carboxyl, thiol, alkylthio, alkyl, alkenyl, alkynyl, heterocyclyl, aralkyl, aminosulfonyl, sulfonylamino, sulfonyl, oxo, and the like. The term "unsubstituted" means that the specified group bears no substituents. When the term "substituted" is used to describe a structural system, substitution is intended to occur at any valence-allowed position on the system. When a group or moiety bears more than one substituent, it is understood that the substituents may be the same or different. In some embodiments, a substituted group or moiety bears from one to five substituents. In some embodiments, a substituted group or moiety bears one substituent. In some embodiments, a substituted group or moiety bears two substituents. In some embodiments, the substituted group or moiety has three substituents. In some embodiments, the substituted group or moiety has four substituents. In some embodiments, the substituted group or moiety has five substituents.

[0243] "Optionally" means that the then-described event or circumstance may or may not occur, and that the description includes instances where the event or circumstance occurs and instances where it does not. For example, "optionally substituted alkyl" encompasses both "alkyl" and "substituted alkyl" as defined herein. With respect to any group containing one or more substituents, it will be understood by those skilled in the art that the group does not wish to introduce any substitution or substitution pattern that is sterically impractical, synthetically unfeasible, and / or inherently unstable. It will also be understood that when a group or moiety is optionally substituted, the present invention includes embodiments where the group or moiety is substituted as well as embodiments where the group or moiety is not substituted.

[0244] The compounds disclosed and / or described herein may be in isotopically enriched forms, e.g. 2 H. 3 H. 11 C. 13 C and / or 14In one embodiment, the compound contains at least one deuterium atom. The deuterated form can be produced, for example, by the procedures described in U.S. Patent Nos. 5,846,514 and 6,334,997. The deuterated compound can enhance the potency of the compounds disclosed and / or described herein and increase their duration of action. Deuterium-substituted compounds can be synthesized using a variety of methods, such as those described in Dean, D., Recent Advances in the Synthesis and Applications of Radiolabeled Compounds for Drug Discovery and Development, Curr. Pharm. Des., 2000; 6(10); Kabalka, G. et al., The Synthesis of Radiolabeled Compounds via Organometallic Intermediates, Tetrahedron, 1989, 45(21), 6601-21; and Evans, E., Synthesis of radiolabeled compounds, J. Radioanal. Chem., 1981, 64(1-2), 9-32.

[0245] The term "pharmaceutically acceptable carrier" or "pharmaceutically acceptable excipient" includes any and all solvents, dispersion media, coatings, antibacterial and antifungal agents, isotonic and absorption delaying agents, and the like. The use of such media and agents for pharmaceutically active substances is well known in the art. Unless any conventional media or agents are incompatible with the active ingredient, their use in pharmaceutical compositions is contemplated. Supplementary active ingredients may also be incorporated into pharmaceutical compositions.

[0246] The terms "patient," "individual," and "subject" refer to an animal, such as a mammal, bird, or fish. In some embodiments, the patient or subject is a mammal. Mammals include, for example, mice, rats, dogs, cats, pigs, sheep, horses, cows, and humans. In some embodiments, the patient or subject is a human, such as a human who has been or will be the subject of treatment, observation, or experimentation. The compounds, compositions, and methods described herein can be used in both human therapy and veterinary applications.

[0247] As used herein, the term "treat" refers to the ability to modulate cardiac sarcomeres. As used herein, "modulate" refers to a change in activity as a direct or indirect reaction to the presence of a chemical entity as described herein, relative to the activity in the absence of the chemical entity. The change can be an increase in activity or a decrease in activity, and may be due to a direct interaction of the chemical entity with the target or due to the interaction of the chemical entity with one or more other factors that in turn affect the activity of the target. For example, the presence of a chemical entity can be, for example, by directly binding to the target, by causing another factor to increase or decrease the activity of the target (directly or indirectly), or by increasing or decreasing the amount of the target present in a cell or organism (directly or indirectly).

[0248] The term "therapeutically effective amount" or "effective amount" refers to the amount of a compound disclosed and / or described herein that is sufficient to affect treatment (as defined herein) when administered to a patient in need of such treatment. A therapeutically effective amount of a compound can be an amount sufficient to treat a disease responsive to modulation of cardiac sarcomeres. The therapeutically effective amount will depend, for example, on the subject and disease condition being treated, the subject's weight and age, the severity of the disease condition, the specific compound, the dosing regimen to be followed, the time course of administration, the mode of administration, all of which can be readily determined by one of ordinary skill in the art. A therapeutically effective amount can be determined experimentally, for example, by measuring the blood concentration of the chemical entity, or theoretically by calculating bioavailability.

[0249] "Treating" includes one or more of the following: inhibiting a disease or condition; slowing or arresting the development of clinical symptoms of a disease or condition; and / or alleviating a disease or condition (i.e., causing a reduction or regression of clinical symptoms). The term encompasses complete or partial alleviation of a disease or condition, as well as complete or partial alleviation of the clinical symptoms of a disease or condition. Thus, the compounds described and / or disclosed herein can prevent an existing disease or condition from worsening, help control a disease or condition, or alleviate or eliminate a disease or condition.

[0250] "ATPase" refers to an enzyme that hydrolyzes ATP. ATPases include proteins that contain molecular motors, such as myosin.

[0251] As used herein, "selectively binds" or "selectively binds" refers to preferential binding to a target protein of one type of muscle or myofiber over another. For example, a compound selectively binds to fast skeletal troponin C if it preferentially binds to troponin C in troponin complexes of fast skeletal muscle fibers or sarcomeres compared to troponin C in troponin complexes of slow muscle fibers or sarcomeres or to troponin C in troponin complexes of cardiac sarcomeres.

[0252] It should be understood that embodiments described herein as "comprising" include "consisting of" and "consisting essentially of" embodiments.

[0253] Compound

[0254] Compounds and their salts (such as pharmaceutically acceptable salts) are described in detail herein, including in the Summary of the Invention and the appended claims. Also provided are uses of all compounds described herein (including any and all stereoisomers, including geometric isomers (cis / trans), E / Z isomers, enantiomers, diastereomers, and mixtures thereof in any ratio, including racemic mixtures; salts and solvates of the compounds described herein), as well as methods of making the compounds. Any compound described herein may also be referred to as a pharmaceutical.

[0255] In one aspect, there is provided a compound of formula (I) or a pharmaceutically acceptable salt thereof:

[0256]

[0257] in:

[0258] R 1 selected from the group consisting of substituted or unsubstituted phenyl and substituted or unsubstituted pyridyl;

[0259] R 2A 、R 2B and R 3 Defined by any of (i) to (iii):

[0260] (i)R 2A is H or substituted or unsubstituted alkyl;

[0261] R 2B is selected from the group consisting of H, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted cycloalkenyl, substituted or unsubstituted cycloalkynyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl, and substituted or unsubstituted heteroaryl; and

[0262] R 3 is substituted or unsubstituted phenyl or substituted or unsubstituted pyridyl;

[0263] or

[0264] (ii)R 2A is H or substituted or unsubstituted alkyl;

[0265] R 2B is substituted or unsubstituted phenyl or substituted or unsubstituted pyridyl; and

[0266] R 3 is a substituted or unsubstituted alkyl group;

[0267] or

[0268] (iii)R 2A and R 2B Together with the carbon atom to which they are attached, they form G 1 , where G 1 is a substituted or unsubstituted cycloalkyl, substituted or unsubstituted cycloalkenyl, substituted or unsubstituted cycloalkynyl, or substituted or unsubstituted heterocyclyl ring, each of which is optionally fused to a phenyl ring; and

[0269] R 3 selected from the group consisting of substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted cycloalkenyl, substituted or unsubstituted cycloalkynyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl, and substituted or unsubstituted heteroaryl;

[0270] R 4 is H or substituted or unsubstituted alkyl; and

[0271] R 5 is H or substituted or unsubstituted alkyl;

[0272] Where one or more of the provisions (a) to (c) apply, then R 1 is substituted or unsubstituted pyridyl or phenyl substituted with at least one substituent other than methyl or methoxy:

[0273] (a)R 2A and R 2B As defined in (i), and R 3 is a substituted or unsubstituted phenyl group;

[0274] (b)R 2A and R 3 As defined in (ii), and R 2B is 4-methoxyphenyl;

[0275] (c)R 2A and R 2B As defined in (iii), and R 3 It is 4-methoxyphenylmethyl.

[0276] In some embodiments of Formula (I), R 4 and R 5 are each independently H. In some embodiments of Formula (I), R 4 and R 5At least one of them is not H. In some embodiments of Formula (I), R 4 is a substituted or unsubstituted alkyl group. In some embodiments of Formula (I), R 4 In some embodiments of Formula (I), R 4 is an alkyl group substituted with an alkoxy group. In some embodiments of Formula (I), R 4 is methoxymethyl. In some embodiments of formula (I), R 5 is a substituted or unsubstituted alkyl group. In some embodiments of Formula (I), R 5 In some embodiments of Formula (I), R 5 is a substituted alkyl. In some embodiments of Formula (I), R 5 It's hydroxymethyl.

[0277] In some embodiments of Formula (I), R 1 is unsubstituted pyridyl or unsubstituted phenyl. In some embodiments of Formula (I), R 1 is 2-pyridyl. In some embodiments of Formula (I), R 1 is phenyl or pyridyl, each of which is substituted with one or more (e.g., 1 or 2 or 3 or 1 to 4 or 1 to 3 or 2 to 4) substituents independently selected from the group consisting of cyano, halo, substituted or unsubstituted alkoxy, substituted or unsubstituted alkyl, and substituted or unsubstituted diazolidinyl. In some embodiments of Formula (I), R 1 is pyridinyl substituted by one or two halo groups selected from the group consisting of F and Cl. In some embodiments of formula (I), R 1 is pyridinyl substituted with -CF3. In some embodiments of formula (I), R 1 is phenyl substituted by one or more (e.g., 1 or 2 or 3 or 1 to 4 or 1 to 3 or 2 to 4) halo selected from the group consisting of F and Cl. In some embodiments of Formula (I), R 1 is phenyl substituted with one or more (e.g., 1 or 2 or 3 or 1 to 4 or 1 to 3 or 2 to 4) methyl groups. In some embodiments of Formula (I), R 1 is phenyl substituted with one or more (e.g., 1 or 2 or 3 or 1 to 4 or 1 to 3 or 2 to 4) cyano groups. In some embodiments of Formula (I), R 1 is phenyl substituted with one or more (e.g., 1 or 2 or 3 or 1 to 4 or 1 to 3 or 2 to 4) -CF3. In some embodiments of Formula (I), R 1 is phenyl substituted with one halo and one cyano. In some embodiments of formula (I), R1 is phenyl substituted with one Cl and one F. In some embodiments of Formula (I), R 1 is phenyl substituted with one halo and one -CF3. In some embodiments of formula (I), R 1 is phenyl substituted with a diazolidinyl group. In some embodiments of Formula (I), R 1 It is a phenyl group substituted by a diaziridinyl group substituted by a trifluoromethyl group.

[0278] In some embodiments of Formula (I), 2A and R 2B The carbon of the moiety is in the "S" stereochemical configuration. In some embodiments of formula (I), the 2A and R 2B It is understood that for any embodiment of Formula (I) and its subformulae provided herein, the present invention includes those wherein the carbon with R 2A and R 2B The embodiment wherein the carbon of the moiety is in the "S" stereochemical configuration and wherein the R 2A and R 2B An embodiment wherein the carbon of EMI14.1 is in the "R" stereochemical configuration.

[0279] It is to be understood that each variable described herein may be combined with other variables as if each and every combination were specifically and individually listed. For example, each R of Formula (I) 1 Can be used individually or collectively with R 2A 、R 2B 、R 3 、R 4 and R 5 It should also be understood that this applies to each combination of Formula (I) and the various subgroups of Formula (Ia)-2, Formula (Ib)-3, Formula (Ic)-4, Formula (Id)-5, Formula (Ie)-6, Formula (If)-7, Formula (Ig)-8, Formula (Ih)-9, Formula (Ii)-10, Formula (Ik-2)-11, Formula (Il)-12, Formula (Im)-13, Formula (In-1) and Formula (In-2) ​​described herein.

[0280] In another aspect, the compound of formula (I) is a compound of formula (Ia) or a pharmaceutically acceptable salt thereof:

[0281]

[0282] where R 1 is selected from the group consisting of: substituted or unsubstituted phenyl and substituted or unsubstituted pyridyl; R 2A is H or substituted or unsubstituted alkyl; R 2BR is selected from the group consisting of H, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted cycloalkenyl, substituted or unsubstituted cycloalkynyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl, and substituted or unsubstituted heteroaryl; 3 is a substituted or unsubstituted phenyl group or a substituted or unsubstituted pyridyl group; R 4 is H or substituted or unsubstituted alkyl; and R 5 is H or substituted or unsubstituted alkyl; wherein, when R 3 When R is a substituted or unsubstituted phenyl group, 1 It is a substituted or unsubstituted pyridyl group or a phenyl group substituted with at least one substituent other than a methyl group or a methoxy group.

[0283] In some embodiments of Formula (Ia), R 4 and R 5 are each independently H. In some embodiments of Formula (Ia), R 4 and R 5 At least one of them is not H.

[0284] In some embodiments of Formula (Ia), R 3 is a substituted or unsubstituted pyridyl group. In some embodiments of Formula (Ia), R 3 is 2-pyridyl. In some embodiments of Formula (Ia), R 3 is unsubstituted phenyl. In some embodiments of Formula (Ia), R 3 is phenyl or pyridyl, each of which is substituted with one or more (e.g., 1 or 2 or 3 or 1 to 4 or 1 to 3 or 2 to 4) halo substituents selected from the group consisting of F and Cl. In some embodiments of Formula (Ia), R 3 is phenyl or pyridyl, each of which is substituted with two halo substituents selected from the group consisting of F and Cl. In some embodiments of Formula (Ia), R 3 is phenyl or pyridyl, each of which is substituted with two Fs. In some embodiments of Formula (Ia), R 3 is phenyl or pyridyl, each of which is substituted with two Cl. In some embodiments of Formula (Ia), R 3 is phenyl or pyridyl, each of which is substituted with one F and one Cl. In some embodiments of Formula (Ia), R 3 is phenyl or pyridyl, each of which is substituted with one or more (e.g., 1 or 2 or 3 or 1 to 4 or 1 to 3 or 2 to 4) CN substituents. In some embodiments of Formula (Ia), R 3is phenyl or pyridyl, each of which is substituted with two CN substituents. In some embodiments of Formula (Ia), R 3 is phenyl or pyridyl, each of which is substituted with one halo and one CN substituent. In some embodiments of Formula (Ia), R 3 is phenyl or pyridyl, each of which is substituted with one Cl and one CN. In some embodiments of Formula (Ia), R 3 is phenyl or pyridyl, each of which is substituted with one F and one CN.

[0285] In some embodiments of Formula (Ia), R 2A is H. In some embodiments of Formula (Ia), R 2A is a substituted or unsubstituted alkyl group. In some embodiments of Formula (Ia), R 2A is a substituted or unsubstituted methyl group. In some embodiments of Formula (Ia), R 2A It's methyl.

[0286] In some embodiments of Formula (Ia), R 2B is H. In some embodiments of Formula (Ia), R 2B is a substituted or unsubstituted alkyl group. In some embodiments of Formula (Ia), R 2B is selected from the group consisting of methyl, isopropyl and propyl. 2B is alkyl substituted with hydroxy or substituted or unsubstituted alkoxy. In some embodiments of Formula (Ia), R 2B In some embodiments of Formula (Ia), R 2B is a substituted alkoxyalkyl. In some embodiments of Formula (Ia), R 2B is trifluoromethoxymethyl. In some embodiments of Formula (Ia), R 2B is a substituted or unsubstituted cycloalkyl. In some embodiments of Formula (Ia), R 2B is a substituted or unsubstituted C3-C7 cycloalkyl. In some embodiments of Formula (Ia), R 2B In some embodiments of Formula (Ia), R 2B is a substituted or unsubstituted heterocyclyl. In some embodiments of Formula (Ia), R 2B is a substituted or unsubstituted C3-C7 heterocyclyl. In some embodiments of Formula (Ia), R 2B is a substituted or unsubstituted C3-C7 heterocyclyl containing one or more (e.g., 1 or 2 or 3 or 1 to 4 or 1 to 3 or 2 to 4) N or O ring atoms. In some embodiments of Formula (Ia), R 2BIn some embodiments of Formula (Ia), R 2B It is 3-oxetanyl.

[0287] In some embodiments of Formula (Ia), R 1 is a substituted or unsubstituted pyridyl group. In some embodiments of Formula (Ia), R 1 is 2-pyridyl. In some embodiments of Formula (Ia), R 1 is unsubstituted phenyl. In some embodiments of Formula (Ia), R 1 is phenyl or pyridyl, each of which is substituted with one or more (e.g., 1 or 2 or 3 or 1 to 4 or 1 to 3 or 2 to 4) substituents independently selected from the group consisting of cyano, halo, alkoxy, -CF3, alkyl, and diaziridinyl. In some embodiments of Formula (Ia), R 1 is phenyl or pyridyl, each of which is substituted with substituted alkyl. In some embodiments of Formula (Ia), R 1 is phenyl or pyridyl, each of which is substituted with -CF3. In some embodiments of Formula (Ia), R 1 It is a phenyl group substituted by 4-CF3.

[0288] In some embodiments of Formula (Ia), R 1 is a phenyl group substituted with -CF3 and R 3 is phenyl substituted with two halo substituents. In some embodiments of Formula (Ia), R 1 is a phenyl group substituted with -CF3 and R 3 is phenyl substituted with one halo and one CN. In some embodiments of Formula (Ia), R 1 is a substituted or unsubstituted pyridyl group and R 3 is phenyl substituted with two halo groups. In some embodiments of Formula (Ia), R 1 is a substituted or unsubstituted pyridyl group and R 3 is phenyl substituted with one halo and one CN. In some embodiments of Formula (Ia), R 1 is 2-pyridyl and R 3 is phenyl substituted with two halo groups. In some embodiments of Formula (Ia), R 1 is 2-pyridyl and R 3 is phenyl substituted with one halo and one CN. In some embodiments of Formula (Ia), R 1 is a phenyl group substituted with -CF3 and R 3 It is phenyl.

[0289] In some embodiments of Formula (Ia), R 1is a phenyl group substituted by -CF3, R 2A It's H, R 2B is 3-oxetanyl, R 3 is phenyl substituted with one or more substituents selected from the group consisting of F and Cl, R 4 is H, and R 5 is H. In some embodiments of Formula (Ia), R 1 is a phenyl group substituted by -CF3, R 2A It's H, R 2B is 3-oxetanyl, R 3 is pyridyl substituted with one or more substituents selected from the group consisting of F and Cl, R 4 is H, and R 5 is H. In some embodiments of Formula (Ia), R 1 is a phenyl group substituted by -CF3, R 2A It's H, R 2B is isopropyl, R 3 is phenyl substituted with one or more substituents selected from the group consisting of F and Cl, R 4 is H, and R 5 is H. In some embodiments of Formula (Ia), R 1 is a phenyl group substituted by -CF3, R 2A It's H, R 2B is isopropyl, R 3 is pyridyl substituted with one or more substituents selected from the group consisting of F and Cl, R 4 is H, and R 5 It’s H.

[0290] In some embodiments of Formula (Ia): R 4 and R 5 Each independently represents H; R 3 is phenyl or pyridyl, each of which is substituted with two halo substituents selected from the group consisting of F and Cl; R 2A is H or methyl; R 2B is selected from the group consisting of methyl, isopropyl, propyl, hydroxymethyl, trifluoromethoxymethyl, cyclobutyl and 3-oxetanyl; and R 1 is phenyl or pyridyl, each of which is substituted by -CF3.

[0291] In another aspect, the compound of formula (I) is a compound of formula (Ib) or a pharmaceutically acceptable salt thereof:

[0292]

[0293] where R 1is selected from the group consisting of: substituted or unsubstituted phenyl and substituted or unsubstituted pyridyl; R 2A is H or substituted or unsubstituted alkyl; R 2B is a substituted or unsubstituted phenyl group or a substituted or unsubstituted pyridyl group; R 3 is a substituted or unsubstituted alkyl group; R 4 is H or substituted or unsubstituted alkyl; and R 5 is H or substituted or unsubstituted alkyl; wherein, when R 2B When it is 4-methoxyphenyl, R 1 It is a substituted or unsubstituted pyridyl group or a phenyl group substituted with at least one substituent other than a methyl group or a methoxy group.

[0294] In some embodiments of Formula (Ib), R 4 and R 5 are each independently H. In some embodiments of Formula (Ib), R 4 and R 5 At least one of them is not H.

[0295] In some embodiments of Formula (Ib), R 2A is H. In some embodiments of Formula (Ib), R 2A is a substituted or unsubstituted alkyl group. In some embodiments of Formula (Ib), R 2A is a substituted or unsubstituted methyl group. In some embodiments of Formula (Ia), R 2A It's methyl.

[0296] In some embodiments of Formula (Ib), R 2B is a substituted or unsubstituted pyridinyl group. In some embodiments of Formula (Ib), R 2B In some embodiments, R 2B is a substituted or unsubstituted phenyl group. In some embodiments of Formula (Ib), R 2B is phenyl or pyridyl, each of which is substituted with one or more (e.g., 1 or 2 or 3 or 1 to 4 or 1 to 3 or 2 to 4) substituents independently selected from the group consisting of halo, substituted or unsubstituted alkoxy, and substituted or unsubstituted alkyl. In some embodiments of Formula (Ib), R 2B is pyridinyl substituted with one or more (e.g., 1 or 2 or 3 or 1 to 4 or 1 to 3 or 2 to 4) substituents selected from the group consisting of halo and substituted or unsubstituted alkyl. In some embodiments of Formula (Ib), R 2Bis pyridinyl substituted by one or more (eg, 1 or 2 or 3 or 1 to 4 or 1 to 3 or 2 to 4) halo. In some embodiments of Formula (Ib), R 2B is phenyl substituted by one or more (eg, 1 or 2 or 3 or 1 to 4 or 1 to 3 or 2 to 4) halo. In some embodiments of Formula (Ib), R 2B is phenyl substituted with one or more (e.g., 1 or 2 or 3 or 1 to 4 or 1 to 3 or 2 to 4) -CF3. In some embodiments of Formula (Ib), R 2B is phenyl substituted with one or more (eg, 1 or 2 or 3 or 1 to 4 or 1 to 3 or 2 to 4) alkoxy groups. In some embodiments of Formula (Ib), R 2B is phenyl substituted by one or more (eg, 1 or 2 or 3 or 1 to 4 or 1 to 3 or 2 to 4) methoxy groups.

[0297] In some embodiments of Formula (Ib), R 3 is substituted or unsubstituted C1-C 10 In some embodiments of Formula (Ib), R 3 is an unsubstituted C1-C 10 In some embodiments of Formula (Ib), R 3 is an unsubstituted C2-C6 alkyl. In some embodiments of Formula (Ib), R 3 is an unsubstituted C3-C5 alkyl. In some embodiments of Formula (Ib), R 3 is an unsubstituted C3 alkyl. In some embodiments of Formula (Ib), R 3 is an unsubstituted isopropyl group.

[0298] In some embodiments of Formula (Ib), R 1 is a substituted or unsubstituted pyridinyl group. In some embodiments of Formula (Ib), R 1 is 2-pyridyl. In some embodiments of Formula (Ib), R 1 is a substituted or unsubstituted phenyl group. In some embodiments of Formula (Ib), R 1 is phenyl or pyridyl, each of which is substituted with one or more (e.g., 1 or 2 or 3 or 1 to 4 or 1 to 3 or 2 to 4) substituents independently selected from the group consisting of cyano, halo, substituted or unsubstituted alkoxy, substituted or unsubstituted alkyl, and substituted or unsubstituted diazolidinyl. In some embodiments of Formula (Ib), R 1is pyridinyl substituted by one or more (eg, 1 or 2 or 3 or 1 to 4 or 1 to 3 or 2 to 4) halo. In some embodiments of Formula (Ib), R 1 is pyridinyl substituted with one or more (e.g., 1 or 2 or 3 or 1 to 4 or 1 to 3 or 2 to 4) -CF3. In some embodiments of Formula (Ib), R 1 is phenyl substituted by one or more (eg, 1 or 2 or 3 or 1 to 4 or 1 to 3 or 2 to 4) halo. In some embodiments of Formula (Ib), R 1 is phenyl substituted with one or more (e.g., 1 or 2 or 3 or 1 to 4 or 1 to 3 or 2 to 4) -CF3. In some embodiments of Formula (Ib), R 1 is phenyl substituted with one or more (e.g., 1 or 2 or 3 or 1 to 4 or 1 to 3 or 2 to 4) -CN. In some embodiments of Formula (Ib), R 1 is phenyl substituted by one or more (eg, 1 or 2 or 3 or 1 to 4 or 1 to 3 or 2 to 4) methyl groups.

[0299] In some embodiments of Formula (Ib), R 2B is 4-methoxyphenyl and R 1 is a substituted or unsubstituted pyridinyl group. In some embodiments of Formula (Ib), R 2B is 4-methoxyphenyl and R 1 is 2-pyridyl. In some embodiments of Formula (Ib), R 2B is 4-methoxyphenyl and R 1 is 2-pyridyl substituted by one or more (e.g., 1 or 2 or 3 or 1 to 4 or 1 to 3 or 2 to 4) halo. In some embodiments of Formula (Ib), R 2B is 4-methoxyphenyl and R 1 is phenyl substituted by one or more (eg, 1 or 2 or 3 or 1 to 4 or 1 to 3 or 2 to 4) halo. In some embodiments of Formula (Ib), R 2B is 4-methoxyphenyl and R 1 It is a phenyl group substituted by 4-Cl.

[0300] In some embodiments of Formula (Ib), R 1 is pyridyl substituted by one or more substituents independently selected from the group consisting of halo and -CF3, R 2A It's H, R 2B is pyridyl substituted with one or more substituents selected from the group consisting of F and Cl, R 3is isopropyl, R 4 is H, and R 5 is H. In some embodiments of Formula (Ib), R 1 is phenyl substituted by one or more substituents independently selected from the group consisting of halo, -CF3, -CN and methyl, R 2A It's H, R 2B is pyridyl substituted with one or more substituents selected from the group consisting of F and Cl, R 3 is isopropyl, R 4 is H, and R 5 is H. In some embodiments of Formula (Ib), R 1 is pyridyl substituted by one or more substituents independently selected from the group consisting of halo and -CF3, R 2A is methyl, R 2B is pyridyl substituted with one or more substituents selected from the group consisting of F and Cl, R 3 is isopropyl, R 4 is H, and R 5 is H. In some embodiments of Formula (Ib), R 1 is phenyl substituted by one or more substituents independently selected from the group consisting of halo, -CF3, -CN and methyl, R 2A is methyl, R 2B is pyridyl substituted with one or more substituents selected from the group consisting of F and Cl, R 3 is isopropyl, R 4 is H, and R 5 It’s H.

[0301] In another aspect, the compound of formula (I) is a compound of formula (Ic) or a pharmaceutically acceptable salt thereof:

[0302]

[0303] where R 1 is selected from the group consisting of substituted or unsubstituted pyridyl and substituted or unsubstituted phenyl; R 2A and R 2B Together with the carbon atom to which they are attached, they form G 1 , where G 1 is a substituted or unsubstituted cycloalkyl, substituted or unsubstituted cycloalkenyl, substituted or unsubstituted cycloalkynyl, or substituted or unsubstituted heterocyclyl ring, each of which is optionally fused to a phenyl ring; R 3is selected from the group consisting of substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted cycloalkenyl, substituted or unsubstituted cycloalkynyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl, and substituted or unsubstituted heteroaryl; R 4 is H or substituted or unsubstituted alkyl; and R 5 is H or substituted or unsubstituted alkyl; wherein, when R 3 When it is 4-methoxyphenylmethyl, R 1 It is a substituted or unsubstituted pyridyl group or a phenyl group substituted with at least one substituent other than a methyl group or a methoxy group.

[0304] In some embodiments of Formula (Ic), R 4 and R 5 are each independently H. In some embodiments of Formula (Ic), R 4 and R 5 At least one of them is not H. In some embodiments of Formula (Ic), R 4 is a substituted or unsubstituted alkyl group. In some embodiments of Formula (Ic), R 4 In some embodiments of Formula (Ic), R 4 is an alkyl group substituted with an alkoxy group. In some embodiments of Formula (Ic), R 4 is methoxymethyl. In some embodiments of Formula (Ic), R 5 is a substituted or unsubstituted alkyl group. In some embodiments of Formula (Ic), R 5 In some embodiments of Formula (Ic), R 5 is a substituted alkyl. In some embodiments of Formula (Ic), R 5 It's hydroxymethyl.

[0305] In some embodiments of Formula (Ic), G 1 is selected from the group consisting of substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocyclyl, and substituted or unsubstituted 2,3-dihydro-1H-indene. In some embodiments of Formula (Ic), G 1 is a substituted or unsubstituted C3-C6 cycloalkyl. In some embodiments of Formula (Ic), G 1 is a substituted or unsubstituted C3-C6 heterocyclyl. In some embodiments of Formula (Ic), G 1 is a substituted or unsubstituted cyclopropyl. In some embodiments of Formula (Ic), G 1 is a substituted or unsubstituted cyclobutyl. In some embodiments of Formula (Ic), G 1is a substituted or unsubstituted azetidinyl group. In some embodiments of Formula (Ic), G 1 is substituted or unsubstituted tetrahydrofuranyl. In some embodiments of Formula (Ic), G 1 is a substituted or unsubstituted pyrrolidinyl group. In some embodiments of Formula (Ic), G 1 is a substituted or unsubstituted pyrrolidin-2-one-yl group.

[0306] In some embodiments of Formula (Ic), G 1 is a heterocyclyl or cycloalkyl group, each of which is substituted by one or more (e.g., 1 or 2 or 3 or 1 to 4 or 1 to 3 or 2 to 4) substituents selected from the group consisting of substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted alkoxycarbonyl, substituted or unsubstituted aminoacyl, substituted or unsubstituted acyl, substituted or unsubstituted aminosulfinyl, substituted or unsubstituted aminocarbonylamino, and substituted or unsubstituted alkyl. In some embodiments of Formula (Ic), G 1 is a heterocyclyl substituted with substituted or unsubstituted phenyl. In some embodiments of Formula (Ic), G 1 is a heterocyclyl substituted by a phenyl group substituted by a halo group. In some embodiments of Formula (Ic), G 1 is a heterocyclyl substituted with a substituted or unsubstituted heteroaryl. In some embodiments of Formula (Ic), G 1 is a heterocyclyl substituted with a substituted or unsubstituted pyridyl. In some embodiments of Formula (Ic), G 1 is a heterocyclyl substituted with one or more (e.g., 1 or 2 or 3 or 1 to 4 or 1 to 3 or 2 to 4) substituents selected from the group consisting of alkyl, CN, hydroxy, alkoxycarbonyl, methoxycarbonyl, alkoxy, carboxyl, cycloalkyl, halo, and aminoacyl. In some embodiments of Formula (Ic), G 1 is a heterocyclyl substituted with a substituted or unsubstituted pyrimidinyl. In some embodiments of Formula (Ic), G 1 is a heterocyclyl substituted with substituted or unsubstituted pyrazolyl. In some embodiments of Formula (Ic), G 1 is a heterocyclyl substituted with an alkyl-substituted pyrazolyl. In some embodiments of Formula (Ic), G 1 is a heterocyclyl substituted with a substituted or unsubstituted thiazolyl. In some embodiments of Formula (Ic), G 1 is a heterocyclyl substituted with a thiazolyl substituted with an aminoacyl group. In some embodiments of Formula (Ic), G 1 is a heterocyclyl substituted with a substituted or unsubstituted alkoxycarbonyl. In some embodiments of Formula (Ic), G 1is a heterocyclyl substituted with methoxycarbonyl. In some embodiments of Formula (Ic), G 1 is a heterocyclyl substituted with a substituted or unsubstituted aminoacyl. In some embodiments of Formula (Ic), G 1 is a heterocyclyl substituted with a methylaminoacyl group. In some embodiments of Formula (Ic), G 1 is an aminoacyl-substituted heterocyclyl substituted with one or more (e.g., 1 or 2 or 3 or 1 to 4 or 1 to 3 or 2 to 4) substituents selected from the group consisting of aryl, cycloalkyl, pyridyl, pyrazolyl, and alkoxyalkyl. In some embodiments of Formula (Ic), G 1 is a heterocyclyl substituted with a substituted or unsubstituted pyridin-one-yl. In some embodiments of Formula (Ic), G 1 is a heterocyclyl substituted with an alkyl-substituted pyridin-one-yl. In some embodiments of Formula (Ic), G 1 is a heterocyclyl substituted with a substituted or unsubstituted oxadiazolyl. In some embodiments of Formula (Ic), G 1 is a heterocyclyl substituted with one or more (e.g., 1 or 2 or 3 or 1 to 4 or 1 to 3 or 2 to 4) substituents selected from the group consisting of alkyl and phenyl. In some embodiments of Formula (Ic), G 1 is a heterocyclyl substituted with a substituted or unsubstituted 9-membered bicyclic heterocyclyl. In some embodiments of Formula (Ic), G 1 is a heterocyclyl substituted with -C(O)H. In some embodiments of Formula (Ic), G 1 is a heterocyclyl substituted with a substituted or unsubstituted pyridazinyl. In some embodiments of Formula (Ic), G 1 is a heterocyclyl substituted with one or more (e.g., 1 or 2 or 3 or 1 to 4 or 1 to 3 or 2 to 4) substituents selected from the group consisting of halo, alkoxy, alkyl, and aminoacyl. In some embodiments of Formula (Ic), G 1 is a heterocyclyl substituted with a substituted or unsubstituted aminosulfinyl. In some embodiments of Formula (Ic), G 1 is a heterocyclyl substituted with an aminosulfinyl substituted with an alkyl group. In some embodiments of Formula (Ic), G 1 is a heterocyclyl substituted with substituted or unsubstituted acyl. In some embodiments of Formula (Ic), G 1 is an acyl-substituted heterocyclyl substituted with one or more (e.g., 1 or 2 or 3 or 1 to 4 or 1 to 3 or 2 to 4) substituents selected from the group consisting of cycloalkyl, alkyl, and heterocyclyl. In some embodiments of Formula (Ic), G 1is a heterocyclyl substituted with an acyl substituted with a morpholinyl. In some embodiments of Formula (Ic), G 1 is a heterocyclyl substituted with a substituted or unsubstituted aminocarbonylamino group. In some embodiments of Formula (Ic), G 1 is an aminocarbonylamino-substituted heterocyclyl substituted by one or more (eg, 1 or 2 or 3 or 1 to 4 or 1 to 3 or 2 to 4) substituents selected from the group consisting of cycloalkyl and heterocyclyl.

[0307] In some embodiments of Formula (Ic), G 1 is a cycloalkyl group substituted with substituted or unsubstituted phenyl. In some embodiments of Formula (Ic), G 1 is a cycloalkyl group substituted with a substituted or unsubstituted thiazolyl group. In some embodiments of Formula (Ic), G 1 is a cycloalkyl group substituted with an alkyl group substituted with a thiazolyl group. In some embodiments of Formula (Ic), G 1 is a cycloalkyl group substituted with substituted or unsubstituted oxazolyl. In some embodiments of Formula (Ic), G 1 is cycloalkyl substituted with oxazolyl substituted with alkyl. In some embodiments of Formula (Ic), G 1 is a cycloalkyl group substituted with a substituted or unsubstituted aminoacyl group. In some embodiments of Formula (Ic), G 1 Cycloalkyl substituted with one or more (e.g., 1 or 2 or 3 or 1 to 4 or 1 to 3 or 2 to 4) substituents selected from the group consisting of alkyl, heterocyclyl, and cycloalkyl. In some embodiments of Formula (Ic), G 1 is a cycloalkyl group substituted with a substituted or unsubstituted oxadiazolyl group. In some embodiments of Formula (Ic), G 1 is cycloalkyl substituted with one or more (e.g., 1 or 2 or 3 or 1 to 4 or 1 to 3 or 2 to 4) substituents selected from the group consisting of cycloalkyl and alkyl. In some embodiments of Formula (Ic), G 1 is a cycloalkyl group substituted with substituted or unsubstituted acyl. In some embodiments of Formula (Ic), G 1 is cycloalkyl substituted with acyl substituted with heterocyclyl. In some embodiments of Formula (Ic), G 1 is a cycloalkyl group substituted with a substituted or unsubstituted aminocarbonylamino group. In some embodiments of Formula (Ic), G 1 is an aminocarbonylamino-substituted cycloalkyl group substituted with one or more (e.g., 1 or 2 or 3 or 1 to 4 or 1 to 3 or 2 to 4) substituents selected from the group consisting of alkyl, cycloalkyl, and heterocyclyl. In some embodiments of Formula (Ic), G1 is a cycloalkyl group substituted with a substituted or unsubstituted alkoxycarbonyl group. In some embodiments of Formula (Ic), G 1 is a cycloalkyl substituted with an alkyl substituted alkoxycarbonyl. In some embodiments of Formula (Ic), G 1 is a cycloalkyl group substituted with a substituted or unsubstituted alkyl group. In some embodiments of Formula (Ic), G 1 is a cycloalkyl substituted with an alkyl substituted with a hydroxy group. In some embodiments of Formula (Ic), G 1 It is a cycloalkyl group substituted with a hydroxy group.

[0308] In some embodiments of Formula (Ic), R 3 is selected from the group consisting of substituted or unsubstituted alkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocyclyl, and substituted or unsubstituted aryl. In some embodiments of Formula (Ic), R 3 is phenyl substituted with one or more (e.g., 1 or 2 or 3 or 1 to 4 or 1 to 3 or 2 to 4) substituents selected from the group consisting of nitro, alkoxy, halo, cycloalkyl, cyano, alkenyl, alkoxycarbonyl, phenylcarbonyl, and alkyl. In some embodiments of Formula (Ic), R 3 is cycloalkyl substituted with one or more (e.g., 1 or 2 or 3 or 1 to 4 or 1 to 3 or 2 to 4) substituents selected from the group consisting of alkyl, cyano, and halo. In some embodiments of Formula (Ic), R 3 is an alkyl group substituted with one or more (eg, 1 or 2 or 3 or 1 to 4 or 1 to 3 or 2 to 4) substituents selected from the group consisting of alkoxy, cyano, and halo.

[0309] In some embodiments of Formula (Ic), R 1 is a substituted or unsubstituted pyridinyl. In some embodiments of Formula (Ic), R 1 is 2-pyridyl. In some embodiments of Formula (Ic), R 1 is substituted or unsubstituted phenyl. In some embodiments of Formula (Ic), R 1 is phenyl or pyridyl, each of which is substituted with one or more (e.g., 1 or 2 or 3 or 1 to 4 or 1 to 3 or 2 to 4) substituents independently selected from the group consisting of cyano, halo, substituted or unsubstituted alkoxy, substituted or unsubstituted alkyl, and substituted or unsubstituted diazolidinyl. In some embodiments of Formula (Ic), R 1 is phenyl substituted by one or more (eg, 1 or 2 or 3 or 1 to 4 or 1 to 3 or 2 to 4) halo. In some embodiments of Formula (Ic), R1 is phenyl substituted with one or more (e.g., 1 or 2 or 3 or 1 to 4 or 1 to 3 or 2 to 4) -CF3. In some embodiments of Formula (Ic), R 1 is phenyl substituted with one or more (e.g., 1 or 2 or 3 or 1 to 4 or 1 to 3 or 2 to 4) methyl groups. In some embodiments of Formula (Ic), R 1 is phenyl substituted with one or more (e.g., 1 or 2 or 3 or 1 to 4 or 1 to 3 or 2 to 4) diaziridinyl groups. In some embodiments of Formula (Ic), R 1 It is a phenyl group substituted by a trifluoromethyldiazirinyl group.

[0310] In some embodiments of Formula (Ic), R 1 is a phenyl group substituted with Cl and R 3 is substituted with 4-methoxyphenylmethyl. In some embodiments of Formula (Ic), R 1 is a phenyl group substituted by F and R 3 is substituted with 4-methoxyphenylmethyl. In some embodiments of Formula (Ic), R 1 is a phenyl group substituted with -CF3 and R 3 is substituted with 4-methoxyphenylmethyl. In some embodiments of Formula (Ic), R 1 is a phenyl group substituted with a trifluoromethyldiazirinyl group and R 3 Substituted with 4-methoxyphenylmethyl.

[0311] In another aspect, the compound of formula (I) is a compound of formula (Id) or a pharmaceutically acceptable salt thereof:

[0312]

[0313] where R 2A is H or substituted or unsubstituted alkyl; R 2B is selected from the group consisting of H, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted cycloalkenyl, substituted or unsubstituted cycloalkynyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl, and substituted or unsubstituted heteroaryl; n is 0, 1, or 2; each R 3a are independently selected from the group consisting of halo and cyano; and R 4 It’s H.

[0314] In some embodiments of Formula (Id), R 2A is H. In some embodiments of Formula (Id), R 2Ais a substituted or unsubstituted alkyl. In some embodiments of Formula (Id), R 2A is a substituted or unsubstituted methyl group. In some embodiments of Formula (Id), R 2A It's methyl.

[0315] In some embodiments of Formula (Id), R 2B is H. In some embodiments of Formula (Id), R 2B is a substituted or unsubstituted alkyl. In some embodiments of Formula (Id), R 2B is selected from the group consisting of methyl, isopropyl, and propyl. 2B is alkyl substituted with hydroxy or substituted or unsubstituted alkoxy. In some embodiments of Formula (Id), R 2B In some embodiments of Formula (Id), R 2B is a substituted alkoxyalkyl. In some embodiments of Formula (Id), R 2B is trifluoromethoxymethyl. In some embodiments of Formula (Id), R 2B is a substituted or unsubstituted cycloalkyl. In some embodiments of Formula (Id), R 2B is a substituted or unsubstituted C3-C7 cycloalkyl. In some embodiments of Formula (Id), R 2B In some embodiments of Formula (Id), R 2B is a substituted or unsubstituted heterocyclyl. In some embodiments of Formula (Id), R 2B is a substituted or unsubstituted C3-C7 heterocyclyl. In some embodiments of Formula (Id), R 2B is a substituted or unsubstituted C3-C7 heterocyclyl containing one or more (e.g., 1 or 2 or 3 or 1 to 4 or 1 to 3 or 2 to 4) S, N, or O ring atoms. In some embodiments of Formula (Id), R 2B In some embodiments of Formula (Id), R 2B It is 3-oxetanyl.

[0316] In some embodiments of Formula (Id), n is 0. In some embodiments of Formula (Id), n is 1. In some embodiments of Formula (Id), n is 2. In some embodiments of Formula (Id), each R 3a is halo, such as Cl or F. In some embodiments of Formula (Id), each R 3a In some embodiments of Formula (Id), n is 2, one R 3a is halogenated and one R 3aIn some embodiments of Formula (Id), n is 2 and both R 3a In some embodiments of Formula (Id), n is 2 and both R 3a In some embodiments of Formula (Id), n is 2 and R 3a is 2-F and 4-F. In some embodiments of Formula (Id), n is 2 and R 3a In some embodiments of Formula (Id), n is 2 and R 3a is 2-F and 4-Cl. In some embodiments of Formula (Id), n is 2 and R 3a is 2-F and 4-CN. In some embodiments of Formula (Id), n is 2 and R 3a is 2-Cl and 4-CN. In some embodiments of Formula (Id), n is 2 and R 3a In some embodiments of Formula (Id), n is 2 and R 3a is 2-CN and 4-F. In some embodiments of Formula (Id), n is 2 and R 3a They are 2-CN and 4-CN.

[0317] In some embodiments of Formula (Id), R 2A It's H, R 2B is trifluoromethoxymethyl, n is 1, and R 3a is cyano or halo. In some embodiments of Formula (Id), R 2A It's H, R 2B is 3-oxetanyl, n is 1, and R 3a is cyano or halo. In some embodiments of Formula (Id), R 2A It's H, R 2B is cyclobutyl, n is 1, and R 3a is cyano or halo. In some embodiments of Formula (Id), R 2A It's H, R 2B is trifluoromethoxymethyl, n is 2, and each R 3a is independently cyano or halo. In some embodiments of Formula (Id), R 2A It's H, R 2B is 3-oxetanyl, n is 2, and each R 3a is independently cyano or halo. In some embodiments of Formula (Id), R 2A It's H, R 2B is cyclobutyl, n is 2, and each R 3a are independently cyano or halo.

[0318] In another aspect, the compound of formula (I) is a compound of formula (Ie) or a pharmaceutically acceptable salt thereof:

[0319]

[0320] where R 1 is selected from the group consisting of: substituted or unsubstituted phenyl and substituted or unsubstituted pyridyl; R 2A is H or substituted or unsubstituted alkyl; R 2B is substituted or unsubstituted phenyl or substituted or unsubstituted pyridyl; and R 4 is H; among them, when R 2B When it is 4-methoxyphenyl, R 1 It is a substituted or unsubstituted pyridyl group or a phenyl group substituted with at least one substituent other than a methyl group or a methoxy group.

[0321] In some embodiments of Formula (Ie), R 2A is H. In some embodiments of Formula (Ie), R 2A is a substituted or unsubstituted alkyl group. In some embodiments of Formula (Ie), R 2A is a substituted or unsubstituted methyl group. In some embodiments of Formula (Ie), R 2A It's methyl.

[0322] In some embodiments of Formula (Ie), R 2B is a substituted or unsubstituted pyridinyl. In some embodiments of Formula (Ie), R 2B In some embodiments, R 2B is a substituted or unsubstituted phenyl group. In some embodiments of Formula (Ie), R 2B is phenyl or pyridyl, each of which is substituted with one or more (e.g., 1 or 2 or 3 or 1 to 4 or 1 to 3 or 2 to 4) substituents independently selected from the group consisting of halo, substituted or unsubstituted alkoxy, and substituted or unsubstituted alkyl. In some embodiments of Formula (Ie), R 2B is pyridinyl substituted with one or more (e.g., 1 or 2 or 3 or 1 to 4 or 1 to 3 or 2 to 4) substituents selected from the group consisting of halo and substituted or unsubstituted alkyl. In some embodiments of Formula (Ie), R 2B is pyridinyl substituted by one or more (eg, 1 or 2 or 3 or 1 to 4 or 1 to 3 or 2 to 4) halo. In some embodiments of Formula (Ie), R 2B is phenyl substituted by one or more (eg, 1 or 2 or 3 or 1 to 4 or 1 to 3 or 2 to 4) halo. In some embodiments of Formula (Ie), R2B is phenyl substituted with one or more (e.g., 1 or 2 or 3 or 1 to 4 or 1 to 3 or 2 to 4) -CF3. In some embodiments of Formula (Ie), R 2B is phenyl substituted with one or more (eg, 1 or 2 or 3 or 1 to 4 or 1 to 3 or 2 to 4) alkoxy groups. In some embodiments of Formula (Ie), R 2B is phenyl substituted by one or more (eg, 1 or 2 or 3 or 1 to 4 or 1 to 3 or 2 to 4) methoxy groups.

[0323] In some embodiments of Formula (Ie), R 1 is a substituted or unsubstituted pyridinyl. In some embodiments of Formula (Ie), R 1 is 2-pyridyl. In some embodiments of Formula (Ie), R 1 is unsubstituted phenyl. In some embodiments of Formula (Ie), R 1 is phenyl or pyridyl, each of which is substituted with one or more substituents independently selected from the group consisting of cyano, halo, and substituted or unsubstituted alkyl. In some embodiments of Formula (Ie), R 1 is pyridinyl substituted by one or more (eg, 1 or 2 or 3 or 1 to 4 or 1 to 3 or 2 to 4) halo. In some embodiments of Formula (Ie), R 1 is pyridinyl substituted with one or more (e.g., 1 or 2 or 3 or 1 to 4 or 1 to 3 or 2 to 4) -CF3. In some embodiments of Formula (Ie), R 1 is phenyl substituted by one or more (eg, 1 or 2 or 3 or 1 to 4 or 1 to 3 or 2 to 4) halo. In some embodiments of Formula (Ie), R 1 is phenyl substituted with one or more (e.g., 1 or 2 or 3 or 1 to 4 or 1 to 3 or 2 to 4) -CF3. In some embodiments of Formula (Ie), R 1 is phenyl substituted with one or more (e.g., 1 or 2 or 3 or 1 to 4 or 1 to 3 or 2 to 4) CN. In some embodiments of Formula (Ie), R 1 is phenyl substituted by one or more (eg, 1 or 2 or 3 or 1 to 4 or 1 to 3 or 2 to 4) methyl groups.

[0324] In some embodiments of Formula (Ie), R 2B is 4-methoxyphenyl and R 1 is a substituted or unsubstituted pyridinyl. In some embodiments of Formula (Ie), R 2Bis 4-methoxyphenyl and R 1 is 2-pyridyl. In some embodiments of Formula (Ie), R 2B is 4-methoxyphenyl and R 1 is 2-pyridyl substituted by one or more (e.g., 1 or 2 or 3 or 1 to 4 or 1 to 3 or 2 to 4) halo. In some embodiments of Formula (Ie), R 2B is 4-methoxyphenyl and R 1 is phenyl substituted by one or more (eg, 1 or 2 or 3 or 1 to 4 or 1 to 3 or 2 to 4) halo. In some embodiments of Formula (Ie), R 2B is 4-methoxyphenyl and R 1 It is a phenyl group substituted by 4-Cl.

[0325] In another aspect, the compound of formula (I) is a compound of formula (If) or a pharmaceutically acceptable salt thereof:

[0326]

[0327] Among them G 1 is selected from the group consisting of a substituted or unsubstituted cycloalkyl, a substituted or unsubstituted cycloalkenyl, a substituted or unsubstituted cycloalkynyl, and a substituted or unsubstituted heterocyclyl ring, each of which is optionally fused to a phenyl ring; R 1a is selected from the group consisting of cyano, halo, substituted or unsubstituted alkoxy, substituted or unsubstituted alkyl and substituted or unsubstituted heterocyclyl; each R 2a R is independently selected from the group consisting of substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted alkoxycarbonyl, substituted or unsubstituted aminoacyl, substituted or unsubstituted acyl, substituted or unsubstituted aminosulfonyl, substituted or unsubstituted aminocarbonylamino, and substituted or unsubstituted alkyl; n is 0, 1, 2, or 3; R 3 is selected from the group consisting of substituted or unsubstituted alkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocyclyl, and substituted or unsubstituted aryl; and R 4 is H; among them, when R 3 When it is 4-methoxyphenylmethyl, R 1a Not methyl or methoxy.

[0328] It should be understood that G 1 The group is a ring including the carbon atom it shares with the piperazinedione ring.

[0329] In some embodiments of Formula (If), G 1is selected from the group consisting of substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocyclyl, and substituted or unsubstituted 2,3-dihydro-1H-indene. In some embodiments of Formula (Ic), G 1 is a substituted or unsubstituted C3-C6 cycloalkyl. In some embodiments of Formula (Ic), G 1 is a substituted or unsubstituted C3-C6 heterocyclyl. In some embodiments of Formula (Ic), G 1 is a substituted or unsubstituted cyclopropyl. In some embodiments of Formula (Ic), G 1 is a substituted or unsubstituted cyclobutyl. In some embodiments of Formula (Ic), G 1 is a substituted or unsubstituted azetidinyl group. In some embodiments of Formula (Ic), G 1 is substituted or unsubstituted tetrahydrofuranyl. In some embodiments of Formula (Ic), G 1 is a substituted or unsubstituted pyrrolidinyl group. In some embodiments of Formula (Ic), G 1 is a substituted or unsubstituted pyrrolidin-2-one-yl group.

[0330] In some embodiments of Formula (If), G 1 is one or more (e.g. 1 or 2 or 3 or 1 to 4 or 1 to 3 or 2 to 4) R 2a Substituted heterocyclic group. Each R 2a is selected from the group consisting of substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted alkoxycarbonyl, substituted or unsubstituted aminoacyl, substituted or unsubstituted acyl, substituted or unsubstituted aminosulfinyl, substituted or unsubstituted aminocarbonylamino, and substituted or unsubstituted alkyl. In some embodiments of Formula (If), R 2a is a substituted or unsubstituted phenyl group. In some embodiments of Formula (If), R 2a is phenyl substituted by halo. In some embodiments of Formula (If), R 2a is a substituted or unsubstituted heteroaryl. In some embodiments of Formula (If), R 2a is a substituted or unsubstituted pyridinyl. In some embodiments of Formula (If), R 2a is pyridinyl substituted with one or more (e.g., 1 or 2 or 3 or 1 to 4 or 1 to 3 or 2 to 4) substituents selected from the group consisting of alkyl, CN, hydroxy, alkoxycarbonyl, methoxycarbonyl, alkoxy, carboxyl, cycloalkyl, halo, and aminoacyl. In some embodiments of Formula (If), R 2a is a substituted or unsubstituted pyrimidinyl. In some embodiments of Formula (If), R 2ais substituted or unsubstituted pyrazolyl. In some embodiments of Formula (If), R 2a is pyrazolyl substituted with alkyl. In some embodiments of Formula (If), R 2a is a substituted or unsubstituted thiazolyl. In some embodiments of Formula (If), R 2a is thiazolyl substituted with aminoacyl. In some embodiments of Formula (If), R 2a is a substituted or unsubstituted alkoxycarbonyl group. In some embodiments of Formula (If), R 2a In some embodiments of Formula (If), R 2a is a substituted or unsubstituted aminoacyl group. In some embodiments of Formula (If), R 2a In some embodiments of Formula (If), R 2a is an aminoacyl group substituted with one or more (e.g., 1 or 2 or 3 or 1 to 4 or 1 to 3 or 2 to 4) substituents selected from the group consisting of aryl, cycloalkyl, pyridyl, pyrazolyl, and alkoxyalkyl. In some embodiments of Formula (If), R 2a is a substituted or unsubstituted pyridin-one-yl. In some embodiments of Formula (If), R 2a is a pyridin-one-yl group substituted with an alkyl group. In some embodiments of Formula (If), R 2a is a substituted or unsubstituted oxadiazolyl group. In some embodiments of Formula (If), R 2a is oxadiazolyl substituted with one or more (e.g., 1 or 2 or 3 or 1 to 4 or 1 to 3 or 2 to 4) substituents selected from the group consisting of alkyl and phenyl. In some embodiments of Formula (If), R 2a is a substituted or unsubstituted 9-membered bicyclic heterocyclyl. In some embodiments of Formula (If), R 2a is -C(O)H. In some embodiments of Formula (If), R 2a is a substituted or unsubstituted pyridazinyl. In some embodiments of Formula (If), R 2a is pyridazinyl substituted with one or more (e.g., 1 or 2 or 3 or 1 to 4 or 1 to 3 or 2 to 4) substituents selected from the group consisting of halo, alkoxy, alkyl, and aminoacyl. In some embodiments of Formula (If), R 2a is a substituted or unsubstituted aminosulfinyl group. In some embodiments of Formula (If), R 2a is aminosulfinyl substituted with alkyl. In some embodiments of Formula (If), R 2a is a substituted or unsubstituted acyl group. In some embodiments of Formula (If), R 2ais acyl substituted with one or more (e.g., 1 or 2 or 3 or 1 to 4 or 1 to 3 or 2 to 4) substituents selected from the group consisting of cycloalkyl, alkyl, and heterocyclyl. In some embodiments of Formula (If), R 2a is acyl substituted with morpholinyl. In some embodiments of Formula (If), R 2a is a substituted or unsubstituted aminocarbonylamino group. In some embodiments of Formula (If), R 2a is aminocarbonylamino substituted by one or more (eg, 1 or 2 or 3 or 1 to 4 or 1 to 3 or 2 to 4) substituents selected from the group consisting of cycloalkyl and heterocyclyl.

[0331] In some embodiments of Formula (If), G 1 is one or more (e.g. 1 or 2 or 3 or 1 to 4 or 1 to 3 or 2 to 4) R 2a In some embodiments of Formula (If), R 2a is a substituted or unsubstituted phenyl group. In some embodiments of Formula (If), R 2a is a substituted or unsubstituted thiazolyl. In some embodiments of Formula (If), R 2a is thiazolyl substituted with alkyl. In some embodiments of Formula (If), R 2a is substituted or unsubstituted oxazolyl. In some embodiments of Formula (If), R 2a is oxazolyl substituted with alkyl. In some embodiments of Formula (If), R 2a is a substituted or unsubstituted aminoacyl group. In some embodiments of Formula (If), R 2a is an aminoacyl group substituted with one or more (e.g., 1 or 2 or 3 or 1 to 4 or 1 to 3 or 2 to 4) substituents selected from the group consisting of alkyl, heterocyclyl, and cycloalkyl. In some embodiments of Formula (If), R 2a is a substituted or unsubstituted oxadiazolyl group. In some embodiments of Formula (If), R 2a is oxadiazolyl substituted with one or more (e.g., 1 or 2 or 3 or 1 to 4 or 1 to 3 or 2 to 4) substituents selected from the group consisting of cycloalkyl and alkyl. In some embodiments of Formula (If), R 2a is a substituted or unsubstituted acyl group. In some embodiments of Formula (If), R 2a is acyl substituted with heterocyclyl. In some embodiments of Formula (If), R 2a is a substituted or unsubstituted aminocarbonylamino group. In some embodiments of Formula (If), R 2ais aminocarbonylamino substituted with one or more (e.g., 1 or 2 or 3 or 1 to 4 or 1 to 3 or 2 to 4) substituents selected from the group consisting of alkyl, cycloalkyl, and heterocyclyl. In some embodiments of Formula (If), R 2a is a substituted or unsubstituted alkoxycarbonyl group. In some embodiments of Formula (If), R 2a is an alkoxycarbonyl substituted with an alkyl group. In some embodiments of Formula (If), R 2a is a substituted or unsubstituted alkyl. In some embodiments of Formula (If), R 2a is an alkyl group substituted with a hydroxyl group. In some embodiments of Formula (If), R 2a It is a hydroxyl group.

[0332] In some embodiments of Formula (If), R 3 is selected from the group consisting of substituted or unsubstituted alkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocyclyl, and substituted or unsubstituted aryl. 3 is phenyl substituted with one or more (e.g., 1 or 2 or 3 or 1 to 4 or 1 to 3 or 2 to 4) substituents selected from the group consisting of nitro, alkoxy, halo, cycloalkyl, cyano, alkenyl, alkoxycarbonyl, phenylcarbonyl, and alkyl. In some embodiments of Formula (If), R 3 is a cycloalkyl group substituted with one or more (e.g., 1 or 2 or 3 or 1 to 4 or 1 to 3 or 2 to 4) substituents selected from the group consisting of alkyl, cyano, and halo. In some embodiments of Formula (If), R 3 is an alkyl group substituted with one or more (eg, 1 or 2 or 3 or 1 to 4 or 1 to 3 or 2 to 4) substituents selected from the group consisting of alkoxy, cyano, and halo.

[0333] In some embodiments of Formula (If), R 1a is selected from the group consisting of cyano, halo, substituted or unsubstituted alkoxy, substituted or unsubstituted alkyl, and substituted or unsubstituted diazolidinyl. In some embodiments of Formula (If), R 1a In some embodiments of Formula (If), R 1a In some embodiments of Formula (If), R 1a In some embodiments of Formula (If), R 1a In some embodiments of Formula (If), R 1a It is trifluoromethyldiazirinyl.

[0334] In some embodiments of Formula (If), R 1a is Cl and R 3 is substituted with 4-methoxyphenylmethyl. In some embodiments of Formula (If), R 1a is F and R 3 is substituted with 4-methoxyphenylmethyl. In some embodiments of Formula (If), R 1a is -CF3 and R 3 is substituted with 4-methoxyphenylmethyl. In some embodiments of Formula (If), R 1a is trifluoromethyldiazirinyl and R 3 Substituted with 4-methoxyphenylmethyl.

[0335] In some embodiments of Formula (I), Formula (Ic), and Formula (If), G 1 Select from the group consisting of:

[0336]

[0337] Where * indicates the connection point with the parent structure,

[0338] R 2a is selected from the group consisting of substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted alkoxycarbonyl, substituted or unsubstituted aminoacyl, substituted or unsubstituted acyl, substituted or unsubstituted aminosulfonyl, substituted or unsubstituted aminocarbonylamino, and substituted or unsubstituted alkyl; and

[0339] n is 0, 1, 2 or 3.

[0340] In some embodiments of Formula (I), Formula (Ic), and Formula (If), G 1 R is one or more (e.g., 1 or 2 or 3 or 1 to 4 or 1 to 3 or 2 to 4) independently selected from the group consisting of 2a replace:

[0341]

[0342]

[0343] wherein n is 0 to 3 and each X is independently selected from the group consisting of H, halo, alkyl, cyano, hydroxy, cycloalkyl, alkoxycarbonyl, carboxyl, aminoacyl, aryl, heteroaryl, alkoxy, alkoxyalkyl, aminosulfinyl, and heterocyclyl.

[0344] In another aspect, a compound of formula (Ig) or a pharmaceutically acceptable salt thereof is provided:

[0345]

[0346] where R 1a is selected from the group consisting of cyano, halo, substituted or unsubstituted alkoxy, substituted or unsubstituted alkyl, and substituted or unsubstituted heterocyclyl; R 2a is selected from the group consisting of substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted alkoxycarbonyl, substituted or unsubstituted aminoacyl, substituted or unsubstituted acyl, substituted or unsubstituted aminosulfonyl, substituted or unsubstituted aminocarbonylamino, and substituted or unsubstituted alkyl; n is 0, 1, 2, or 3; each R 3a are independently selected from the group consisting of substituted or unsubstituted alkoxy, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, halo, nitro, and cyano; and R 4 It’s H.

[0347] In some embodiments of Formula (Ig), R 1a is selected from the group consisting of cyano, halo, substituted or unsubstituted alkoxy, substituted or unsubstituted alkyl, and substituted or unsubstituted diazolidinyl. In some embodiments of Formula (Ig), R 1a In some embodiments of Formula (Ig), R 1a is -CF3. In some embodiments of Formula (Ig), R 1a In some embodiments of Formula (Ig), R 1a In some embodiments of Formula (Ig), R 1a It is trifluoromethyldiazirinyl.

[0348] In some embodiments of Formula (Ig), n is 0. In some embodiments of Formula (Ig), n is 1. In some embodiments of Formula (Ig), n is 2. In some embodiments of Formula (Ig), each R 3a is halo, such as Cl or F. In some embodiments of Formula (Ig), each R 3a In some embodiments of Formula (Ig), n is 2, one R 3a is halogenated and one R 3a In some embodiments of Formula (If), n is 2 and both R 3a In some embodiments of Formula (If), n is 2 and both R 3a In some embodiments of Formula (If), n is 2 and R 3a is 2-F and 4-F. In some embodiments of Formula (Ig), n is 2 and R 3aIn some embodiments of Formula (Ig), n is 2 and R 3a is 2-F and 4-Cl. In some embodiments of Formula (Ig), n is 2 and R 3a is 3-F and 4-Cl. In some embodiments of Formula (Ig), n is 2 and R 3a is 3-F and 4-CN. In some embodiments of Formula (Ig), n is 2 and R 3a is 4-F and 3-Cl. In some embodiments of Formula (Ig), n is 2 and R 3a is 2-F and 4-CN. In some embodiments of Formula (Ig), n is 2 and R 3a is 2-Cl and 4-CN. In some embodiments of Formula (Ig), n is 2 and R 3a In some embodiments of Formula (Ig), n is 2 and R 3a is 2-CN and 4-F. In some embodiments of Formula (Ig), n is 2 and R 3a is 2-CN and 4-CN. In some embodiments of Formula (Ig), R 3a In some embodiments of Formula (Ig), n is 1 and R 3a is 4-nitro. In some embodiments of Formula (Ig), n is 1 and R 3a is 4-Cl or 3-Cl. In some embodiments of Formula (Ig), n is 1 and R 3a is 4-F or 3-F. In some embodiments of Formula (Ig), n is 1 and R 3a is 4-CN or 3-CN. In some embodiments of Formula (Ig), R 3a In some embodiments of Formula (Ig), R 3a In some embodiments of Formula (Ig), R 3a In some embodiments of Formula (Ig), n is 2 and R 3a is 3-methyl and 4-Cl. In some embodiments of Formula (Ig), n is 2 and R 3a is 3-methyl and 4-CN. In some embodiments of Formula (Ig), n is 2 and R 3a It is 3-F and 4-difluoromethoxy.

[0349] In some embodiments of Formula (Ig), R 2a is substituted or unsubstituted phenyl. In some embodiments of Formula (Ig), R 2a is a substituted or unsubstituted aminoacyl group. In some embodiments of Formula (Ig), R 2ais an aminoacyl group substituted with one or more (e.g., 1 or 2 or 3 or 1 to 4 or 1 to 3 or 2 to 4) substituents selected from the group consisting of alkyl, heterocyclyl, and cycloalkyl. In some embodiments of Formula (Ig), R 2a is a substituted or unsubstituted oxadiazolyl group. In some embodiments of Formula (Ig), R 2a is oxadiazolyl substituted with one or more (e.g., 1 or 2 or 3 or 1 to 4 or 1 to 3 or 2 to 4) substituents selected from the group consisting of cycloalkyl and alkyl. In some embodiments of Formula (Ig), R 2a is a substituted or unsubstituted acyl group. In some embodiments of Formula (Ig), R 2a is acyl substituted with heterocyclyl. In some embodiments of Formula (Ig), R 2a is acyl substituted with aryl. In some embodiments of Formula (Ig), R 2a is acyl substituted with phenyl. In some embodiments of Formula (Ig), R 2a is acyl substituted with alkyl. In some embodiments of Formula (Ig), R 2a is a substituted or unsubstituted pyridinyl. In some embodiments of Formula (Ig), R 2a is pyridinyl substituted by CN or halo. In some embodiments of Formula (Ig), R 2a is a substituted or unsubstituted aminocarbonylamino group. In some embodiments of Formula (Ig), R 2a is aminocarbonylamino substituted with one or more (e.g., 1 or 2 or 3 or 1 to 4 or 1 to 3 or 2 to 4) substituents selected from the group consisting of alkyl, cycloalkyl, and heterocyclyl. In some embodiments of Formula (Ig), R 2a is a substituted or unsubstituted alkoxycarbonyl group. In some embodiments of Formula (Ig), R 2a is an alkoxycarbonyl substituted with an alkyl group. In some embodiments of Formula (Ig), R 2a is a substituted or unsubstituted alkyl group. In some embodiments of Formula (Ig), R 2a is an alkyl group substituted with a hydroxyl group. In some embodiments of Formula (Ig), R 2a is alkyl substituted by halo. In some embodiments of Formula (Ig), R 2a In some embodiments of Formula (Ig), R 2a is a substituted or unsubstituted aminosulfonyl group. In some embodiments of Formula (Ig), R 2a It is an aminosulfonyl group substituted by an alkyl group.

[0350] In another aspect, a compound of formula (Ih) or a pharmaceutically acceptable salt thereof is provided:

[0351]

[0352] where R 1a is selected from the group consisting of cyano, halo, substituted or unsubstituted alkoxy, substituted or unsubstituted alkyl, and substituted or unsubstituted heterocyclyl; R 2a is selected from the group consisting of substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted alkoxycarbonyl, substituted or unsubstituted aminoacyl, substituted or unsubstituted acyl, substituted or unsubstituted aminosulfonyl, substituted or unsubstituted aminocarbonylamino, and substituted or unsubstituted alkyl; R 3 is selected from the group consisting of substituted or unsubstituted alkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocyclyl, and substituted or unsubstituted aryl; and R 4 is H; among them, when R 3 When it is 4-methoxyphenylmethyl, R 1a Not methyl or methoxy.

[0353] In some embodiments of Formula (Ih), R 1a is selected from the group consisting of cyano, halo, substituted or unsubstituted alkoxy, substituted or unsubstituted alkyl, and substituted or unsubstituted diazolidinyl. In some embodiments of Formula (Ih), R 1a In some embodiments of Formula (Ih), R 1a is -CF3. In some embodiments of Formula (Ih), R 1a In some embodiments of Formula (Ih), R 1a In some embodiments of Formula (Ih), R 1a It is trifluoromethyldiazirinyl.

[0354] In some embodiments of Formula (Ih), R 2a is substituted or unsubstituted phenyl. In some embodiments of Formula (Ih), R 2a is a substituted or unsubstituted aminoacyl group. In some embodiments of Formula (Ih), R 2a is an aminoacyl group substituted with one or more (e.g., 1 or 2 or 3 or 1 to 4 or 1 to 3 or 2 to 4) substituents selected from the group consisting of alkyl, heterocyclyl, and cycloalkyl. In some embodiments of Formula (Ih), R 2a is a substituted or unsubstituted oxadiazolyl group. In some embodiments of Formula (Ih), R 2ais oxadiazolyl substituted with one or more (e.g., 1 or 2 or 3 or 1 to 4 or 1 to 3 or 2 to 4) substituents selected from the group consisting of cycloalkyl and alkyl. In some embodiments of Formula (Ih), R 2a is a substituted or unsubstituted acyl group. In some embodiments of Formula (Ih), R 2a is acyl substituted with heterocyclyl. In some embodiments of Formula (Ih), R 2a is acyl substituted with aryl. In some embodiments of Formula (Ih), R 2a is acyl substituted with phenyl. In some embodiments of Formula (Ih), R 2a is acyl substituted with alkyl. In some embodiments of Formula (Ih), R 2a is a substituted or unsubstituted pyridinyl. In some embodiments of Formula (Ih), R 2a is pyridinyl substituted by CN or halo. In some embodiments of Formula (Ih), R 2a is a substituted or unsubstituted aminocarbonylamino group. In some embodiments of Formula (Ih), R 2a is aminocarbonylamino substituted with one or more (e.g., 1 or 2 or 3 or 1 to 4 or 1 to 3 or 2 to 4) substituents selected from the group consisting of alkyl, cycloalkyl, and heterocyclyl. In some embodiments of Formula (Ih), R 2a is a substituted or unsubstituted alkoxycarbonyl group. In some embodiments of Formula (Ih), R 2a is an alkoxycarbonyl group substituted with an alkyl group. In some embodiments of Formula (Ih), R 2a is a substituted or unsubstituted alkyl group. In some embodiments of Formula (Ih), R 2a is an alkyl group substituted with a hydroxyl group. In some embodiments of Formula (Ih), R 2a is alkyl substituted by halo. In some embodiments of Formula (Ih), R 2a In some embodiments of Formula (Ih), R 2a is a substituted or unsubstituted aminosulfonyl group. In some embodiments of Formula (Ih), R 2a is aminosulfonyl substituted with alkyl. In some embodiments of Formula (Ih), R 2a is a substituted or unsubstituted thiazolyl. In some embodiments of Formula (Ih), R 2a is thiazolyl substituted with alkyl. In some embodiments of Formula (Ih), R 2a is substituted or unsubstituted oxazolyl. In some embodiments of Formula (Ih), R 2a It is an oxazolyl group substituted by an alkyl group.

[0355] In some embodiments of Formula (Ih), R 3 is selected from the group consisting of substituted or unsubstituted alkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocyclyl, and substituted or unsubstituted aryl. In some embodiments of Formula (Ih), R 3 is phenyl substituted with one or more (e.g., 1 or 2 or 3 or 1 to 4 or 1 to 3 or 2 to 4) substituents selected from the group consisting of nitro, alkoxy, halo, cycloalkyl, cyano, alkenyl, alkoxycarbonyl, phenylcarbonyl, and alkyl. In some embodiments, R 3 is phenyl substituted with CN and F. In some embodiments of Formula (Ih), R 3 is alkyl substituted with one or more (e.g., 1 or 2 or 3 or 1 to 4 or 1 to 3 or 2 to 4) substituents selected from the group consisting of alkoxy, cyano, and halo. 3 It is isopropyl.

[0356] In another aspect, a compound of formula (Ii) or a pharmaceutically acceptable salt thereof is provided:

[0357]

[0358] where R 1a is selected from the group consisting of cyano, halo, substituted or unsubstituted alkoxy, substituted or unsubstituted alkyl, and substituted or unsubstituted heterocyclyl; R 2a is selected from the group consisting of substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted alkoxycarbonyl, substituted or unsubstituted aminoacyl, substituted or unsubstituted acyl, substituted or unsubstituted aminosulfonyl, substituted or unsubstituted aminocarbonylamino, and substituted or unsubstituted alkyl; R 3 is selected from the group consisting of: substituted or unsubstituted alkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocyclic and substituted or unsubstituted aryl; R 4 It is H; R 5 is H or substituted or unsubstituted alkyl; and X and Y are independently -CH2- or -C(O)-; wherein, when R 3 When it is 4-methoxyphenylmethyl, R 1a Not methyl or methoxy.

[0359] In some embodiments of Formula (Ii), R 1a is selected from the group consisting of cyano, halo, substituted or unsubstituted alkoxy, substituted or unsubstituted alkyl, and substituted or unsubstituted diazolidinyl. In some embodiments of Formula (Ii), R 1aIn some embodiments of Formula (Ii), R 1a In some embodiments of Formula (Ii), R 1a In some embodiments of Formula (Ii), R 1a Is Cl. In some embodiments of Formula (Ih), R 1a It is trifluoromethyldiazirinyl.

[0360] In some embodiments of Formula (Ii), R 2a is a substituted or unsubstituted phenyl group. In some embodiments of Formula (Ii), R 2a is a substituted or unsubstituted pyridinyl. In some embodiments of Formula (Ii), R 2a is pyridinyl substituted by alkyl, CN or halo. In some embodiments of Formula (Ii), R 2a is a substituted or unsubstituted pyrimidinyl. In some embodiments of Formula (Ii), R 2a is a substituted or unsubstituted pyridazinyl. In some embodiments of Formula (Ii), R 2a is pyridazinyl substituted with one or more (e.g., 1 or 2 or 3 or 1 to 4 or 1 to 3 or 2 to 4) substituents selected from the group consisting of halo, alkoxy, alkyl, and aminoacyl. In some embodiments of Formula (Ii), R 2a is a substituted or unsubstituted aminoacyl group. In some embodiments of Formula (Ii), R 2a is an aminoacyl group substituted with one or more (e.g., 1 or 2 or 3 or 1 to 4 or 1 to 3 or 2 to 4) substituents selected from the group consisting of alkyl, heterocyclyl, aryl, heteroaryl, and cycloalkyl. In some embodiments of Formula (Ii), R 2a is a substituted or unsubstituted pyrazolyl. In some embodiments of Formula (Ii), R 2a is pyrazolyl substituted with alkyl. In some embodiments of Formula (Ii), R 2a is a substituted or unsubstituted oxadiazolyl group. In some embodiments of Formula (Ii), R 2a is oxadiazolyl substituted with one or more (e.g., 1 or 2 or 3 or 1 to 4 or 1 to 3 or 2 to 4) substituents selected from the group consisting of cycloalkyl and alkyl. In some embodiments of Formula (Ii), R 2a is a substituted or unsubstituted acyl group. In some embodiments of Formula (Ii), R 2a is acyl substituted with heterocyclyl. In some embodiments of Formula (Ii), R 2a is acyl substituted with aryl. In some embodiments of Formula (Ii), R 2ais acyl substituted with phenyl. In some embodiments of Formula (Ii), R 2a is acyl substituted with alkyl. In some embodiments of Formula (Ii), R 2a is a substituted or unsubstituted aminocarbonylamino group. In some embodiments of Formula (Ii), R 2a is aminocarbonylamino substituted with one or more (e.g., 1 or 2 or 3 or 1 to 4 or 1 to 3 or 2 to 4) substituents selected from the group consisting of alkyl, cycloalkyl, and heterocyclyl. In some embodiments of Formula (Ii), R 2a is a substituted or unsubstituted alkoxycarbonyl group. In some embodiments of Formula (Ii), R 2a is an alkoxycarbonyl substituted with an alkyl group. In some embodiments of Formula (Ii), R 2a is a substituted or unsubstituted alkyl. In some embodiments of Formula (Ii), R 2a is an alkyl group substituted with a hydroxyl group. In some embodiments of Formula (Ii), R 2a is alkyl substituted by halo. In some embodiments of Formula (Ii), R 2a In some embodiments of Formula (Ii), R 2a is a substituted or unsubstituted aminosulfonyl group. In some embodiments of Formula (Ii), R 2a is aminosulfonyl substituted with alkyl. In some embodiments of Formula (Ii), R 2a is a substituted or unsubstituted thiazolyl. In some embodiments of Formula (Ii), R 2a is thiazolyl substituted with alkyl. In some embodiments of Formula (Ii), R 2a is substituted or unsubstituted oxazolyl. In some embodiments of Formula (Ii), R 2a It is an oxazolyl group substituted by an alkyl group.

[0361] In some embodiments of Formula (Ii), R 3 is selected from the group consisting of substituted or unsubstituted alkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocyclyl, and substituted or unsubstituted aryl. 3 is phenyl substituted with one or more (e.g., 1 or 2 or 3 or 1 to 4 or 1 to 3 or 2 to 4) substituents selected from the group consisting of nitro, alkoxy, halo, cycloalkyl, cyano, alkenyl, alkoxycarbonyl, phenylcarbonyl, and alkyl. In some embodiments of Formula (Ii), R 3 is phenyl substituted with CN and F. In some embodiments of Formula (Ii), R 3 is phenyl substituted with CN or Cl. In some embodiments of Formula (Ii), R3 is a cycloalkyl group substituted with one or more (e.g., 1 or 2 or 3 or 1 to 4 or 1 to 3 or 2 to 4) substituents selected from the group consisting of alkyl, cyano, and halo. In some embodiments of Formula (Ii), R 3 is cyclopropyl substituted with alkyl. In some embodiments of Formula (Ii), R 3 is alkyl substituted with one or more (e.g., 1 or 2 or 3 or 1 to 4 or 1 to 3 or 2 to 4) substituents selected from the group consisting of alkoxy, cyano, and halo. In some embodiments of Formula (Ii), R 3 is isopropyl, methyl or ethyl. In some embodiments of Formula (Ii), R 3 is a substituted or unsubstituted heterocyclyl. In some embodiments of Formula (Ii), R 3 It is a furyl group.

[0362] In some embodiments of Formula (Ii), R 5 is a substituted or unsubstituted alkyl. In some embodiments of Formula (Ii), R 5 In some embodiments of Formula (Ii), R 5 is a substituted alkyl. In some embodiments of Formula (Ii), R 5 In some embodiments of Formula (Ii), R 5 It’s H.

[0363] In some embodiments of formula (Ii), X and Y are independently -CH2- or -C(O)-. In some embodiments of formula (Ii), X and Y are both -CH2-. In some embodiments of formula (Ii), X is -CH2- and Y is -C(O)-. In some embodiments of formula (Ii), Y is -CH2- and X is -C(O)-.

[0364] In another aspect, the compound of formula (I) is a compound of formula (Ij) or a pharmaceutically acceptable salt thereof:

[0365]

[0366] where R 1 is a substituted or unsubstituted phenyl group; each R 2b are independently substituted or unsubstituted alkyl; R 3 is a substituted or unsubstituted phenyl group or a substituted or unsubstituted pyridyl group; R 4 It is H; R 5 is H or substituted or unsubstituted alkyl; n is 0, 1 or 2; and q is 0 or 1; wherein, when R 3 When it is a substituted or unsubstituted phenyl group, R 1It is a substituted or unsubstituted pyridyl group or a phenyl group substituted with at least one substituent other than a methyl group or a methoxy group.

[0367] In some embodiments of Formula (Ij), R 1 is substituted or unsubstituted phenyl. In some embodiments of Formula (Ij), R 1 is phenyl substituted with one or more (e.g., 1 or 2 or 3 or 1 to 4 or 1 to 3 or 2 to 4) substituents selected from the group consisting of halo, unsubstituted alkyl, and alkyl substituted with one or more halo groups. In some embodiments of Formula (Ij), R 1 is phenyl substituted by halo. In some embodiments of Formula (Ij), R 1 is phenyl substituted with F or Cl. In some embodiments of Formula (Ij), R 1 is phenyl substituted with unsubstituted alkyl. In some embodiments of Formula (Ij), R 1 is phenyl substituted with methyl or ethyl. In some embodiments of Formula (Ij), R 1 is phenyl substituted by alkyl substituted by one or more halo groups. In some embodiments of Formula (Ij), R 1 is phenyl substituted with -CHF2 or -CF3. In some embodiments of Formula (Ij), R 1 is phenyl substituted with 4-Cl. In some embodiments of Formula (Ij), R 1 is phenyl substituted with 4-CF3. In some embodiments of Formula (Ij), R 1 is phenyl substituted with two or more groups selected from the group consisting of F, Cl, methyl and -CF3. In some embodiments of Formula (Ij), R 1 is phenyl substituted with two F groups. In some embodiments of Formula (Ij), R 1 is phenyl substituted with F and Cl. In some embodiments of Formula (Ij), R 1 is phenyl substituted with F and methyl. In some embodiments of Formula (Ij), R 1 It is a phenyl group substituted by F and -CF3.

[0368] In some embodiments of Formula (Ij), n is 0, 1, or 2. In some embodiments of Formula (Ij), n is 0. In some embodiments of Formula (Ij), n is 1. In some embodiments of Formula (Ij), n is 1, and R 2b is a substituted or unsubstituted alkyl group. In some embodiments of Formula (Ij), n is 1, and R 2b is an unsubstituted alkyl group. In some embodiments of Formula (Ij), n is 1, and R 2bIt's methyl.

[0369] In some embodiments of Formula (Ij), R 3 is substituted or unsubstituted phenyl. In some embodiments of Formula (Ij), R 3 is phenyl substituted with one or more (e.g., 1 or 2 or 3 or 1 to 4 or 1 to 3 or 2 to 4) substituents selected from the group consisting of halo and cyano. In some embodiments of Formula (Ij), R 3 is phenyl substituted by halo. In some embodiments of Formula (Ij), R 3 is phenyl substituted with F, Cl or Br. In some embodiments of Formula (Ij), R 3 is phenyl substituted with cyano. In some embodiments of Formula (Ij), R 3 is phenyl substituted with two or more groups selected from the group consisting of F, Cl, Br and cyano. In some embodiments of Formula (Ij), R 3 is phenyl substituted with F and Cl. In some embodiments of Formula (Ij), R 3 is phenyl substituted with F and Br. In some embodiments of Formula (Ij), R 3 It is a phenyl group substituted by F and cyano.

[0370] In some embodiments of Formula (Ij), R 3 is a substituted or unsubstituted pyridinyl. In some embodiments of Formula (Ij), R 3 is pyridinyl substituted with one or more (e.g., 1 or 2 or 3 or 1 to 4 or 1 to 3 or 2 to 4) substituents selected from the group consisting of halo, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, and substituted or unsubstituted alkoxy. In some embodiments of Formula (Ij), R 3 is pyridinyl substituted by halo. In some embodiments of Formula (Ij), R 3 is pyridinyl substituted with F or Cl. In some embodiments of Formula (Ij), R 3 is pyridinyl substituted with unsubstituted alkyl. In some embodiments of Formula (Ij), R 3 is pyridinyl substituted with methyl. In some embodiments of Formula (Ij), R 3 is pyridinyl substituted with unsubstituted alkenyl. In some embodiments of Formula (Ij), R 3 is pyridinyl substituted with -CH=CH2. In some embodiments of Formula (Ij), R 3 is pyridinyl substituted by alkoxy optionally substituted by halo. In some embodiments of Formula (Ij), R 3is pyridinyl substituted with methoxy or -OCHF2. In some embodiments of Formula (Ij), R 3 is pyridinyl substituted with two or more groups selected from the group consisting of halo, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, and substituted or unsubstituted alkoxy. In some embodiments of Formula (Ij), R 3 is pyridinyl substituted with F and Cl. In some embodiments of Formula (Ij), R 3 is pyridinyl substituted with Cl and methyl. In some embodiments of Formula (Ij), R 3 is pyridinyl substituted with F and methoxy. In some embodiments of Formula (Ij), R 3 is pyridinyl substituted with F and -OCHF2. In some embodiments of Formula (Ij), R 3 is pyridinyl substituted with F and -CH=CH2. In some embodiments of Formula (Ij), R 3 It is a substituted or unsubstituted pyridin-2-yl group.

[0371] In some embodiments of Formula (Ij), R 5 is H. In some embodiments of Formula (Ij), R 5 is a substituted or unsubstituted alkyl group. In some embodiments of Formula (Ij), R 5 It's methyl.

[0372] In some embodiments of Formula (Ij), q is 0. In some embodiments of Formula (Ij), q is 1.

[0373] In some embodiments of Formula (Ij), R 1 is phenyl substituted by one or more substituents selected from the group consisting of F, Cl, methyl, -CHF2 and -CF3, n is 0, R 3 is pyridyl substituted by one or more substituents selected from the group consisting of F, Cl, methyl, -CH=CH2, methoxy and -OCHF2, R 5 is H, and q is 0. In some embodiments of Formula (Ij), R 1 is phenyl substituted by one or more substituents selected from the group consisting of F, Cl, methyl, -CHF2 and -CF3, n is 0, R 3 is phenyl substituted by one or more substituents selected from the group consisting of F, Cl, Br and cyano, R 5 is H, and q is 0. In some embodiments of Formula (Ij), R 1 is phenyl substituted by one or more substituents selected from the group consisting of F, Cl, methyl, -CHF2 and -CF3, n is 1, R 2b is methyl, R3 is pyridyl substituted by one or more substituents selected from the group consisting of F, Cl, methyl, -CH=CH2, methoxy and -OCHF2, R 5 is H, and q is 0. In some embodiments of Formula (Ij), R 1 is phenyl substituted by one or more substituents selected from the group consisting of F, Cl, methyl, -CHF2 and -CF3, n is 1, R 2b is methyl, R 3 is phenyl substituted by one or more substituents selected from the group consisting of F, Cl, Br and cyano, R 5 is H, and q is 0. In some embodiments of Formula (Ij), R 1 is phenyl substituted by one or more substituents selected from the group consisting of F, Cl, methyl, -CHF2 and -CF3, n is 0, R 3 is pyridyl substituted by one or more substituents selected from the group consisting of F, Cl, methyl, -CH=CH2, methoxy and -OCHF2, R 5 is H, and q is 1. In some embodiments of Formula (Ij), R 1 is phenyl substituted by one or more substituents selected from the group consisting of F, Cl, methyl, -CHF2 and -CF3, n is 0, R 3 is phenyl substituted by one or more substituents selected from the group consisting of F, Cl, Br and cyano, R 5 is H, and q is 1. In some embodiments of Formula (Ij), R 1 is phenyl substituted by one or more substituents selected from the group consisting of F, Cl, methyl, -CHF2 and -CF3, n is 1, R 2b is methyl, R 3 is pyridyl substituted by one or more substituents selected from the group consisting of F, Cl, methyl, -CH=CH2, methoxy and -OCHF2, R 5 is H, and q is 1. In some embodiments of Formula (Ij), R 1 is phenyl substituted by one or more substituents selected from the group consisting of F, Cl, methyl, -CHF2 and -CF3, n is 1, R 2b is methyl, R 3 is phenyl substituted by one or more substituents selected from the group consisting of F, Cl, Br and cyano, R 5 is H, and q is 1.

[0374] In some embodiments of Formula (Ij): R 1is phenyl substituted with a substituent selected from the group consisting of F, Cl, methyl, ethyl, -CHF2 or -CF3; n is 0 or n is 1, and R 2b is methyl; R 3 is pyridyl substituted with two substituents selected from the group consisting of F, Cl, methyl, -CH=CH2, methoxy and -OCHF2; R 5 is H; and q is 0 or 1.

[0375] In another aspect, the compound of formula (I) is a compound of formula (Ik-1) or a pharmaceutically acceptable salt thereof:

[0376]

[0377] where R 2A is H or substituted or unsubstituted alkyl; R 2B is selected from the group consisting of: substituted or unsubstituted alkyl, substituted or unsubstituted cycloalkyl, and substituted or unsubstituted heterocyclyl; m is 0, 1, or 2; p is 0, 1, or 2; each R 1a are independently selected from the group consisting of: halogenated and substituted or unsubstituted alkyl; each R 3a are independently selected from the group consisting of halo, cyano, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, and substituted or unsubstituted alkoxy; and R 4 It’s H.

[0378] In some embodiments of Formula (Ik-1), R 2A is H. In some embodiments of Formula (Ik-1), R 2A is a substituted or unsubstituted alkyl group. In some embodiments of Formula (Ik-1), R 2A is a substituted or unsubstituted methyl group. In some embodiments of Formula (Ik-1), R 2A It's methyl.

[0379] In some embodiments of Formula (Ik-1), R 2B is a substituted or unsubstituted alkyl group. In some embodiments of Formula (Ik-1), R 2B In some embodiments of Formula (Ik-1), R 2B is a substituted alkyl. In some embodiments of Formula (Ik-1), R 2B is an alkyl group substituted with halogen. In some embodiments of formula (Ik-1), R 2B is -CHF2. In some embodiments of Formula (Ik-1), R 2B is an alkyl group substituted with -OH. In some embodiments of Formula (Ik-1), R 2Bis -CH(OH)CH3. In some embodiments of Formula (Ik-1), R 2B is -CH2OH. In some embodiments of Formula (Ik-1), R 2B is -CH2CH2SCH3. In some embodiments of Formula (Ik-1), R 2B is -CH2CH2S(O)2CH3. In some embodiments of Formula (Ik-1), R 2B is -CH2N(H)C(O)CH3. In some embodiments of Formula (Ik-1), R 2B is -CH2CH2C(O)NH2. In some embodiments of Formula (Ik-1), R 2B is an alkyl group substituted with a heterocyclyl group. In some embodiments of Formula (Ik-1), R 2B is a C1-C2 alkyl group substituted with a heterocyclyl group. In some embodiments of formula (Ik-1), R 2B is methyl substituted with oxetanyl. In some embodiments of Formula (Ik-1), R 2B It is a methyl group substituted by an azetidinyl group.

[0380] In some embodiments of Formula (Ik-1), R 2B is a substituted or unsubstituted cycloalkyl group. In some embodiments of Formula (Ik-1), R 2B is a substituted or unsubstituted C3-C5 cycloalkyl group. In some embodiments of formula (Ik-1), R 2B is an unsubstituted cyclopropyl group. In some embodiments of Formula (Ik-1), R 2B is unsubstituted cyclobutyl. In some embodiments of Formula (Ik-1), R 2B is a cyclobutyl group substituted with a hydroxyl group. In some embodiments of Formula (Ik-1), R 2B is cyclobutyl substituted with methoxy. In some embodiments of Formula (Ik-1), R 2B is a polycyclic cycloalkyl group. In some embodiments of Formula (Ik-1), R 2B is a substituted or unsubstituted bicyclo[1.1.1]pentyl group. In some embodiments of Formula (Ik-1), R 2B is a bicyclo[1.1.1]pentyl group substituted by a group selected from the group consisting of hydroxy, alkoxycarbonyl, carbamoyl and hydroxymethyl.

[0381] In some embodiments of Formula (Ik-1), R 2B is a substituted or unsubstituted heterocyclic group. In some embodiments of Formula (Ik-1), R 2B is a substituted or unsubstituted 4- to 7-membered heterocyclic group. In some embodiments of Formula (Ik-1), R2B is a substituted or unsubstituted 4- to 7-membered heterocyclyl containing one or more (e.g., 1 or 2 or 3 or 1 to 4 or 1 to 3 or 2 to 4) N, O, or S atoms. In some embodiments of Formula (Ik-1), R 2B is a substituted or unsubstituted 4- to 6-membered heterocyclic group containing one N atom. In some embodiments of formula (Ik-1), R 2B is a substituted or unsubstituted azetidinyl group. In some embodiments of Formula (Ik-1), R 2B is 3-azetidinyl substituted with aminoacyl or acyl. In some embodiments of Formula (Ik-1), R 2B is a substituted or unsubstituted 4- to 6-membered heterocyclic group containing one O atom. In some embodiments of formula (Ik-1), R 2B is a substituted or unsubstituted oxetanyl group. In some embodiments of Formula (Ik-1), R 2B is unsubstituted 3-oxetanyl. In some embodiments of Formula (Ik-1), R 2B is 3-oxetanyl substituted with methyl. In some embodiments of Formula (Ik-1), R 2B is substituted or unsubstituted tetrahydro-2H-pyranyl. In some embodiments of Formula (Ik-1), R 2B is unsubstituted tetrahydro-2H-pyranyl. In some embodiments of Formula (Ik-1), R 2B is a substituted or unsubstituted 4- to 6-membered heterocyclic group containing one S atom. In some embodiments of formula (Ik-1), R 2B It is a substituted or unsubstituted 4-tetrahydro-2H-thiopyranyl group.

[0382] In some embodiments of Formula (Ik-1), R 2A and R 2B In some embodiments of Formula (Ik-1), R 2A is methyl and R 2B is a substituted methyl group. In some embodiments of Formula (Ik-1), R 2A is methyl and R 2B is -CH2OH. In some embodiments of Formula (Ik-1), R 2A is methyl and R 2B is -CH2N(H)C(O)CH3. In some embodiments of Formula (Ik-1), R 2A is methyl and R 2B It is -CHF2.

[0383] In some embodiments of Formula (Ik-1), m is 0. In some embodiments of Formula (Ik-1), m is 1. In some embodiments of Formula (Ik-1), m is 2. In some embodiments of Formula (Ik-1), each R 1a are independently selected from the group consisting of: halo and substituted or unsubstituted alkyl. In some embodiments of Formula (Ik-1), m is 1, and R 1a is at the 4-position of the phenyl moiety. In some embodiments of Formula (Ik-1), m is 1, and R 1a In some embodiments of Formula (Ik-1), m is 1, and R 1a is 4-F. In some embodiments of Formula (Ik-1), m is 1, and R 1a In some embodiments of Formula (Ik-1), m is 1, and R 1a is a substituted or unsubstituted C1-C3 alkyl group. In some embodiments of Formula (Ik-1), m is 1, and R 1a In some embodiments of Formula (Ik-1), m is 1, and R 1a In some embodiments of Formula (Ik-1), m is 1, and R 1a is 4-CHF2. In some embodiments of Formula (Ik-1), m is 1, and R 1a In some embodiments of Formula (Ik-1), m is 2, and both R 1a The groups are located at the 3 and 4 positions of the phenyl moiety. In some embodiments of Formula (Ik-1), m is 2, and R 1a is 3-F and 4-F. In some embodiments of Formula (Ik-1), m is 2, and R 1a In some embodiments of Formula (Ik-1), m is 2, and R 1a In some embodiments of Formula (Ik-1), m is 2, and R 1a In some embodiments of Formula (Ik-1), m is 2, and R 1a In some embodiments of Formula (Ik-1), m is 2, and R 1a It is 3-methyl and 4-F.

[0384] In some embodiments of Formula (Ik-1), p is 0. In some embodiments of Formula (Ik-1), p is 1. In some embodiments of Formula (Ik-1), p is 2. In some embodiments of Formula (Ik-1), p is 2, and each R 3ais independently selected from the group consisting of halo, cyano, substituted or unsubstituted C1-C3 alkyl, substituted or unsubstituted C2-C3 alkenyl, and substituted or unsubstituted C1-C3 alkoxy. In some embodiments of Formula (Ik-1), p is 2, and each R 3a R is independently F, Cl, Br, cyano, methyl, -CH=CH2, -OCH3 or -OCHF2. In some embodiments of formula (Ik-1), p is 2, and at least one R 3a is F. In some embodiments of Formula (Ik-1), p is 2, and at least one R 3a is 3-F. In some embodiments of Formula (Ik-1), p is 2, and one R 3a It is 3-F and one R 3a is at the 5-position of the pyridyl moiety and is selected from the group consisting of halo, cyano, unsubstituted C1-C3 alkyl, unsubstituted C2-C3 alkenyl, and substituted or unsubstituted C1-C3 alkoxy. In some embodiments of Formula (Ik-1), p is 2, and R 3a is 3-F and 5-Cl. In some embodiments of Formula (Ik-1), p is 2, and R 3a is 3-F and 5-Br. In some embodiments of Formula (Ik-1), p is 2, and R 3a In some embodiments of Formula (Ik-1), p is 2, and R 3a is 3-F and 5-methyl. In some embodiments of Formula (Ik-1), p is 2, and R 3a In some embodiments of Formula (Ik-1), p is 2, and R 3a is 3-F and 5-methoxy. In some embodiments of Formula (Ik-1), p is 2, and R 3a is 3-F and 5-OCH3. In some embodiments of Formula (Ik-1), p is 2, and R 3a In some embodiments of Formula (Ik-1), p is 2, and R 3a It is 3-methyl and 5-Cl.

[0385] In some embodiments of Formula (Ik-1), R 2A It's H, R 2B is isopropyl, m is 1, R 1a is selected from the group consisting of F, Cl and -CF3, p is 1, and R 3a is selected from the group consisting of F, Cl and cyano. In some embodiments of formula (Ik-1), R 2A It's H, R 2Bis 3-oxetanyl, m is 1, R 1a is selected from the group consisting of F, Cl and -CF3, p is 1, and R 3a is selected from the group consisting of F, Cl and cyano. In some embodiments of formula (Ik-1), R 2A is methyl, R 2B is methyl, m is 1, R 1a is selected from the group consisting of F, Cl and -CF3, p is 1, and R 3a Selected from the group consisting of F, Cl and cyano.

[0386] In some embodiments of Formula (Ik-1), R 2A It's H, R 2B is isopropyl, m is 1, R 1a is selected from the group consisting of F, Cl and -CF3, p is 2, and each R 3a are independently selected from the group consisting of F, Cl and cyano. In some embodiments of formula (Ik-1), R 2A It's H, R 2B is 3-oxetanyl, m is 1, R 1a is selected from the group consisting of F, Cl and -CF3, p is 2, and each R 3a are independently selected from the group consisting of F, Cl and cyano. In some embodiments of formula (Ik-1), R 2A is methyl, R 2B is methyl, m is 1, R 1a is selected from the group consisting of F, Cl and -CF3, p is 2, and each R 3a Independently selected from the group consisting of F, Cl and cyano.

[0387] In some embodiments of Formula (Ik-1), R 2A It's H, R 2B isopropyl, m is 2, each R 1a are independently selected from the group consisting of F, Cl and -CF3, p is 1, and R 3a is selected from the group consisting of F, Cl and cyano. In some embodiments of formula (Ik-1), R 2A It's H, R 2B is 3-oxetanyl, m is 2, each R 1a are independently selected from the group consisting of F, Cl and -CF3, p is 1, and R 3a is selected from the group consisting of F, Cl and cyano. In some embodiments of formula (Ik-1), R 2A is methyl, R 2B is methyl, m is 2, each R 1aare independently selected from the group consisting of F, Cl and -CF3, p is 1, and R 3a Selected from the group consisting of F, Cl and cyano.

[0388] In some embodiments of Formula (Ik-1), R 2A It's H, R 2B isopropyl, m is 2, each R 1a are independently selected from the group consisting of F, Cl and -CF3, p is 2, and each R 3a are independently selected from the group consisting of F, Cl and cyano. In some embodiments of formula (Ik-1), R 2A It's H, R 2B is 3-oxetanyl, m is 2, each R 1a are independently selected from the group consisting of F, Cl and -CF3, p is 2, and each R 3a are independently selected from the group consisting of F, Cl and cyano. In some embodiments of formula (Ik-1), R 2A is methyl, R 2B is methyl, m is 2, each R 1a are independently selected from the group consisting of F, Cl and -CF3, p is 2, and each R 3a Independently selected from the group consisting of F, Cl and cyano.

[0389] In some embodiments of Formula (Ik-1): R 2A is H or methyl; R 2B is selected from the group consisting of isopropyl, -CHF2, -CH(OH)CH3, -CH2OH, -CH2CH2SCH3, -CH2CH2S(O)2CH3, -CH2N(H)C(O)CH3, -CH2CH2C(O)NH2, methyl substituted by oxetanyl or azetidinyl, cyclopropyl, cyclobutyl, 3-azetidinyl substituted by aminoacyl or acyl, 3-oxetanyl, 3-oxetanyl substituted by methyl, tetrahydro-2H-pyranyl, and 4-tetrahydro-2H-thiopyranyl; m is 1; R 1a are 4-F, 4-Cl, 4-methyl, 4-CHF2 and 4-CF3; p is 2; and both R 3a The group is selected from the group consisting of 3-F and 5-Cl, 3-F and 5-Br, 3-F and 5-cyano, 3-F and 5-methyl, 3-F and 5-vinyl, 3-F and 5-methoxy, 3-F and 5-OCH3, 3-F and 5-OCHF2, and 3-methyl and 5-Cl.

[0390] In another aspect, the compound of formula (I) is a compound of formula (Ik-2) or a pharmaceutically acceptable salt thereof:

[0391]

[0392] Among them G 1 is selected from the group consisting of: substituted or unsubstituted cycloalkyl and substituted or unsubstituted heterocyclyl; each R 1a are independently selected from the group consisting of: halogenated and substituted or unsubstituted alkyl; each R 2a are independently selected from the group consisting of substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted alkoxycarbonyl, substituted or unsubstituted aminoacyl, substituted or unsubstituted acyl, substituted or unsubstituted aminosulfinyl, substituted or unsubstituted aminocarbonylamino, and substituted or unsubstituted alkyl; each R 3a are independently selected from the group consisting of halo, cyano, and substituted or unsubstituted alkyl; R 4 It is H; R 5 is H or substituted or unsubstituted alkyl; m is 0, 1 or 2; n is 0, 1 or 2; and p is 0, 1 or 2.

[0393] In some embodiments of Formula (Ik-2), G 1 is a substituted or unsubstituted cycloalkyl group. In some embodiments of Formula (Ik-2), G 1 is a substituted or unsubstituted cyclopropyl. In some embodiments of Formula (Ik-2), G 1 is a substituted or unsubstituted cyclobutyl. In some embodiments of Formula (Ik-2), G 1 is a substituted or unsubstituted 4- to 6-membered heterocyclyl containing one or more (e.g., 1 or 2 or 3 or 1 to 4 or 1 to 3 or 2 to 4) N or O atoms. In some embodiments of Formula (Ik-2), G 1 is a substituted or unsubstituted 4- to 6-membered heterocyclic group containing one N atom. In some embodiments of Formula (Ik-2), G 1 is a substituted or unsubstituted azetidinyl group. In some embodiments of Formula (Ik-2), G 1 is a substituted or unsubstituted piperidinyl. In some embodiments of Formula (Ik-2), G 1 is a substituted or unsubstituted 4- to 6-membered heterocyclic group containing one O atom. In some embodiments of Formula (Ik-2), G 1 is a substituted or unsubstituted oxetanyl group. In some embodiments of Formula (Ik-2), G 1 It is a substituted or unsubstituted tetrahydrofuranyl group.

[0394] In some embodiments of Formula (Ik-2), m is 0. In some embodiments of Formula (Ik-2), m is 1, and R1a is selected from the group consisting of: halo and substituted or unsubstituted alkyl. In some embodiments of Formula (Ik-2), m is 1, and R 1a is at the 4-position of the phenyl moiety. In some embodiments of Formula (Ik-2), m is 1, and R 1a is 4-F. In some embodiments of Formula (Ik-2), m is 1, and R 1a In some embodiments of Formula (Ik-2), m is 1, and R 1a is a C1-C3 alkyl group optionally substituted with halogen. In some embodiments of Formula (Ik-2), m is 1, and R 1a In some embodiments of Formula (Ik-2), m is 1, and R 1a is 4-CHF2. In some embodiments of Formula (Ik-2), m is 1, and R 1a It is 4-CF3.

[0395] In some embodiments of Formula (Ik-2), n is 0. In some embodiments of Formula (Ik-2), n is 1. In some embodiments of Formula (Ik-2), n is 2.

[0396] In some embodiments of Formula (Ik-2), each R 2a is independently selected from the group consisting of halo, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted alkoxycarbonyl, substituted or unsubstituted aminoacyl, substituted or unsubstituted acyl, substituted or unsubstituted alkyl, and hydroxy. In some embodiments of Formula (Ik-2), R 2a is halogenated, such as fluoro. In some embodiments of formula (Ik-2), R 2a is a substituted or unsubstituted aryl group. In some embodiments of Formula (Ik-2), R 2a is a substituted or unsubstituted phenyl group. In some embodiments of Formula (Ik-2), R 2a is phenyl substituted by one or more (e.g., 1 or 2 or 3 or 1 to 4 or 1 to 3 or 2 to 4) substituents selected from the group consisting of halo, alkoxycarbonyl, substituted or unsubstituted amino, and substituted or unsubstituted aminoacyl. In some embodiments of Formula (Ik-2), R 2a is phenyl substituted by halo. In some embodiments of formula (Ik-2), R 2a is phenyl substituted by alkoxycarbonyl. In some embodiments of formula (Ik-2), R 2a is phenyl substituted with methoxycarbonyl. In some embodiments of formula (Ik-2), R 2ais a substituted or unsubstituted amino-substituted phenyl. In some embodiments of Formula (Ik-2), R 2a is phenyl substituted with methylamino. In some embodiments of Formula (Ik-2), R 2a is a substituted or unsubstituted aminoacyl substituted phenyl. In some embodiments of Formula (Ik-2), R 2a is phenyl substituted with methylaminoacyl. In some embodiments of formula (Ik-2), R 2a is a phenyl group substituted with two substituents selected from the group consisting of methoxycarbonyl, methylamino, and methylaminoacyl. In some embodiments of formula (Ik-2), R 2a is a substituted or unsubstituted heteroaryl. In some embodiments of Formula (Ik-2), R 2a is a substituted or unsubstituted oxadiazolyl group. In some embodiments of Formula (Ik-2), R 2a is unsubstituted oxadiazolyl. In some embodiments of Formula (Ik-2), R 2a is oxadiazolyl substituted with cycloalkyl. In some embodiments of Formula (Ik-2), R 2a is oxadiazolyl substituted with cyclopropyl. In some embodiments of Formula (Ik-2), R 2a is a substituted or unsubstituted pyridyl group. In some embodiments of Formula (Ik-2), R 2a is an unsubstituted pyridyl group. In some embodiments of Formula (Ik-2), R 2a is pyridinyl substituted with halo such as F. In some embodiments of Formula (Ik-2), R 2a is pyridinyl substituted with cyano. In some embodiments of Formula (Ik-2), R 2a is a substituted or unsubstituted pyridin-2-yl. In some embodiments of Formula (Ik-2), R 2a is a substituted or unsubstituted alkoxycarbonyl group. In some embodiments of formula (Ik-2), R 2a In some embodiments of Formula (Ik-2), R 2a In some embodiments of Formula (Ik-2), R 2a is a substituted or unsubstituted aminoacyl group. In some embodiments of Formula (Ik-2), R 2a is an unsubstituted aminoacyl group. In some embodiments of Formula (Ik-2), R 2a is an aminoacyl group substituted with one or more (e.g., 1 or 2 or 3 or 1 to 4 or 1 to 3 or 2 to 4) substituents selected from the group consisting of C1-C3 alkyl, C3-C6 cycloalkyl, and 4- to 7-membered heterocyclyl. In some embodiments of Formula (Ik-2), R2a is an aminoacyl group substituted with a C1-C3 alkyl group. In some embodiments of formula (Ik-2), R 2a is methylaminoacyl, ethylaminoacyl or isopropylaminoacyl. In some embodiments of formula (Ik-2), R 2a In some embodiments of Formula (Ik-2), R 2a Is cyclopropylaminoacyl. In some embodiments of Formula (Ik-2), R 2a is tetrahydropyranylaminoacyl. In some embodiments of Formula (Ik-2), R 2a is a substituted or unsubstituted acyl group. In some embodiments of Formula (Ik-2), R 2a is an unsubstituted acyl group. In some embodiments of Formula (Ik-2), R 2a is acyl substituted with one or more (e.g., 1 or 2 or 3 or 1 to 4 or 1 to 3 or 2 to 4) substituents selected from the group consisting of substituted or unsubstituted alkyl and substituted or unsubstituted aryl. In some embodiments of Formula (Ik-2), R 2a is an acyl group substituted with a methyl group. In some embodiments of Formula (Ik-2), R 2a is an acyl group substituted with phenyl, wherein the phenyl group is optionally substituted with amino. In some embodiments of Formula (Ik-2), R 2a is a substituted or unsubstituted alkyl group. In some embodiments of Formula (Ik-2), R 2a is a C1-C3 alkyl substituted by halogen. In some embodiments of formula (Ik-2), R 2a is an ethyl group substituted with two fluoro groups, such as -CH2CHF2. In some embodiments of formula (Ik-2), R 2a It is a hydroxyl group.

[0397] In some embodiments of Formula (Ik-2), p is 0. In some embodiments of Formula (Ik-2), p is 1. In some embodiments of Formula (Ik-2), p is 1, and R 3a In some embodiments of Formula (Ik-2), p is 1, and R 3a is 5-Cl. In some embodiments of Formula (Ik-2), p is 2. In some embodiments of Formula (Ik-2), p is 2, and each R 3a R is independently halo, cyano, or substituted or unsubstituted C1-C3 alkyl. In some embodiments of Formula (Ik-2), p is 2, and each R 3a R is independently F, Cl, Br, cyano or methyl. In some embodiments of Formula (Ik-2), p is 2, and at least one R 3ais F or methyl. In some embodiments of Formula (Ik-2), p is 2, and at least one R 3a is 3-F or 3-methyl. In some embodiments of Formula (Ik-2), p is 2, and one R 3a is at position 3 of the pyridyl moiety and is selected from the group consisting of F and methyl, and one R 3a is at the 5-position of the pyridyl moiety and is selected from the group consisting of halo, cyano, and unsubstituted C1-C3 alkyl. In some embodiments of Formula (Ik-2), p is 2, and R 3a In some embodiments of Formula (Ik-2), p is 2, and R 3a is 3-F and 5-Br. In some embodiments of Formula (Ik-1), p is 2, and R 3a In some embodiments of Formula (Ik-2), p is 2, and R 3a In some embodiments of Formula (Ik-2), p is 2, and R 3a It is 3-methyl and 5-cyano.

[0398] In some embodiments of Formula (Ik-2), R 5 is H. In some embodiments of Formula (Ik-2), R 5 is a substituted or unsubstituted alkyl group. In some embodiments of Formula (Ik-2), R 5 It's methyl.

[0399] In some embodiments of Formula (Ik-2), G 1 is cyclobutyl, m is 1, R 1a is selected from the group consisting of F, Cl and -CF3, n is 0, p is 1, R 3a is selected from the group consisting of F, Cl and cyano, and R 5 is H. In some embodiments of Formula (Ik-2), G 1 is azetidinyl, m is 1, R 1a is selected from the group consisting of F, Cl and -CF3, n is 0, p is 1, R 3a is selected from the group consisting of F, Cl and cyano and R 5 is H. In some embodiments of Formula (Ik-2), G 1 is oxetane, m is 1, R 1a is selected from the group consisting of F, Cl and -CF3, n is 0, p is 1, R 3a is selected from the group consisting of F, Cl and cyano, and R 5 is H. In some embodiments of Formula (Ik-2), G 1is cyclobutyl, m is 1, R 1a is selected from the group consisting of F, Cl and -CF3, n is 0, p is 1, R 3a is selected from the group consisting of F, Cl and cyano, and R 5 In some embodiments of Formula (Ik-2), G 1 is azetidinyl, m is 1, R 1a is selected from the group consisting of F, Cl and -CF3, n is 0, p is 1, R 3a is selected from the group consisting of F, Cl and cyano, and R 5 In some embodiments of Formula (Ik-2), G 1 is oxetane, m is 1, R 1a is selected from the group consisting of F, Cl and -CF3, n is 0, p is 1, R 3a is selected from the group consisting of F, Cl and cyano, and R 5 It's methyl.

[0400] In some embodiments of Formula (Ik-2), G 1 is cyclobutyl, m is 1, R 1a Selected from the group consisting of F, Cl and -CF3, n is 0, p is 2, each R 3a are independently selected from the group consisting of F, Cl and cyano, and R 5 is H. In some embodiments of Formula (Ik-2), G 1 is azetidinyl, m is 1, R 1a Selected from the group consisting of F, Cl and -CF3, n is 0, p is 2, each R 3a are independently selected from the group consisting of F, Cl and cyano, and R 5 is H. In some embodiments of Formula (Ik-2), G 1 is oxetane, m is 1, R 1a Selected from the group consisting of F, Cl and -CF3, n is 0, p is 2, each R 3a are independently selected from the group consisting of F, Cl and cyano, and R 5 is H. In some embodiments of Formula (Ik-2), G 1 is cyclobutyl, m is 1, R 1a Selected from the group consisting of F, Cl and -CF3, n is 0, p is 2, each R 3a are independently selected from the group consisting of F, Cl and cyano, and R 5 In some embodiments of Formula (Ik-2), G 1 is azetidinyl, m is 1, R 1aSelected from the group consisting of F, Cl and -CF3, n is 0, p is 2, each R 3a are independently selected from the group consisting of F, Cl and cyano, and R 5 In some embodiments of Formula (Ik-2), G 1 is oxetane, m is 1, R 1a Selected from the group consisting of F, Cl and -CF3, n is 0, p is 2, each R 3a are independently selected from the group consisting of F, Cl and cyano, and R 5 It's methyl.

[0401] In some embodiments of Formula (Ik-2), G 1 is cyclobutyl, m is 2, each R 1a are independently selected from the group consisting of F, Cl and -CF3, n is 0, p is 1, R 3a is selected from the group consisting of F, Cl and cyano, and R 5 is H. In some embodiments of Formula (Ik-2), G 1 is azetidinyl, m is 2, each R 1a are independently selected from the group consisting of F, Cl and -CF3, n is 0, p is 1, R 3a is selected from the group consisting of F, Cl and cyano, and R 5 is H. In some embodiments of Formula (Ik-2), G 1 is an oxetane group, m is 2, each R 1a are independently selected from the group consisting of F, Cl and -CF3, n is 0, p is 1, R 3a is selected from the group consisting of F, Cl and cyano, and R 5 is H. In some embodiments of Formula (Ik-2), G 1 is cyclobutyl, m is 2, each R 1a are independently selected from the group consisting of F, Cl and -CF3, n is 0, p is 1, R 3a is selected from the group consisting of F, Cl and cyano, and R 5 In some embodiments of Formula (Ik-2), G 1 is azetidinyl, m is 2, each R 1a are independently selected from the group consisting of F, Cl and -CF3, n is 0, p is 1, R 3a is selected from the group consisting of F, Cl and cyano, and R 5 In some embodiments of Formula (Ik-2), G 1 is an oxetane group, m is 2, each R 1aare independently selected from the group consisting of F, Cl and -CF3, n is 0, p is 1, R 3a is selected from the group consisting of F, Cl and cyano, and R 5 It's methyl.

[0402] In some embodiments of Formula (Ik-2), G 1 is cyclobutyl, m is 2, each R 1a are independently selected from the group consisting of F, Cl and -CF3, n is 0, p is 2, each R 3a are independently selected from the group consisting of F, Cl and cyano, and R 5 is H. In some embodiments of Formula (Ik-2), G 1 is azetidinyl, m is 2, each R 1a are independently selected from the group consisting of F, Cl and -CF3, n is 0, p is 2, each R 3a are independently selected from the group consisting of F, Cl and cyano, and R 5 is H. In some embodiments of Formula (Ik-2), G 1 is an oxetane group, m is 2, each R 1a are independently selected from the group consisting of F, Cl and -CF3, n is 0, p is 2, each R 3a are independently selected from the group consisting of F, Cl and cyano, and R 5 is H. In some embodiments of Formula (Ik-2), G 1 is cyclobutyl, m is 2, each R 1a are independently selected from the group consisting of F, Cl and -CF3, n is 0, p is 2, each R 3a are independently selected from the group consisting of F, Cl and cyano, and R 5 In some embodiments of Formula (Ik-2), G 1 is azetidinyl, m is 2, each R 1a are independently selected from the group consisting of F, Cl and -CF3, n is 0, p is 2, each R 3a are independently selected from the group consisting of F, Cl and cyano, and R 5 In some embodiments of Formula (Ik-2), G 1 is an oxetane group, m is 2, each R 1a are independently selected from the group consisting of F, Cl and -CF3, n is 0, p is 2, each R 3a are independently selected from the group consisting of F, Cl and cyano, and R 5 It's methyl.

[0403] In another aspect, the compound of formula (I) is a compound of formula (II) or a pharmaceutically acceptable salt thereof:

[0404]

[0405] where R 2A is H or substituted or unsubstituted alkyl; R 2b is selected from the group consisting of: H, substituted or unsubstituted alkyl, substituted or unsubstituted alkoxycarbonyl, substituted or unsubstituted aminoacyl, and hydroxy; m is 0, 1, or 2; p is 0, 1, or 2; each R 1a are independently selected from the group consisting of: halogenated and substituted or unsubstituted alkyl; each R 3a are independently halo; and R 4 It’s H.

[0406] In some embodiments of Formula (I1), R 2A It’s H.

[0407] In some embodiments of Formula (I1), R 2b is selected from the group consisting of substituted or unsubstituted alkyl, substituted or unsubstituted alkoxycarbonyl, substituted or unsubstituted aminoacyl and hydroxy. In some embodiments of Formula (II), R 2b is selected from the group consisting of substituted or unsubstituted alkyl, substituted or unsubstituted alkoxycarbonyl, substituted or unsubstituted aminoacyl and hydroxy. In some embodiments of Formula (II), R 2b is selected from the group consisting of: substituted C1-C3 alkyl, unsubstituted C1-C3 alkoxycarbonyl, unsubstituted aminoacyl and hydroxy. In some embodiments of formula (II), R 2b is a C1-C3 alkyl group substituted with a hydroxyl group. 2b Is -CH2OH. In some embodiments of Formula (I1), R 2b In some embodiments of Formula (I1), R 2b In some embodiments of Formula (I1), R 2b is an unsubstituted aminoacyl group. In some embodiments of Formula (I1), R 2b It is a hydroxyl group.

[0408] In some embodiments of Formula (I1), m is 1, and R 1a is selected from the group consisting of: halo and substituted or unsubstituted alkyl. In some embodiments of Formula (II), m is 1, and R 1a In some embodiments of Formula (II), m is 1, and R 1ais 4-F. In some embodiments of Formula (I1), m is 1, and R 1a In some embodiments of Formula (II), m is 1, and R 1a is a C1-C3 alkyl group optionally substituted with halogen. In some embodiments of Formula (I1), m is 1, and R 1a In some embodiments of Formula (II), m is 1, and R 1a is 4-CHF2. In some embodiments of Formula (I1), m is 1, and R 1a It is 4-CF3.

[0409] In some embodiments of Formula (II), p is 2, and each R 3a In some embodiments of Formula (II), p is 2, and each R 3a are independently F or Cl. In some embodiments of Formula (II), p is 2, and one R 3a is 3-halogenated and one R 3a In some embodiments of Formula (II), p is 2, and R 3a It is 3-F and 5-Cl.

[0410] In another aspect, the compound of formula (I) is a compound of formula (Im) or a pharmaceutically acceptable salt thereof:

[0411]

[0412] Where Q is -O- or -N(R 2b )-;R 2b is selected from the group consisting of: H and substituted or unsubstituted acyl; m is 0, 1 or 2; p is 0, 1 or 2; each R 1a are independently selected from the group consisting of: halogenated and substituted or unsubstituted alkyl; each R 3a are independently halo; and R 4 It’s H.

[0413] In some embodiments of Formula (Im), Q is -O-. In some embodiments of Formula (Im), Q is -N(R 2b )-.

[0414] In some embodiments of Formula (Im), R 2b is a substituted or unsubstituted acyl group. In some embodiments of Formula (Im), R 2b is an unsubstituted acyl group. In some embodiments of Formula (Im), R 2b is acyl substituted with alkyl. In some embodiments of Formula (Im), R 2bIt is an acyl group substituted with a methyl group.

[0415] In some embodiments of Formula (Im), m is 1, and R 1a is selected from the group consisting of: halo and substituted or unsubstituted alkyl. In some embodiments of Formula (Im), m is 1, and R 1a In some embodiments of Formula (Im), m is 1, and R 1a is 4-F. In some embodiments of Formula (Im), m is 1, and R 1a In some embodiments of Formula (Im), m is 1, and R 1a is a C1-C3 alkyl group optionally substituted with halogen. In some embodiments of Formula (Im), m is 1, and R 1a In some embodiments of Formula (Im), m is 1, and R 1a is 4-CHF2. In some embodiments of Formula (Im), m is 1, and R 1a It is 4-CF3.

[0416] In some embodiments of Formula (Im), p is 2, and each R 3a In some embodiments of Formula (Im), p is 2, and each R 3a is independently F or Cl. In some embodiments of Formula (Im), p is 2, and one R 3a is 3-halogenated and one R 3a In some embodiments of Formula (Im), p is 2, and R 3a It is 3-F and 5-Cl.

[0417] In another aspect, the compound of formula (I) is a compound of formula (In-1) or formula (In-2), or a pharmaceutically acceptable salt thereof:

[0418]

[0419] in:

[0420] R 1 selected from the group consisting of substituted or unsubstituted phenyl and substituted or unsubstituted pyridyl;

[0421] R 2A 、R 2B and R 3 Defined by any of (i) to (iii):

[0422] (i)R 2A is H or substituted or unsubstituted alkyl;

[0423] R 2B is selected from the group consisting of H, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted cycloalkenyl, substituted or unsubstituted cycloalkynyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl, and substituted or unsubstituted heteroaryl; and

[0424] R 3 is substituted or unsubstituted phenyl or substituted or unsubstituted pyridyl;

[0425] or

[0426] (ii)R 2A is H or substituted or unsubstituted alkyl;

[0427] R 2B is substituted or unsubstituted phenyl or substituted or unsubstituted pyridyl; and

[0428] R 3 is a substituted or unsubstituted alkyl group;

[0429] or

[0430] (iii)R 2A and R 2B Together with the carbon atom to which they are attached, they form G 1 , where G 1 is a substituted or unsubstituted cycloalkyl, substituted or unsubstituted cycloalkenyl, substituted or unsubstituted cycloalkynyl, or substituted or unsubstituted heterocyclyl ring, each of which is optionally fused to a phenyl ring; and

[0431] R 3 selected from the group consisting of substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted cycloalkenyl, substituted or unsubstituted cycloalkynyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl, and substituted or unsubstituted heteroaryl;

[0432] R 4 is H or substituted or unsubstituted alkyl; and

[0433] R 5 is H or substituted or unsubstituted alkyl;

[0434] Where one or more of the provisions (a) to (c) apply, then R 1 is substituted or unsubstituted pyridyl or phenyl substituted with at least one substituent other than methyl or methoxy:

[0435] (a)R 2A and R2B As defined in (i), and R 3 is a substituted or unsubstituted phenyl group;

[0436] (b)R 2A and R 3 As defined in (ii), and R 2B is 4-methoxyphenyl;

[0437] (c)R 2A and R 2B As defined in (iii), and R 3 It is 4-methoxyphenylmethyl.

[0438] In some embodiments, provided herein are the compounds described in Table 1 and salts thereof.

[0439]

[0440]

[0441]

[0442]

[0443]

[0444]

[0445]

[0446]

[0447]

[0448]

[0449]

[0450]

[0451]

[0452]

[0453]

[0454]

[0455]

[0456]

[0457]

[0458]

[0459]

[0460]

[0461]

[0462]

[0463]

[0464]

[0465]

[0466]

[0467]

[0468]

[0469]

[0470]

[0471]

[0472]

[0473]

[0474]

[0475]

[0476]

[0477]

[0478]

[0479]

[0480]

[0481]

[0482]

[0483]

[0484]

[0485]

[0486]

[0487]

[0488]

[0489]

[0490]

[0491]

[0492]

[0493]

[0494]

[0495]

[0496]

[0497]

[0498]

[0499]

[0500]

[0501]

[0502]

[0503]

[0504]

[0505]

[0506]

[0507]

[0508]

[0509]

[0510]

[0511]

[0512]

[0513]

[0514]

[0515]

[0516]

[0517]

[0518]

[0519]

[0520]

[0521]

[0522]

[0523]

[0524]

[0525]

[0526]

[0527]

[0528]

[0529]

[0530]

[0531]

[0532]

[0533]

[0534]

[0535]

[0536]

[0537]

[0538]

[0539]

[0540]

[0541]

[0542]

[0543]

[0544]

[0545]

[0546]

[0547]

[0548]

[0549]

[0550]

[0551]

[0552]

[0553]

[0554]

[0555]

[0556]

[0557]

[0558]

[0559]

[0560]

[0561]

[0562]

[0563]

[0564]

[0565]

[0566]

[0567]

[0568]

[0569]

[0570]

[0571]

[0572]

[0573]

[0574]

[0575]

[0576]

[0577]

[0578]

[0579]

[0580]

[0581]

[0582]

[0583]

[0584]

[0015] In some variations, any of the compounds described herein, such as compounds of Formula (A)-7, (la)-8, (lb)-9, (lc)-10, (Id)-11, (Ie)-12, (If)-13, (Ig)-14, (Ih)-15, (Ii)-16, (Ij)-17, (Ik-2)-18, (Il)-19, (Im)-20, (In-1)-21, or (In-2) ​​or any variation thereof, or the compounds of Table 1, may be deuterated (e.g., hydrogen atoms are replaced with deuterium atoms). In some of these variations, the compound is deuterated at a single site. In other variations, the compound is deuterated at multiple sites. Deuterated compounds can be prepared from deuterated starting materials in a manner similar to the preparation of the corresponding undeuterated compounds. Hydrogen atoms can also be replaced with deuterium atoms using other methods known in the art.

[0585] It is intended that any formula provided herein, such as Formula (A)-7, (la), (lb), (lc), (Id), (le), (If), (Ig), (Ih), (Ii), (Ij), (Ik-1), (Ik-2), (Il), (Im), (In-1), or (In-2), represents a compound having the structure depicted by the structural formula, as well as certain variations or forms. Specifically, the compound of any formula provided herein may have asymmetric centers and therefore exist in different enantiomeric or diastereomeric forms. All optical isomers and stereoisomers of the compounds of the general formula, and mixtures thereof in any ratio, are considered to be within the scope of the formula. Therefore, any formula provided herein is intended to represent a racemate, one or more enantiomeric forms, one or more diastereomeric forms, one or more conformational forms, and mixtures thereof in any ratio. When the compounds of Table 1 are depicted with a specific stereochemical configuration, any alternative stereochemical configurations of the compounds are also provided herein, as well as mixtures of any ratios of compound stereoisomers. For example, when the compounds of Table 1 have a stereocenter in an "S" stereochemical configuration, enantiomers of the compounds are also provided herein, wherein the stereocenter is in an "R" stereochemical configuration. Similarly, when the compounds of Table 1 have a stereocenter in an "R" configuration, enantiomers of the compounds in an "S" stereochemical configuration are also provided herein. Mixtures of compounds with "S" and "R" stereochemical configurations are also provided. In addition, if the compounds of Table 1 have two or more stereocenters, any enantiomers or diastereomers of the compounds are also provided. For example, if a compound of Table 1 contains a first stereocenter and a second stereocenter having stereochemical configurations of "R" and "R," respectively, further provided are stereoisomers of the compound containing first and second stereocenters having stereochemical configurations of "S" and "S," stereochemical configurations of "S" and "R," respectively, and stereochemical configurations of "R" and "S," respectively. For example, if a compound of Table 1 contains a first stereocenter and a second stereocenter having stereochemical configurations of "S" and "S," respectively, further provided are stereoisomers of the compound containing first and second stereocenters having stereochemical configurations of "R" and "R," stereochemical configurations of "S" and "R," respectively, and stereochemical configurations of "R" and "S," respectively. For example, if a compound of Table 1 contains a first stereocenter and a second stereocenter having "S" and "R" stereochemical configurations, respectively, then stereoisomers of the compound containing the first and second stereocenters having "R" and "S" stereochemical configurations, respectively, having "R" and "R" stereochemical configurations, respectively, and having "S" and "S" stereochemical configurations, respectively, are also provided.Similarly, if a compound of Table 1 contains a first stereocenter and a second stereocenter having "R" and "S" stereochemical configurations, respectively, then stereoisomers of the compound containing a first and a second stereocenter having "S" and "R" stereochemical configurations, respectively, "R" and "R" stereochemical configurations, respectively, and "S" and "S" stereochemical configurations, respectively, are also provided. In addition, certain structures can exist as geometric isomers (i.e., cis-isomers and trans-isomers), as tautomers, or as conformational isomers. In addition, any formula provided herein is intended to refer to any of the hydrates, solvates, and amorphous and polymorphous forms of the compound, and mixtures thereof, even if the form is not specifically listed. In some embodiments, the solvent is water and the solvate is a hydrate.

[0586] Representative examples of the compounds (including intermediates and final compounds) described in detail herein are depicted in the tables and other sections herein. It should be understood that, in one aspect, any of the compounds described herein can be used in the methods described in detail herein, including (where applicable) intermediate compounds that can be isolated and administered to an individual or subject.

[0587] The compounds described herein may exist in salt form even if not depicted as salts, and it is understood that the compositions and methods provided herein encompass all salts and solvates of the compounds described herein, as well as non-salt and non-solvate forms of the compounds, as well as those skilled in the art. In some embodiments, the salts of the compounds provided herein are pharmaceutically acceptable salts.

[0588] In one variation, the compounds described herein are synthetic compounds prepared for administration to an individual or subject. In another variation, compositions containing the compounds in substantially pure form are provided. In another variation, pharmaceutical compositions comprising the compounds detailed herein and a pharmaceutically acceptable carrier are provided. In another variation, methods of administering the compounds are provided. The purified forms of the compounds, pharmaceutical compositions, and methods of administration are applicable to any compound or form thereof described in detail herein.

[0589] This article provides G 1 、R 1 、R 2A 、R 2B 、R 3 、R 4 and R 5 Any variation or implementation can be combined with G 1 、R 1 、R 2A 、R 2B 、R 3 、R 4 and R 5Each other variation or embodiment combination is described as if each combination were individually and specifically described.

[0590] This article provides G 1 、R 1 、R 2A 、R 2B 、R 3 、R 4 、R 5 、R 1a 、R 2a 、R 2b 、R 3a Any variation or embodiment of m, n, p, q, X and Q can be used with G 1 、R 1 、R 2A 、R 2B 、R 3 、R 4 、R 5 、R 1a 、R 2a 、R 2b 、R 3a Each other variation or embodiment combination of , m, n, p, q, X, and Q is as if each combination had been individually and specifically described.

[0591] As used herein, when any variable occurs more than one time in a formula, its definition on each occurrence is independent of its definition at every other occurrence.

[0592] Formula (I) includes all subformulae thereof. For example, Formula (I) includes compounds of Formula (Ia), Formula (Ib), Formula (Ic), Formula (Id), Formula (Ie), Formula (If), Formula (Ig), Formula (Ih), Formula (Ii), Formula (Ij), Formula (Ik-1), Formula (Ik-2), Formula (Il), Formula (Im), Formula (In-1), and Formula (In-2).

[0593] Certain compound names provided herein (including those in Table 1) are provided by ChemBioDraw Professional 15.0.0.106. It will be appreciated by those skilled in the art that various generally recognized nomenclature systems and symbols may be used to name or identify compounds. For example, compounds may be named or identified using common names, systematic or non-systematic names. Generally recognized nomenclature systems and symbols in the chemical arts include, for example, Chemical Abstract Service (CAS), ChemBioDraw Ultra, and International Union of Pure and Applied Chemistry (IUPAC).

[0594] Composition

[0595] Also provided are compositions, such as pharmaceutical compositions, comprising the compounds disclosed and / or described herein and one or more other medicinal agents, pharmaceutical preparations, adjuvants, carriers, excipients, and the like. Suitable medicinal and pharmaceutical preparations include those described herein. In some embodiments, the pharmaceutical composition comprises a pharmaceutically acceptable excipient or adjuvant and at least one chemical entity as described herein. Examples of pharmaceutically acceptable excipients include, but are not limited to, mannitol, lactose, starch, magnesium stearate, sodium saccharin, talc, cellulose, cross-linked sodium carboxymethyl cellulose, glucose, gelatin, sucrose, and magnesium carbonate. In some embodiments, compositions, such as pharmaceutical compositions, containing one or more compounds described herein or pharmaceutically acceptable salts thereof are provided.

[0596] In some embodiments, a pharmaceutically acceptable composition is provided, comprising a compound of Formula (A)-7, (Ia)-8, (Ib)-9, (Ic)-10, (Id)-11, (Ie)-12, (Ig)-13, (Ih)-14, (Ii)-15, (Ij)-16, (Ik-2)-17, (Il)-18, (Im)-19, (In-1) or (In-2) ​​or a compound of Table 1, or a pharmaceutically acceptable salt thereof. In some aspects, the composition may contain synthetic intermediates that can be used to prepare the compounds described herein. The compositions described herein may contain any other suitable active or inactive agents.

[0597] Any composition described herein can be sterile or contain sterile components. Sterilization can be achieved by methods known in the art. Any composition described herein can contain one or more substantially pure compounds or combinations.

[0598] Also provided are packaged pharmaceutical compositions comprising a pharmaceutical composition as described herein and instructions for using the composition to treat a patient suffering from a disease or condition described herein.

[0599] How to use

[0600] The compounds and pharmaceutical compositions herein can be used to treat or prevent a disease or disorder in an individual or subject.

[0601] When used in a prophylactic manner, the compounds disclosed and / or described herein can prevent the development of a disease or condition, or lessen the extent of a disease or condition that may be developed, in an individual or subject at risk of developing the disease or condition.

[0602] Without being bound by theory, it is believed that the compounds and pharmaceutical compositions disclosed herein act by inhibiting myosin. This inhibition may reduce the number of independent myosin heads that interact with actin filaments, thereby reducing the amount of contraction. Reducing myocardial contractility may be important for treating heart diseases where excessive contraction is a problem. In some embodiments, methods of treating or preventing heart disease in an individual or subject are provided, comprising administering to an individual or subject in need thereof a compound of Formula (A)-77, or a compound of formula (Ia)-77, or a compound of formula (Ib)-77, or a compound of formula (Ic)-77, or a compound of formula (Id)-77, or a compound of formula (Ie)-77, or a compound of formula (Ig)-77, or a compound of formula (Ih)-77, or a compound of formula (Ii)-77, or a compound of formula (Ik-1)-77, or a pharmaceutically acceptable salt thereof. In some embodiments, methods of treating or preventing heart disease in a subject in need thereof are provided, comprising administering to the subject a therapeutically effective amount of at least one chemical entity as described herein. In some embodiments, a method of treating a cardiac disease in a subject in need thereof is provided, comprising administering to the subject a therapeutically effective amount of at least one chemical entity as described herein. In some embodiments, a method of treating an established or diagnosed cardiac disease in a subject in need thereof is provided, comprising administering to the subject a therapeutically effective amount of at least one chemical entity as described herein. In some embodiments, a method of preventing a cardiac disease in a subject in need thereof is provided, comprising administering to the subject a prophylactically effective amount of at least one chemical entity as described herein.

[0603] Also provided herein is the use of a compound of Formula (A)-7, (Ia)-8, (Ib)-9, (Ic)-10, (Id)-11, (Ie)-12, (Ig)-13, (Ih)-14, (Ii)-15, (Ij)-16, (Ik-2)-17, (Il)-18, (Im)-19, (In-2)-20, or a compound of Table 1, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for treating a cardiac disease in a subject. In some aspects, a compound or composition as described herein is provided for use in a method of treating the human or animal body by therapy. In some embodiments, provided herein are compounds of Formula (I)-(la)-(la)-(la)-b)-(la)c-(ld)-(le)-(If)-(Ig)-(Ih)-(Ii)-(Ij)-(Ik-1)-(Ik-2)-(Il)-(Im)-(In-1)-(In-2) ​​or compounds of Table 1, or pharmaceutically acceptable salts thereof, for use in a method of treating the human or animal body by therapy. In some embodiments, provided herein are compounds of Formula (I)-(la)-(la)-(la)-b)-(la)c-(ld)-(le)-(If)-(Ig)-(Ih)-(Ii)-(Ij)-(Ik-1)-(Ik-2)-(Il)-(Im)-(In-1)-(In-2) ​​or compounds of Table 1, or pharmaceutically acceptable salts thereof, for use in treating or preventing heart disease. In some embodiments, provided herein are compounds of Formula (I)-(la)-(la)-(la)-b)-(la)c-(ld)-(le)-(If)-(Ig)-(Ih)-(Ii)-(Ij)-(Ik-1) or (Ik-2) or compounds of Table 1, or pharmaceutically acceptable salts thereof, for use in treating a cardiac disease. In some embodiments, provided herein are compounds of Formula (I)-(la)-(la)-(la)-b)-(la)c-(ld)-(le)-(If)-(Ig)-(Ih)-(Ii)-(Ij)-(Ik-1) or (Ik-2) or compounds of Table 1, or pharmaceutically acceptable salts thereof, for use in treating an established or diagnosed cardiac disease. In other embodiments, provided herein are compounds of Formula (I)-(Ia), (Ib), (Ic), (Id), (Ie), (If), (Ig), (Ih), (Ii), (Ij), (Ik-1), or (Ik-2), or a compound of Table 1, or a pharmaceutically acceptable salt thereof, for use in preventing heart disease.In some embodiments, provided herein are compounds of Formula (I)-(la)-(la)-(la)-b)-(la)c-(Id)-(le)-(If)-(Ig)-(Ih)-(Ii)-(Ij)-(Ik-1) or (Ik-2) or compounds of Table 1, or pharmaceutically acceptable salts thereof, for use in treating a disease or condition associated with HCM. In some embodiments, provided herein are compounds of Formula (I)-(la)-(la)-(la)-b)-(la)c-(Id)-(le)-(If)-(Ig)-(Ih)-(Ii)-(Ij)-(Ik-1) or (Ik-2) or compounds of Table 1, or pharmaceutically acceptable salts thereof, for use in treating a disease or condition associated with secondary left ventricular wall thickening. In some embodiments, provided herein are compounds of Formula (I)-(Ia)-(Ib)-(Ic), (Id)-(Ie), (If)-(Ig)-(Ih), (Ii)-(Ij), (Ik-1)-(Ik-2), or compounds of Table 1, or pharmaceutically acceptable salts thereof, for use in improving symptoms associated with heart disease. In other embodiments, provided herein are compounds of Formula (I)-(Ia)-(Ib)-(Ic), (Id)-(Ie), (If)-(Ig)-(Ih), (Ii)-(Ij), (Ik-1)-(Ik-2), or compounds of Table 1, or pharmaceutically acceptable salts thereof, for use in reducing the risk of symptoms associated with heart disease. In other embodiments, provided herein are compounds of Formula (A)-(Ia)-(Ib)-(Ic)-(Id)-(Ie)-(If)-(Ig)-(Ih)-(Ii)-(Ij)-(Ik-1) or (Ik-2) or a compound of Table 1, or a pharmaceutically acceptable salt thereof, for use in treating a disease or condition associated with left ventricular chamber stenosis, chamber occlusion, hyperdynamic left ventricular contraction, left ventricular blood outflow obstruction, cardiac hypertrophy, small stroke volume, impaired left ventricular relaxation, high left ventricular filling pressure, myocardial ischemia, or cardiac fibrosis. In certain embodiments, provided herein are compounds of Formula (A)-(Ia)-(Ib)-(Ic)-(Id)-(Ie)-(If)-(Ig)-(Ih)-(Ii)-(Ij)-(Ik-1) or (Ik-2) or a compound of Table 1, or a pharmaceutically acceptable salt thereof, for use in treating diseases or conditions associated with left ventricular chamber stenosis and chamber occlusion, hyperdynamic left ventricular contraction, myocardial ischemia, or cardiac fibrosis.In some embodiments, provided herein are compounds of Formula (I)-(la)-(la)-(la)-b)-(la)c-(ld)-(le)-(If)-(Ig)-(Ih)-(Ii)-(Ij)-(Ik-1) or (Ik-2) or compounds of Table 1, or pharmaceutically acceptable salts thereof, for use in treating muscular dystrophy. In some embodiments, provided herein are compounds of Formula (I)-(la)-(la)-(la)-b)-(la)c-(ld)-(le)-(If)-(Ig)-(Ih)-(Ii)-(Ij)-(Ik-1) or (Ik-2) or compounds of Table 1, or pharmaceutically acceptable salts thereof, for use in treating glycogen storage diseases. In other embodiments, provided herein are compounds of Formula (I)-(Ia)-(Ib)-(Ic)-(Id)-(Ie)-(If)-(Ig)-(Ih)-(Ii)-(Ij)-(Ik-1) or (Ik-2) or compounds of Table 1, or pharmaceutically acceptable salts thereof, for use in modulating cardiac sarcomeres, such as inhibiting cardiac sarcomeres. In other embodiments, provided herein are compounds of Formula (I)-(Ia)-(Ib)-(Ic)-(Id)-(Ie)-(If)-(Ig)-(Ih)-(Ii)-(Ij)-(Ik-1) or (Ik-2) or compounds of Table 1, or pharmaceutically acceptable salts thereof, for use in strengthening cardiac myosin.

[0604] In some embodiments, the subject is a mammal. In some embodiments, the subject is a mouse, rat, dog, cat, pig, sheep, horse, cow or human. In some embodiments, the subject is a human. In some embodiments, the subject suffers from a determined or diagnosed heart disease. In some embodiments, the subject suffers from a determined or diagnosed hypertrophic cardiomyopathy (HCM). In some embodiments, the subject has a risk of suffering from a heart disease. In some embodiments, the subject has a mutation that increases the risk of heart disease. In some embodiments, the subject has a mutation that increases the risk of hypertrophic cardiomyopathy (HCM). In some embodiments, the mutation is a sarcomere mutation. In some embodiments, the mutation is a mutation in myosin heavy chain beta (MHC-β), cardiac troponin T (cTnT), tropomyosin alpha-1 chain (TPM1), cardiac myosin binding protein C (MYBPC3), cardiac troponin I (cTnI), myosin essential light chain (ELC), titin (TTN), myosin regulatory light chain 2 ventricular / cardiac isoform (MLC-2), cardiac alpha-actin, muscle LIM protein (MLP), or protein kinase AMP-activated non-catalytic subunit gamma 2 (PRKAG2). In some embodiments, the mutation is a mutation in MHC-β. In some embodiments, the subject has established or diagnosed hypertrophic cardiomyopathy without a proven genetic cause.

[0605] In some embodiments, the subject has a high risk of progressive symptoms. In some embodiments, the subject has a high risk of atrial fibrillation, ventricular tachycardia, stroke, and / or sudden death. In some embodiments, the subject has reduced exercise capacity. In some embodiments, the reduced exercise capacity is compared to an age-matched control group. In some embodiments, the subject is suitable for surgical intervention or percutaneous removal to treat the heart disease.

[0606] In some embodiments, the heart disease is hypertrophic cardiomyopathy (HCM). In some embodiments, the heart disease is obstructive HCM. In some embodiments, the heart disease is non-obstructive HCM. In some embodiments, the HCM is associated with a sarcomeric mutation. In some embodiments, the HCM is associated with a non-sarcomeric mutation. In some embodiments, the heart disease is obstructive or non-obstructive HCM caused by a sarcomeric and / or non-sarcomeric mutation. In some embodiments, the sarcomeric mutation is a mutation in myosin heavy chain β (MHC-β), cardiac troponin T (cTnT), tropomyosin α-1 chain (TPM1), cardiac myosin binding protein C (MYBPC3), cardiac troponin I (cTnI), myosin essential light chain (ELC), titin (TTN), myosin regulatory light chain 2 ventricular / cardiac isoform (MLC-2), cardiac α-actin, or muscle LIM protein (MLP). In some embodiments, the sarcomeric mutation is a mutation in MHC-β. In some embodiments, the non-sarcomeric mutation is a mutation in protein kinase AMP-activated non-catalytic subunit gamma 2 (PRKAG2).

[0607] In some embodiments, provided herein are methods of treating a disease or condition associated with HCM, comprising administering to an individual or subject in need thereof a compound of Formula (A)-7, (la), (lb), (lc), (Id), (le), (If), (Ig), (Ih), (Ii), (Ij), (Ik-1), (Ik-2), (II), (Im), (In-1), or (In-2), or a compound of Table 1, or a pharmaceutically acceptable salt thereof. In some embodiments, the disease or condition is Fabry disease, Danon disease, mitochondrial cardiomyopathy, or Noonan syndrome.

[0608] Also provided herein is the use of a compound of Formula (I)-7, Formula Ia, Formula Ib, Formula Ic, Formula Id, Formula Ie, Formula (If), Formula (Ig), Formula (Ih), Formula (Ii), Formula (Ij), Formula (Ik-1), Formula (Ik-2), Formula (Il), Formula (Im), Formula (In-1), or Formula (In-2), or a compound of Table 1, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for treating a disease or condition associated with HCM.

[0609] In some embodiments, the heart disease is heart failure with preserved ejection fraction (HFpEF). In some embodiments, the heart disease is diastolic dysfunction. In some embodiments, the heart disease is cardiomyopathy. In some embodiments, the heart disease is primary or secondary restrictive cardiomyopathy. In some embodiments, the heart disease is a disorder or symptom caused by coronary artery disease. In some embodiments, the heart disease is myocardial infarction or angina pectoris. In some embodiments, the heart disease is left ventricular outflow tract obstruction. In some embodiments, the heart disease is hypertensive heart disease. In some embodiments, the heart disease is congenital heart disease. In some embodiments, the heart disease is cardiac ischemia and / or coronary heart disease. In some embodiments, the heart disease is diabetic heart disease. In other embodiments, the heart disease is congestive heart failure. In some embodiments, the heart disease is right heart failure. In other embodiments, the heart disease is cardiorenal syndrome. In some embodiments, the heart disease is infiltrative cardiomyopathy. In some embodiments, the heart disease is diastolic dysfunction due to heart aging or aging, or a condition related thereto. In some embodiments, the heart disease is left ventricular hypertrophy and / or concentric left ventricular remodeling, or a condition related thereto.

[0610] In some embodiments, a method of treating a disease or condition associated with secondary left ventricular wall thickening in an individual or subject is provided, comprising administering to the individual or subject in need thereof a compound of Formula (A)-7, (la), (lb), (lc), (Id), (le), (If), (Ig), (Ih), (Ii), (Ij), (Ik-1), (Ik-2), (II), (Im), (In-1), or (In-2), or a compound of Table 1, or a pharmaceutically acceptable salt thereof. In some embodiments, the disease is hypertension, valvular heart disease (aortic stenosis, mitral insufficiency), metabolic syndrome (diabetes, obesity), end-stage renal disease, scleroderma, sleep apnea, amyloidosis, Fabry disease, Friedreich's ataxia, Danon's disease, Noonan syndrome, or Pompe disease.

[0611] Also provided herein is the use of a compound of Formula (I), Formula (Ia), Formula (Ib), Formula (Ic), Formula (Id), Formula (Ie), Formula (If), Formula (Ig), Formula (Ih), Formula (Ii), Formula (Ij), Formula (Ik-1), Formula (Ik-2), Formula (Il), Formula (Im), Formula (In-1) or Formula (In-2) ​​or a compound of Table 1 or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for treating a disease or condition associated with secondary left ventricular wall thickening.

[0612] In some embodiments, a method for improving symptoms associated with heart disease in a subject is provided, the method comprising administering to an individual or subject in need thereof a compound of Formula (I)-(Ia), (Ib), (Ic), (Id), (Ie), (If), (Ig), (Ih), (Ii), (Ij), (Ik-1), or (Ik-2), or a compound of Table 1, or a pharmaceutically acceptable salt thereof, wherein the symptom is selected from poor or decreased cardiac elasticity, One or more of poor or decreased diastolic left ventricular relaxation, abnormal left atrial pressure (e.g., abnormally high left atrial pressure), paroxysmal or permanent atrial fibrillation, increased left atrial and pulmonary capillary wedge pressures, increased left ventricular diastolic pressure, syncope, ventricular relaxation during diastole, ventricular fibrosis, left ventricular hypertrophy, left ventricular mass, increased left ventricular wall thickness, left ventricular mid-cavity obstruction, increased systolic anterior motion of the mitral valve, left ventricular outflow tract obstruction, chest pain, dyspnea on exertion, presyncope, abnormal exercise capacity, and fatigue.

[0613] In some embodiments, a method of reducing the risk of a symptom associated with cardiac disease in a subject is provided, the method comprising administering to an individual or subject in need thereof a compound of Formula (A)-(Ia)-(Ib)-(Ic)-(Id)-(Ie)-(If)-(Ig)-(Ih)-(Ii)-(Ij)-(Ik-1) or (Ik-2) or a compound of Table 1, or a pharmaceutically acceptable salt thereof, wherein the symptom is selected from sudden cardiac death, cardiac inelasticity, One or more of: poor or decreased diastolic left ventricular relaxation, poor or decreased diastolic left ventricular relaxation, abnormal left atrial pressure (e.g., abnormally high left atrial pressure), paroxysmal or permanent atrial fibrillation, increased left atrial and pulmonary capillary wedge pressures, increased left ventricular diastolic pressure, syncope, ventricular relaxation during diastole, ventricular fibrosis, left ventricular hypertrophy, left ventricular mass, increased left ventricular wall thickness, left ventricular mid-cavity obstruction, increased systolic anterior motion of the mitral valve, left ventricular outflow tract obstruction, chest pain, dyspnea on exertion, presyncope, abnormal exercise capacity, and fatigue.

[0614] In some embodiments, a method is provided for treating a disease or condition associated with left ventricular chamber stenosis, chamber occlusion, hyperdynamic left ventricular contraction, left ventricular blood outflow obstruction, cardiac hypertrophy, small stroke volume, impaired left ventricular relaxation, high left ventricular filling pressure, myocardial ischemia, or cardiac fibrosis in an individual or subject, the method comprising administering to the individual or subject in need thereof a compound of Formula (A)-(Ia)-(Ib)-(Ic)-(Id)-(Ie)-(If)-(Ig)-(Ih)-(Ii)-(Ij)-(Ik-1) or (Ik-2) or a compound of Table 1 or a pharmaceutically acceptable salt thereof.

[0615] In some embodiments, a method is provided for treating a disease or condition associated with left ventricular chamber stenosis and chamber occlusion, hyperdynamic left ventricular contraction, myocardial ischemia, or cardiac fibrosis in an individual or subject, the method comprising administering to the individual or subject in need thereof a compound of Formula (A)-7, Formula Ia, Formula Ib, Formula Ic, Formula Id, Formula If, Formula Ig, Formula Ih, Formula Ii, Formula Ij, Formula Ik-1, Formula Ik-2, Formula Il, Formula Im, Formula In-1, or Formula In-2, or a compound of Table 1 or a pharmaceutically acceptable salt thereof.

[0616] Also provided herein is the use of a compound of Formula (I)-7, (la), (lb), (lc), (Id), (le), (If), (Ig), (Ih), (Ii), (Ij), (Ik-1), (Ik-2), (Il), (Im), (In-1), or (In-2), or a compound of Table 1, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for treating a disease or condition associated with left ventricular chamber stenosis and chamber occlusion, hyperdynamic left ventricular contraction, myocardial ischemia, or cardiac fibrosis.

[0617] In some embodiments, a method of treating muscular dystrophy (e.g., Duchenne muscular dystrophy) in an individual or subject is provided, comprising administering to the individual or subject in need thereof a compound of Formula (A)-7, Ia-8, Ib-9, Ic-10, Id-11, Ic-20, Il-11, Im-12, In-13, or In-2, or a compound of Table 1 or a pharmaceutically acceptable salt thereof. Also provided herein is the use of a compound of Formula (I)-7, (la), (lb), (lc), (Id), (le), (If), (Ig), (Ih), (Ii), (Ij), (Ik-1), (Ik-2), (Il), (Im), (In-1), or (In-2), or a compound of Table 1, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for treating muscular dystrophy (e.g., Duchenne muscular dystrophy).

[0618] In some embodiments, a method of treating a glycogen storage disease in an individual or subject is provided, comprising administering to the individual or subject in need thereof a compound of Formula (A)-7, Formula Ia, Formula Ib, Formula Ic, Formula Id, Formula Ie, Formula If, Formula Ig, Formula Ih, Formula Ii, Formula Ij, Formula Ik-1, Formula Ik-2, Formula Il, Formula Im, Formula In-1, or Formula In-2, or a compound of Table 1, or a pharmaceutically acceptable salt thereof. Also provided herein is the use of a compound of Formula (I), Formula (Ia), Formula (Ib), Formula (Ic), Formula (Id), Formula (Ie), Formula (If), Formula (Ig), Formula (Ih), Formula (Ii), Formula (Ij), Formula (Ik-1), Formula (Ik-2), Formula (Il), Formula (Im), Formula (In-1) or Formula (In-2) ​​or a compound of Table 1 or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for treating glycogen storage disease.

[0619] Also provided are methods for regulating cardiac sarcomeres in an individual or subject, the methods comprising administering to an individual or subject in need thereof a therapeutically effective amount of at least one chemical entity as described herein. In some embodiments, a method for inhibiting cardiac sarcomeres is provided, the method comprising contacting the cardiac sarcomere with at least one chemical entity as described herein, such as a compound of Formula (A)-7, Formula Ia, Formula Ib, Formula Ic, Formula Id, Formula Ie, Formula If, Formula Ig, Formula Ih, Formula Ii, Formula Ij, Formula (Ik-1), Formula (Ik-2), Formula (Il), Formula (Im), Formula (In-1) or Formula (In-2), or a compound of Table 1, or a pharmaceutically acceptable salt thereof. Further provided herein is the use of at least one chemical entity as described herein, such as a compound of Formula (A)-7, Formula Ia, Formula Ib, Formula Ic, Formula Id, Formula Ie, Formula If, Formula Ig, Formula Ih, Formula Ii, Formula Ij, Formula Ik-1, Formula Ik-2, Formula II, Formula Im, Formula In-1, or Formula In-2, or a compound of Table 1, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for inhibiting cardiac sarcomere in an individual or subject.

[0620] Also provided are methods of enhancing cardiac myosin in an individual or subject, the method comprising administering to the individual or subject in need thereof a therapeutically effective amount of at least one chemical entity as described herein, such as a compound of Formula (A)-7, Formula Ia, Formula Ib, Formula Ic, Formula Id, Formula Ie, Formula If, Formula Ig, Formula Ih, Formula Ii, Formula Ij, Formula Ik-1, Formula Ik-2, Formula Il, Formula Im, Formula In-1, or Formula In-2, or a compound of Table 1 or a pharmaceutically acceptable salt thereof. Further provided herein is the use of at least one chemical entity as described herein, such as a compound of Formula (A)-7, Formula Ia, Formula Ib, Formula Ic, Formula Id, Formula Ie, Formula If, Formula Ig, Formula Ih, Formula Ii, Formula Ij, Formula Ik-1, Formula Ik-2, Formula II, Formula Im, Formula In-1, or Formula In-2, or a compound of Table 1, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for enhancing cardiac myosin in an individual or subject.

[0621] In some embodiments, the methods provided herein further include monitoring the effectiveness of treatment. Examples of indicators include, but are not limited to, improvements in one or more of the following: New York Heart Association (NYHA) functional class, exercise capacity, cardiac elasticity, diastolic left ventricular relaxation, left atrial pressure, paroxysmal or permanent atrial fibrillation, left atrial and pulmonary capillary wedge pressure, left ventricular diastolic pressure, syncope, ventricular relaxation during diastole, ventricular fibrosis, left ventricular hypertrophy, left ventricular mass, left ventricular wall thickness, left ventricular mid-cavity obstruction, mitral valve systolic anterior motion, left ventricular outflow tract obstruction, chest pain, exercise dyspnea, presyncope, abnormal exercise capacity and fatigue. These indicators can be monitored by techniques known in the art, including self-report; ECG, including ambulatory ECG; cardiac ultrasound; cardiac MRI; CT; biopsy; cardiopulmonary exercise testing (CPET); and wrist actigraphy.

[0622] In some embodiments, the compound reduces the contractility of cardiomyocytes. In some embodiments, the compound reduces the contractility of cardiomyocytes by more than 40%, such as more than 45%, 50%, 60%, 70%, 80% or 90%. In some embodiments, the compound reduces the contractility of cardiomyocytes by 40% to 90%, such as 40% to 80%, 40% to 70%, 50% to 90%, 50% to 80% or 50% to 70%. In some embodiments, the compound does not significantly change the calcium transient value in cardiomyocytes. In some embodiments, the compound reduces the ATPase activity in cardiomyocytes. Methods for measuring contractility, ATPase activity and calcium transient values ​​are known in the art, for example, by calcium labeling, electrophysiological recording and microscopic imaging. In some embodiments, the compound does not significantly inhibit or induce cytochrome P450 (CYP) protein.

[0623] Not bound by theory, it is believed that 2A and R 2B The compounds of formula (I) or any of its variations wherein the carbon atoms of the compound are in the "S" stereochemical configuration are more stereoisomers than those having R 2A and R 2B The corresponding stereoisomers having the carbon of the moiety in the "R" stereochemical configuration are more active as measured by a myofibril assay (such as the assay described in Example B-1). Crystal structures of representative compounds of formula (I) were obtained, illustrating that between the "S" isomer and the "R" isomer, the more active stereoisomer is the one with R 2A and R 2B Some of the stereoisomers have their carbons in the "S" stereochemical configuration as measured by the myofibril assay described in Example B-1.

[0624] In some embodiments, the subject's left ventricular wall is thicker than normal before treatment. In some embodiments, the subject's left ventricular wall thickness is greater than 15 mm, such as greater than 18 mm, 20 mm, 22 mm, 25 mm, or 30 mm, before treatment. In some embodiments, left ventricular wall thickness decreases by more than 5%, such as greater than 8%, 10%, 12%, 15%, 20%, or 30% after treatment. Left ventricular wall thickness can be measured by methods known in the art, such as by cardiac ultrasound, CT scan, or cardiac MRI.

[0625] In some embodiments, the subject has abnormal cardiac fibrosis prior to treatment. In some embodiments, the abnormal cardiac fibrosis is reduced by more than 5%, such as more than 8%, 10%, 12%, 15%, 20%, or 30% after treatment. Cardiac fibrosis can be measured by methods known in the art, such as by biopsy or cardiac MRI.

[0626] In some embodiments, the subject has reduced exercise capacity before treatment. In some embodiments, the subject's exercise capacity increases by more than 5% after treatment, such as more than 8%, 10%, 12%, 15%, 20% or 30%. In some embodiments, exercise capacity is measured by cardiopulmonary exercise testing (CPET). CPET measures changes in oxygen consumption (VO2 maximum). Methods for measuring CPET and VO2 maximum are well known in the art (Malhotra et al., JACC:HeartFailure, 2016, 4(8):607-616; Guazzi et al., JAmer College Cardiol, 2017, 70(13):1618-1636; Rowin et al., JACC:Cariovasc Imaging, 2017, 10(11):1374-1386). In some embodiments, VO2 maximum increases by more than 1 mL / kg / m after treatment. 2 If it exceeds 1.2 mL / kg / m 2 , 1.4 mL / kg / m 2 1.5 mL / kg / m 2 , 1.7 mL / kg / m 2 2mL / kg / m 2 2.2 mL / kg / m 2 2.5 mL / kg / m 2 3mL / kg / m 2 3.2 mL / kg / m 2 or 3.5 mL / kg / m 2 .

[0627] In some embodiments, the subject has New York Heart Association (NYHA) functional class II, III, or IV prior to treatment. In some embodiments, the subject has New York Heart Association (NYHA) functional class III or IV prior to treatment. In some embodiments, the subject has New York Heart Association (NYHA) functional class IV prior to treatment. In some embodiments, the subject maintains the same NYHA functional class or has a decreased NYHA functional class after treatment.

[0628] In some embodiments, after treatment, VO2 max increases by more than 1 mL / kg / m 2 If it exceeds 1.2 mL / kg / m 2 , 1.4 mL / kg / m 2 1.5 mL / kg / m 2 , 1.7 mL / kg / m 2 or 2 mL / kg / m 2 and the subject has a reduced NYHA functional class. In some embodiments, after treatment, VO2 max increases by more than 2.5 mL / kg / m 2 3mL / kg / m 2 3.2 mL / kg / m 2 or 3.5 mL / kg / m 2 And the subject maintains the same NYHA functional class or has a decreased NYHA functional class.

[0629] In some embodiments, the subject's daily function and / or activity level is improved after treatment. The improved daily function and / or activity level can be measured, for example, by diary recording or wrist actigraphy, such as a FitBit or FitBit-like monitor.

[0630] In some embodiments, the subject has one or more of reduced shortness of breath, reduced chest pain, reduced arrhythmia burden (such as atrial fibrillation and ventricular arrhythmias), reduced incidence of heart failure, and reduced ventricular outflow obstruction after treatment.

[0631] dose

[0632] The compounds and compositions disclosed and / or described herein are administered at a therapeutically effective dose, e.g., a dose sufficient to provide treatment for a disease state. Although human dosage levels for the chemical entities described herein remain to be optimized, generally, daily doses are in the range of about 0.01 to 100 mg / kg body weight; in some embodiments, about 0.05 to 10.0 mg / kg body weight, and in some embodiments, about 0.10 to 1.4 mg / kg body weight. Thus, for administration to a 70 kg person, in some embodiments, the dosage range would be about 0.7 to 7000 mg per day; in some embodiments, about 3.5 to 700.0 mg per day, and in some embodiments, about 7 to 100.0 mg per day. The amount of the chemical entity administered will depend, for example, on the subject and disease state being treated, the severity of the condition, the route and schedule of administration, and the discretion of the prescribing physician. For example, an exemplary dosage range for oral administration is about 5 mg to about 500 mg per day, and an exemplary dosage range for intravenous administration is about 5 mg to about 500 mg per day, each depending on the pharmacokinetics of the compound.

[0633] The daily dose is the total amount administered in a day. The daily dose can be, but is not limited to, administered every day, every other day, every week, every two weeks, every month, or at varying intervals. In some embodiments, the daily dose is administered for a period of time ranging from one day to the lifetime of the subject. In some embodiments, the daily dose is administered once a day. In some embodiments, the daily dose is administered in multiple divided doses, such as 2, 3, or 4 divided doses. In some embodiments, the daily dose is administered in 2 divided doses.

[0634] The administration of the compounds and compositions disclosed and / or described herein can be carried out via any acceptable mode of administration of therapeutic agents, including but not limited to oral, sublingual, subcutaneous, parenteral, intravenous, intranasal, topical, transdermal, intraperitoneal, intramuscular, intrapulmonary, vaginal, rectal or intraocular administration. In some embodiments, the compound or composition is administered orally or intravenously. In some embodiments, the compound or composition disclosed and / or described herein is administered orally.

[0635] Pharmaceutically acceptable compositions include solid, semisolid, liquid and aerosol dosage forms, such as tablets, capsules, powders, liquids, suspensions, suppositories and aerosol forms. The compounds disclosed and / or described herein can also be administered in a sustained or controlled release dosage form (e.g., in the form of controlled / sustained release pills, reservoir injections, osmotic pumps or transdermal (including electrotransport) patches) for a long time and / or in a pulsed manner at a predetermined speed. In some embodiments, the composition is provided in a unit dosage form suitable for a single administration of a precise dose.

[0636] The compounds disclosed and / or described herein can be administered alone or in combination with one or more conventional pharmaceutical carriers or excipients (e.g., mannitol, lactose, starch, magnesium stearate, sodium saccharin, talc, cellulose, croscarmellose sodium, glucose, gelatin, sucrose, magnesium carbonate). If desired, the pharmaceutical composition may also contain minor amounts of non-toxic adjuvant substances such as wetting agents, emulsifiers, solubilizers, pH buffers, and the like (e.g., sodium acetate, sodium citrate, cyclodextrin derivatives, sorbitan monolaurate, triethanolamine acetate, triethanolamine oleate). Generally, depending on the intended mode of administration, the pharmaceutical composition will contain about 0.005% to 95% or about 0.5% to 50% by weight of the compounds disclosed and / or described herein. The actual methods of preparing the dosage forms are known or will be apparent to those skilled in the art; for example, see Remington's Pharmaceutical Sciences, Mack Publishing Company, Easton, Pennsylvania.

[0637] In some embodiments, the composition will be in the form of a pill or tablet, and thus the composition may contain a compound disclosed and / or described herein and one or more of a diluent (e.g., lactose, sucrose, dicalcium phosphate), a lubricant (e.g., magnesium stearate), and / or a binder (e.g., starch, acacia, polyvinyl pyrrolidine, gelatin, cellulose, cellulose derivatives). Other solid dosage forms include powders, pills, solutions or suspensions encapsulated in gelatin capsules (e.g., in propylene carbonate, vegetable oils, or triglycerides).

[0638] Liquid pharmaceutically administrable compositions can be prepared, for example, by dissolving, dispersing or suspending the compound disclosed and / or described herein and optional pharmaceutical additives in a carrier (e.g., water, physiological saline, aqueous glucose solution, glycerol, glycol, ethanol or its analogue) to form a solution or suspension. Injectables can be prepared in traditional forms, in the form of liquid solutions or suspensions, in the form of emulsions or in the form of solids suitable for dissolving or suspending in liquids before injection. The percentage of the compound contained in such parenteral compositions depends on, for example, the physical properties of the compound, the activity of the compound and the needs of the subject. However, a solution active ingredient percentage of 0.01% to 10% can be used, and may be higher when the composition is solid, and then diluted to another concentration. In some embodiments, the composition will include about 0.2% to 2% of the compound disclosed and / or described herein in the solution.

[0639] Pharmaceutical compositions of the compounds disclosed and / or described herein can also be administered to the respiratory tract as an aerosol or solution for use with a nebulizer, or as a finely divided powder for insufflation, alone or in combination with an inert carrier such as lactose. In such cases, the particles of the pharmaceutical composition can have a diameter of less than 50 microns, or in some embodiments, less than 10 microns.

[0640] Additionally, pharmaceutical compositions can include the compounds disclosed and / or described herein and one or more other medicinal agents, pharmaceutical formulations, adjuvants, etc. Suitable medicinal and pharmaceutical formulations include those described herein.

[0641] medicine box

[0642] Also provided are articles and kits containing any of the compounds or pharmaceutical compositions provided herein. The articles can include containers with labels. Suitable containers include, for example, bottles, vials, and test tubes. The containers can be formed from a variety of materials, such as glass or plastic. The containers can hold the pharmaceutical compositions provided herein. The label on the container can indicate that the pharmaceutical composition is used to prevent, treat, or inhibit the conditions described herein, and can also provide instructions for in vivo or in vitro use.

[0643] In one aspect, provided herein are kits containing a compound or composition described herein and instructions for use. The kits may contain instructions for use in treating cardiac disease in an individual or subject in need thereof. The kits may additionally contain any materials or equipment useful for administering the compound or composition, such as vials, syringes, or IV bags. The kits may also contain sterile packaging.

[0644] combination

[0645] The compounds and compositions described and / or disclosed herein can be administered alone or in combination with other therapies and / or therapeutic agents useful for treating the aforementioned conditions, diseases, or disorders.

[0646] The compounds and compositions described and / or disclosed herein can be combined with one or more other therapies to treat heart disease, such as HCM or HFpEF. In some embodiments, one or more therapies include delaying the development of heart failure and attempting to prevent cardiac remodeling by down-regulating the neurohormonal stimulation of the heart (e.g., ACE inhibitors, angiotensin receptor blockers (ARB), β-blockers, aldosterone receptor antagonists or neuroendopeptidase inhibitors). In some embodiments, one or more therapies include improving cardiac function by stimulating cardiac contraction (e.g., enhancing myocardial contractility, such as β-adrenergic agonist dobutamine (dobutamine) or phosphodiesterase inhibitor milrinone (milrinone)). In other embodiments, one or more therapies include reducing cardiac preload therapy (e.g., diuretics, such as furosemide (furosemide)) or reducing cardiac afterload therapy (any class of vasodilators, including but not limited to calcium channel blockers, phosphodiesterase inhibitors, endothelin receptor antagonists, renin inhibitors or smooth muscle myosin regulators).

[0647] The compounds and compositions described and / or disclosed herein can be combined with one or more other therapies to treat HCM or HFpEF. In some embodiments, the compounds and / or compositions can be combined with beta-blockers, verapamil, and / or disopyramide.

[0648] General synthetic method

[0649] Compounds of Formula (I), (Ia)-(Ib)-(Ic)-(Id)-(Ie)-(If)-(Ig)-(Ih)-(Ii)-(Ij)-(Ik-1)-(Ik-2)-(Il)-(Im)-(In-1)-(In-2) ​​will now be described with reference to the illustrative synthetic schemes of the following general preparations and the specific examples thereafter. It will be appreciated that, in order to obtain the various compounds herein, the starting material may be suitably selected so that the final desired substituent will complete the reaction process with or without protection to produce the desired product, where appropriate. Additionally, it may be necessary or desirable to replace the final desired substituent with a suitable group that can complete the reaction process and, where appropriate, be replaced with the desired substituent. Additionally, it will be appreciated that protecting groups may be used to protect certain functional groups (amino, carboxyl or side chain groups) from reaction conditions and, where appropriate, to remove the group under standard conditions. Unless otherwise specified, the variables are defined above with reference to Formula (I), (la), (lb), (lc), (Id), (le), (If), (Ig), (Ih), (Ii), (Ij), (Ik-1), (Ik-2), (Il), (Im), (In-1), and (In-2).

[0650] In the case of desiring to obtain a specific enantiomer of a compound, this can be achieved by separating or splitting the enantiomer using any suitable conventional procedure and by a corresponding enantiomeric mixture. Therefore, for example, diastereomeric derivatives can be produced by a mixture of enantiomers, such as a racemate and a suitable chiral compound. The diastereoisomers can then be separated by any convenient means, such as by crystallization, and the desired enantiomer can be recovered. In another method of separation, chiral high performance liquid chromatography can be used to separate the racemate. Additionally, specific enantiomers can be obtained when necessary by using a suitable chiral intermediate in one of the described methods.

[0651] Where it is desired to obtain a specific isomer of a compound or to otherwise purify a reaction product, chromatography, recrystallization, and other conventional separation procedures may also be employed on the intermediates or final products.

[0652] The following exemplary methods describe general methods for preparing the compounds described herein. The variable groups in the processes provided herein are as defined for Formula (I), (Ia), (Ib), (Ic), (Id), (Ie), (If), (Ig), (Ih), (Ii), (Ij), (Ik-1), (Ik-2), (Il), (Im), (In-1), and (In-2), or any variation thereof. Other compounds described herein can be prepared by similar methods.

[0653] In some embodiments, compounds provided herein can be synthesized according to Scheme 1.

[0654] Process 1

[0655]

[0656] where R 1 、R 2A 、R 2B 、R 3 、R 4 and R 5 As defined for Formula (I) or any variation thereof as detailed herein.

[0657] An exemplary embodiment of the preparation method in Scheme 1 is shown in Scheme 1a.

[0658] Process 1a

[0659]

[0660] where R 2A and R 2B As defined for Formula (I) or any variation thereof as detailed herein; and wherein R 1a As defined for Formula (If) or any variation thereof as detailed herein.

[0661] Another exemplary embodiment of the preparation method in Scheme 1 is shown in Scheme 1b.

[0662] Process 1b

[0663]

[0664] where R 1 、R 3 、R 4 and R 5 As defined for Formula (I) or any variation thereof as detailed herein; and wherein R 2a As defined for Formula (If) or any variation thereof as detailed herein.

[0665] Another exemplary embodiment of the preparation method in Scheme 1 is shown in Scheme 1c.

[0666] Process 1c

[0667]

[0668] where R 1a and R 2a As defined for Formula (If) or any variation thereof as detailed herein.

[0669] In some embodiments, the compounds provided herein can be synthesized according to Scheme 2.

[0670] Process 2

[0671]

[0672] where R 1 、R 2A 、R 2B 、R 3 、R 4 and R 5 As defined for Formula (I) or any variation thereof as detailed herein.

[0673] Another exemplary embodiment of the preparation method in Scheme 2 is shown in Scheme 2a.

[0674] Process 2a

[0675]

[0676] where R 2A and R 2B As defined for Formula (I) or any variation thereof as detailed herein; and wherein R 1a As defined for Formula (If) or any variation thereof as detailed herein.

[0677] Another exemplary embodiment of the preparation method in Scheme 2 is shown in Scheme 2b.

[0678] Process 2b

[0679]

[0680] where R 1 、R 3 、R 4 and R 5 As defined for Formula (I) or any variation thereof as detailed herein, wherein R 2a As defined for Formula (If) or any variation thereof as detailed herein, and wherein X is halogen.

[0681] Another exemplary embodiment (eg, another exemplary embodiment of the preparation method in Scheme 2) is shown in Scheme 2c.

[0682] Process 2c

[0683]

[0684] where R 1 、R 3 、R 4 and R 5 As defined for Formula (I) or any variation thereof as detailed herein.

[0685] Another exemplary embodiment of the preparation method in Scheme 2 is shown in Scheme 2d.

[0686] Process 2d

[0687]

[0688] where R 1a and R 2a As defined for Formula (If) or any variation thereof as detailed herein.

[0689] Another exemplary embodiment (eg, another exemplary embodiment of the preparation method in Scheme 2) is shown in Scheme 2e.

[0690] Process 2e

[0691]

[0692] Another exemplary embodiment (eg, another exemplary embodiment of the preparation method in Scheme 2) is shown in Scheme 2f.

[0693] Process 2f

[0694]

[0695] Another exemplary embodiment of the preparation method in Scheme 2 is shown in Scheme 2g.

[0696] Process 2g

[0697]

[0698] Where X is a halide; Where R 2A and R 3 As defined for Formula (I) or any variation thereof as detailed herein; and wherein R 1a and m are as defined for Formula (Ik-1) or any variation thereof detailed herein.

[0699] In some embodiments, the compounds provided herein can be synthesized according to Scheme 3.

[0700] Process 3

[0701]

[0702] where R 1 、R 2A 、R 2B 、R 3 、R 4 and R 5 As defined for Formula (I) or any variation thereof as detailed herein.

[0703] Another exemplary embodiment of the preparation method in Scheme 3 is shown in Scheme 3a.

[0704] Process 3a

[0705]

[0706] where R 1a As defined for Formula (If) or any variation thereof as detailed herein; and wherein R a and R b are independently H or C1-C6 alkyl.

[0707] Another exemplary embodiment of the preparation method in Scheme 3 is shown in Scheme 3b-1.

[0708] Process 3b-1

[0709]

[0710] wherein X is CH or N; and wherein R 1a As defined for Formula (If) or any variation thereof as detailed herein.

[0711] Another exemplary embodiment of the preparation method in Scheme 3 is shown in Scheme 3b-2.

[0712] Process 3b-2

[0713]

[0714] wherein X is CH or N; and wherein R 1a As defined for Formula (If) or any variation thereof as detailed herein.

[0715] Another exemplary embodiment of the preparation method in Scheme 3 is shown in Scheme 3c.

[0716] Process 3c

[0717]

[0718] where R 1a As defined for Formula (If) or any variation thereof as detailed herein.

[0719] Another exemplary embodiment of the preparation method in Scheme 3 is shown in Scheme 3d.

[0720] Process 3D

[0721]

[0722] where R 2A As defined for Formula (I) or any variation thereof as detailed herein; and wherein R 1a is selected from the group consisting of cyano, halo-substituted or unsubstituted alkoxy, substituted or unsubstituted alkyl, and substituted or unsubstituted heterocyclic.

[0723] Another exemplary embodiment of the preparation method in Scheme 3 is shown in Scheme 3e.

[0724] Process 3e

[0725]

[0726] where R 1a is selected from the group consisting of cyano, halo, substituted or unsubstituted alkoxy, substituted or unsubstituted alkyl, and substituted or unsubstituted heterocyclyl.

[0727] Another exemplary embodiment of the preparation method in Scheme 3 is shown in Scheme 3f.

[0728] Process 3f

[0729]

[0730] where R 1a is selected from the group consisting of: halo and substituted or unsubstituted alkyl; and wherein m is 0, 1 or 2.

[0731] Another exemplary embodiment of the preparation method in Scheme 3 is shown in Scheme 3g.

[0732] Process 3g

[0733]

[0734] where R 1a and m are as defined for Formula (Ik-1) or any variation thereof detailed herein.

[0735] Another exemplary preparation method is shown in Scheme 4.

[0736] Process 4

[0737]

[0738] where R 1a 、R 3a , m and p are as defined for Formula (Ik-1) or any variation thereof detailed herein.

[0739] Specific non-limiting examples are provided in the Examples section below.

[0740] Example

[0741] The following examples are provided to illustrate, but not to limit, the compositions, uses and methods provided herein. Compounds are prepared using the general method described above. In the following examples, the stereoisomeric form or stereoisomer mixture of such compounds is indicated by using the compound name followed by a specific letter using the compound number, as apparent from the context of a specific embodiment. Therefore, it should be understood that if a compound such as compound 288 may exist in two separate stereoisomeric forms, two letter names 288A and 288B can be used herein to refer to separate stereoisomeric forms. Similarly, separate diastereomers or mixtures thereof as will be apparent from the following examples can be named 858A, 858B, 858C and 858D. It should be understood that the data tables (e.g., Table A) provided herein will provide data related to specific stereoisomers by using the names indicated in these embodiments when applicable. With regard to the terms used herein, it should also be understood that certain compounds in the specific stereoisomeric form mentioned in these embodiments with letter names can find counterparts in Table 1 indicating the compound by structure and name.

[0742] Throughout the examples, the following abbreviations are used: TEA (trimethylamine), DCM (dichloromethane), (Boc)2O (di(tert-butyl) dicarbonate), EA (ethyl acetate), PE (petroleum ether), DMF (N,N-dimethylformamide), DIEA (N-ethyl-N-isopropylpropan-2-amine), HATU (1-[bis(dimethylamino)methylene]-1H-1,2,3-triazolo[4,5-b]pyridine 3-oxide hexafluorophosphate), HOAt (1-hydroxy-7-azabenzotriazole), HOBt (hydroxybenzotriazole), EDCI (1-ethyl-3-(3-dimethylaminopropyl)carbodiimide), MeOH (methanol), EtOH (ethanol), IPA (iPrOH; propan-2-ol), NMP (1-methylpyrrolidin-2-one), STAB (sodium triacetoxyborohydride), ACN (acetonitrile), TFA (trifluoroacetic acid), DPPA (diphenylphosphoryl azide), DBU (1,8-diazabicyclo(5.4.0)undec-7-ene), THF (tetrahydrofuran), PPh3 (triphenylphosphine), SM (starting material), Hex (hexane), NCS (N-chlorosuccinimide), rt (room temperature), DCE (dichloroethane), FA (formic acid), CHCl3 (chloroform), BnBr (toluene bromide), HCl (hydrogen chloride), equiv (equivalent), RT (retention time), SFC (supercritical fluid chromatography), and DSC (bis(2,5-dioxopyrrolidin-1-yl)carbonate).

[0743] Example 1: Synthesis of Compound 288

[0744] 1. Synthesis of intermediate 1-2:

[0745]

[0746] To a solution of methyl 2-amino-2-(4-chlorophenyl)acetate (1.5 g, 7.51 mmol, 1.0 equiv) in DCE (20 mL) at room temperature was added 4-chlorobenzaldehyde (1.05 g, 7.47 mmol, 1.00 equiv), acetic acid (900 mg, 14.99 mmol, 2.00 equiv) and STAB (2.4 g, 11.32 mmol, 1.50 equiv). The mixture was stirred at room temperature for 2 h, diluted with EA (100 mL), washed twice with brine (50 mL), dried over anhydrous sodium sulfate and concentrated under reduced pressure to give 2.4 g (99%) of methyl 2-(4-chlorophenyl)-2-[[(4-chlorophenyl)methyl]amino]acetate as a brown oil.

[0747] 2. Synthesis of intermediates 1-3:

[0748]

[0749] To a solution of methyl 2-(4-chlorophenyl)-2-[[(4-chlorophenyl)methyl]amino]acetate (2.4 g, 7.40 mmol, 1.00 equiv) in DCM (30 mL) was added TEA (1.5 g, 14.82 mmol, 2.00 equiv) and 2-chloroacetyl chloride (1 g, 8.85 mmol, 1.20 equiv) dropwise at room temperature. The mixture was stirred at room temperature for 2 h, diluted with DCM (50 mL), washed twice with brine (20 mL), dried over anhydrous sodium sulfate, concentrated under reduced pressure, and purified by silica gel column with ACN and water (3:1) to give 2 g (67%) of methyl 2-[2-chloro-N-[(4-chlorophenyl)methyl]acetamido]-2-(4-chlorophenyl)acetate as a brown oil.

[0750] 3. Synthesis of compound 288:

[0751]

[0752] To a solution of methyl 2-[2-chloro-N-[(4-chlorophenyl)methyl]acetamido]-2-(4-chlorophenyl)acetate (150 mg, 0.37 mmol, 1.0 equiv) in ACN (10 mL) at room temperature were added propan-2-amine (66.5 mg, 1.1 mmol, 3.0 equiv) and TEA (115 mg, 1.1 mmol, 3.0 equiv). The mixture was stirred at room temperature for 1 hour and at 80° C. for 2 hours, concentrated under reduced pressure, and purified by Prep-HPLC using the following conditions (Analyse HPLC-SHIMADZU (HPLC-10 No. 2): column, XBridge Shield RP18 OBD column, 5 μm, 19*150 mm; mobile phase, water (0.05% NH 3 H 2 O) and ACN (48.0% ACN to 68.0% in 8 minutes); detector, UV 220 nm) to give 100 mg of 3-(4-chlorophenyl)-4-[(4-chlorophenyl)methyl]-1-(propan-2-yl)piperazine-2,5-dione. LRMS (ES) m / z 391 (M+H). 1 H NMR(DMSO-d6,300MHz)δ7.44-7.33(m,2H),7.36-7.22(m,4H),7.22-7.13(m,2H),4.95(s,1H), 4.88(d,J=15.1Hz,1H), 4.40(h,J=6.9Hz,1H), 4.15(d,J=17.7Hz,1H), 3.98(d,J=17.8Hz,1H),

[0753] 3.86(d,J=15.1Hz,1H), 1.07(d,J=6.8Hz,3H), 0.96(d,J=6.8Hz,3H).

[0754] The following compounds were prepared by methods analogous to those described for compound 288:

[0755]

[0756]

[0757] 4. Separation of compound 288 enantiomers: enantiomer 288A and enantiomer 288B

[0758]

[0759] The racemic compound 3-(4-chlorophenyl)-4-[(4-chlorophenyl)methyl]-1-cyclopentylpiperazine-2,5-dione (80 mg, 0.19 mmol, 1.0 equivalent) was separated by chiral HPLC using the following conditions: (column: CHIRAL ART Cellulose-SB, 2*25 cm, 5 um; mobile phase A: Hex--HPLC, mobile phase B: EtOH--HPLC; flow rate: 20 mL / min; gradient: 30B:30B, 10 min; 220 / 254 nm) to obtain 25.4 mg (first elution peak) of enantiomer 288A and 32 mg (second elution peak) of enantiomer 288B. Chiral analysis data (column: CHIRAL Cellulose-SB; 0.46 cm×15 cm; 5 μm; Hex (0.2% IPAmine):EtOH=70:30, 1 ml / min) showed that enantiomer 288A was the first eluting peak (RT 3.3 minutes) and enantiomer 288B was the second eluting peak (RT 4.0 minutes).

[0760] Enantiomer 288A: LRMS (ES) m / z 391 (M+H). 1 H NMR (300MHz, DMSO-d6) δ7.44-7.34(m,2H),7.39-7.22(m,4H),7.27-7.13(m,2H),4.95(s,1H),4.87(d,J=15.1Hz,1H),4.39(h,J= 6.8Hz, 1H), 4.15 (d, J = 17.7Hz, 1H), 3.97 (d, J = 17.8Hz, 1H), 3.86 (d, J = 15.1Hz, 1H), 1.07 (d, J = 6.8Hz, 3H), 0.96 (d, J = 6.9Hz, 3H).

[0761] Enantiomer 288B: LRMS (ES) m / z 391 (M+H). 1 H NMR (300MHz, DMSO-d6) δ7.44-7.33(m,2H),7.36-7.22(m,4H),7.22-7.13(m,2H),4.95(s,1H),4.87(d,J=15.1Hz,1H),4.41(p,J= 6.8Hz, 1H), 4.15 (d, J = 17.7Hz, 1H), 3.97 (d, J = 17.8Hz, 1H), 3.86 (d, J = 15.1Hz, 1H), 1.07 (d, J = 6.8Hz, 3H), 0.96 (d, J = 6.9Hz, 3H).

[0762] The following compounds were prepared by methods analogous to those described for Enantiomer 288A and Enantiomer 288B:

[0763]

[0764] Example 2: Synthesis of Compound 20

[0765]

[0766] To a solution of 5-(4-chlorobenzyl)-2-(4-fluorophenyl)-8-isopropyl-2,5,8-triazaspiro[3.5]nonane-6,9-dione (20.5 mg, 0.049 mmol, 1.0 eq) in anhydrous THF (2 mL) was added LHMDS (1 M THF solution, 54 μL, 0.054 mmol, 1.1 eq) at -78° C. The mixture was stirred at -78° C. for 2 minutes, and MeI (2 M ether solution, 30 μL, 0.059 mmol, 1.2 eq) was added to the mixture, stirred at -78° C. for 5 minutes, slowly warmed to room temperature and diluted with water and EA. The organic layer was dried over NaSO, filtered, concentrated, and purified by silica gel chromatography (40 g column, 0-60% EtOAc / hexanes) to afford 9.9 mg (47%) of 5-(4-chlorobenzyl)-2-(4-fluorophenyl)-8-isopropyl-7-methyl-2,5,8-triazaspiro[3.5]nonane-6,9-dione as a white solid. LRMS (ES) m / z 430.1 (M+H). 1H-NMR (dichloromethane-d2, 400 MHz, ppm) δ 7.40-7.28 (m, 2H), 7.24-7.13 (m, 2H), 7.06-6.91 (m, 2H), 6.46-6.37 (m, 2H), 5.29 (d, J = 16.2 Hz, 1H), 4.87 (d, J = 16.3 Hz, 1H), 4.72 (d, J = 8.6 Hz, 1H), 4.44 (hept, J = 6.8 Hz, 1H), 4.28-4.14 (m, 2H), 4.03 (dd, J = 9.8, 8.2 Hz, 2H), 1.49 (d, J = 7.0 Hz, 3H), 1.33 (dd, J = 6.9, 5.0 Hz, 6H).

[0767] The following compounds were prepared by methods analogous to those described for compound 20:

[0768] Compound number LRMS(ES)m / z 329 M+H=412.1

[0769] Example 3: Synthesis of Compound 65

[0770] 1. Synthesis of intermediate 3-2

[0771]

[0772] To a solution of 1-(tert-butyl) 3-methyl-3-aminoazetidine-1,3-dicarboxylate (5.0 g, 21.7 mmol, 1.0 equiv) in MeOH (50 mL) was added 4-chlorobenzaldehyde (4.5 g, 32.6 mmol, 1.5 equiv). The mixture was stirred at room temperature for 1 hour. To this mixture was added NaCNBH3 (1.4 g, 21.7 mmol, 1.0 equiv) and AcOH (1 mL). The mixture was stirred for another 4 hours, concentrated under reduced pressure, and diluted with DCM (60 mL) and saturated aqueous sodium bicarbonate solution (60 mL). The aqueous layer was extracted with DCM (25 mL). The combined organic layers were dried over sodium sulfate, filtered through celite, concentrated under reduced pressure, and purified by silica gel chromatography (80 g column, 0-100% EtOAc / hexanes) to afford 6.0 g (78%) of 3-methyl 1-(tert-butyl) 3-methyl 3-((4-chlorobenzyl)amino)azetidine-1,3-dicarboxylate. LRMS (ES) m / z 355.2 (M+H). 1 H-NMR (dichloromethane-d2, 400 MHz, ppm) δ7.35 (s, 4H), 4.19 (d, J = 8.8 Hz, 2H), 3.86 (d, J = 8.8 Hz, 2H), 3.82 (s, 3H), 3.68 (s, 2H), 1.46 (s, 9H).

[0773] 2. Synthesis of intermediate 3-3

[0774]

[0775] To a solution of 3-(tert-butyl)-3-methyl 3-((4-chlorobenzyl)amino)azetidine-1,3-dicarboxylate (6.0 g, 16.9 mmol, 1.0 equiv) in DCM (50 mL) cooled to 0° C. was added TEA (7.1 mL, 50.7 mmol, 3.0 equiv) and chloroacetyl chloride (2.7 mL, 33.8 mmol, 2.0 equiv). The ice bath was removed and the mixture was stirred at room temperature for 3 hours, then poured into saturated aqueous NH4Cl solution (200 mL). The aqueous layer was extracted three times with DCM (100 mL). The combined organic layers were dried over MgSO4 and concentrated to give the intermediate product, 3-(tert-butyl)-3-methyl 3-(2-chloro-N-(4-chlorobenzyl)acetamido)azetidine-1,3-dicarboxylate. LRMS (ES) m / z 431.1 (M+H).

[0776] 3. Synthesis of Intermediates 3-4

[0777]

[0778] To a solution of 1-(tert-butyl)3-methyl 3-(2-chloro-N-(4-chlorobenzyl)acetamido)azetidine-1,3-dicarboxylate (16.9 mmol, 1.0 equiv, assuming 100% yield) in ACN (300 mL) was added isopropylamine (2.9 mL, 33.9 mmol, 2.0 equiv) and TEA (7.1 mL, 50.8 mmol, 3.0 equiv). The mixture was heated to 80° C. for 15 h, concentrated, and purified by silica gel chromatography (80 g, 0-100% EtOAc / hexanes) to afford 6.5 g (91%) of tert-butyl 5-(4-chlorobenzyl)-8-isopropyl-6,9-dioxo-2,5,8-triazaspiro[3.5]nonane-2-carboxylate as a colored solid. LRMS(ES)m / z 366.1(M+H- t Bu).

[0779] 4. Synthesis of Intermediates 3-5

[0780]

[0781] To a solution of tert-butyl 5-(4-chlorobenzyl)-8-isopropyl-6,9-dioxo-2,5,8-triazaspiro[3.5]nonane-2-carboxylate (6.5 g, 15.4 mmol, 1.0 equiv) in DCM (40 mL) was added TFA (12 mL). The mixture was stirred at room temperature for 1 hour, concentrated, diluted with saturated aqueous NaHCO (200 mL), and extracted three times with DCM. The combined organic layers were dried over MgSO, concentrated, and purified by silica gel chromatography (40 g column, 0-50% MeOH / DCM) to afford 4.1 g (83%) of 5-(4-chlorobenzyl)-8-isopropyl-2,5,8-triazaspiro[3.5]nonane-6,9-dione as an off-white solid. LRMS (ES) m / z 322.1 (M+H). 1 H-NMR (dichloromethane-d2, 400 MHz, ppm) δ7.36-7.32 (m, 2H), 7.28-7.24 (m, 2H), 5.16 (s, 2H), 4.85 (p, J = 6.9 Hz, 1H), 4.30-4.19 (m, 4H), 4.00 (s, 2H), 1.24 (d, J = 6.8 Hz, 6H).

[0782] 5. Synthesis of Compound 65

[0783]

[0784] To a solution of 5-(4-chlorobenzyl)-8-isopropyl-2,5,8-triazaspiro[3.5]nonane-6,9-dione (20 mg, 0.062 mmol, 1.0 equiv) in DCM (0.2 mL) was added DIEA (22 μL, 0.12 mmol, 2.0 equiv) and methyl isocyanate (5.0 mg, 0.093 mmol, 1.5 equiv). The mixture was stirred at room temperature for 15 hours, concentrated, and purified by reverse phase HPLC (Phenomenex, Gemini 5μ C18 150×21.2 mm, 10-70% acetonitrile / water (both containing 0.1% formic acid) gradient over 25 minutes) to afford 8.6 mg (37%) of 5-(4-chlorobenzyl)-8-isopropyl-N-methyl-6,9-dioxo-2,5,8-triazaspiro[3.5]nonane-2-carboxamide as a white foamy solid. LRMS (ES) m / z 379.1 (M+H). 1H-NMR: (methanol-d4, 400MHz, ppm) δ7.39-7.34(m,2H),7.32-7.27(m,2H),4.98(s,2H),4.75(hept,J=6 .9Hz,1H),4.41-4.37(m,2H),4.08(s,2H),4.07-4.04(m,2H),2.69(s,3H),1.24(d,J=6.8Hz,6H).

[0785] The following compounds were prepared by methods analogous to those described for compound 65:

[0786] Compound number LRMS(ES)m / z 64 M+H=380.1 66 M+H=445.2 67 M+H=413.1 68 M+H=399.1 69 M+H=384.1 70 M+H=439.2

[0787] Example 4: Synthesis of Compound 373

[0788] 1. Synthesis of intermediate 4-2

[0789]

[0790] To a solution of 1-tert-butyl 3-methyl 3-aminopyrrolidine-1,3-dicarboxylate (1.9 g, 7.78 mmol, 1.0 equiv) in DCE (30 mL) was added 4-chlorobenzaldehyde (1.1 g, 7.83 mmol, 1.0 equiv) and acetic acid (934 mg, 15.55 mmol, 2.0 equiv) at room temperature. The mixture was stirred at room temperature for 10 minutes. STAB (2.5 g, 11.80 mmol, 1.50 equiv) was added portionwise to the mixture. The mixture was stirred for an additional 1.5 hours, quenched with water (20 mL), and extracted twice with DCM (20 mL). The combined organic layers were washed with aqueous NaHCO (20 mL) and brine (20 mL), dried over anhydrous sodium sulfate, concentrated under reduced pressure, and purified by reverse-phase HPLC using the following conditions: (column, C18 silica gel; mobile phase, A: water (10 mmol / L NH4HCO3), B: ACN, 65% B to 75% B gradient, 20 min; detector, UV 210 / 254 nm) to give 2.2 g (77%) of 3-tert-butyl 3-methyl 3-[[(4-chlorophenyl)methyl]amino]pyrrolidine-1,3-dicarboxylate as a brown oil. LRMS (ES) m / z 313 (M+H-56).

[0791] 2. Synthesis of intermediate 4-3

[0792]

[0793] To a solution of 1-tert-butyl 3-methyl 3-[[(4-chlorophenyl)methyl]amino]pyrrolidine-1,3-dicarboxylate (2.28 g, 6.18 mmol, 1.0 equiv) in DCM (30 mL) cooled to 0 ° C was added 2-chloroacetyl chloride (3.12 g, 27.62 mmol, 4.50 equiv) and TEA (5.63 g, 55.64 mmol, 9.00 equiv). The mixture was stirred at room temperature overnight, quenched with water (20 mL), and extracted twice with DCM (20 mL). The combined organic layers were washed twice with brine (20 mL), dried over anhydrous sodium sulfate and concentrated under reduced pressure to give 2.9 g of 1-tert-butyl 3-methyl 3-[2-chloro-N-[(4-chlorophenyl)methyl]acetylamino]pyrrolidine-1,3-dicarboxylate as a brown oil. LRMS (ES) m / z 389 (M+H-56).

[0794] 3. Synthesis of intermediate 4-4

[0795]

[0796] To a solution of 1-tert-butyl 3-methyl 3-[2-chloro-N-[(4-chlorophenyl)methyl]acetamido]pyrrolidine-1,3-dicarboxylate (2.9 g, 6.51 mmol, 1.0 equiv) in ACN (30 mL) at room temperature was added propan-2-amine (1.9 g, 32.14 mmol, 5.00 equiv) and TEA (5.3 g, 8.00 equiv). The mixture was stirred at room temperature for 1 hour and then heated to 80° C. overnight. The next day, the mixture was cooled to room temperature, concentrated under reduced pressure, and purified by reverse-phase HPLC using the following conditions: column, C18 silica gel; mobile phase, A: water (10 mmol / L NH4HCO3), B: ACN, gradient 20% B to 25% B over 20 min; detector, UV 210 / 254 nm, to yield 2.4 g (85%) of tert-butyl 6-[(4-chlorophenyl)methyl]-7,10-dioxo-9-(propan-2-yl)-2,6,9-triazaspiro[4.5]decane-2-carboxylate as a brown solid. LRMS (ES) m / z 380 (M+H-56).

[0797] 4. Synthesis of Intermediates 4-5

[0798]

[0799] To a solution of tert-butyl 6-[(4-chlorophenyl)methyl]-7,10-dioxo-9-(propan-2-yl)-2,6,9-triazaspiro[4.5]decane-2-carboxylate (2.4 g, 5.51 mmol, 1.0 equivalent) in DCM (30 mL) was added TFA (8 mL) at room temperature. The mixture was stirred at room temperature for 1 hour. The pH value of the solution was adjusted to 9 with sodium hydroxide (6N, about 3 mL). The mixture was diluted with water and extracted twice with DCM (20 mL). The combined organic layer was washed twice with brine (20 mL), dried over anhydrous sodium sulfate and concentrated under reduced pressure to give 1.7 g (92%) of 6-[(4-chlorophenyl)methyl]-9-(propan-2-yl)-2,6,9-triazaspiro[4.5]decane-7,10-dione as a brown solid. LRMS (ES) m / z 336 (M+H).

[0800] 5. Synthesis of Compound 373

[0801]

[0802] To a solution of 2-bromopyridine (200 mg, 1.27 mmol, 1.0 equiv) in dioxane (5 mL) under nitrogen was added 6-[(4-chlorophenyl)methyl]-9-(propan-2-yl)-2,6,9-triazaspiro[4.5]decane-7,10-dione (94 mg, 0.28 mmol, 1.0 equiv), Pd2(dba)3CHCl3 (62 mg, 0.06 mmol, 0.10 equiv), Xphos (57 mg, 0.12 mmol 0.20 equiv) and Cs2CO3 (389 mg, 1.19 mmol, 2.0 equiv). The mixture was stirred at 90° C. overnight, cooled to room temperature, filtered to remove solids, and purified by Prep-HPLC using the following conditions (Analyse HPLC-SHIMADZU (HPLC-10 No. 2): column, XBridge Prep C18 OBD column, 5 μm, 19*150 mm; mobile phase, water (10 mmol / L NH4HCO3) and ACN (39.0% ACN to 53.0% gradient, 8 min); detector, UV 254 nm, to obtain 15 mg (6%) of 6-[(4-chlorophenyl)methyl]-9-(propan-2-yl)-2-(pyridin-2-yl)-2,6,9-triazaspiro[4.5]decane-7,10-dione as a white solid. LRMS (ES) m / z 413 (M+H). 1H-NMR: (300MHz, methanol-d4, ppm): δ8.01-7.93 (m, 1H), 7.50 (ddd, J=8.9, 7.2, 1.9Hz, 1 H),7.28-7.19(m,2H),7.10(d,J=8.4Hz,2H),6.61(dd,J=6.9,5.2Hz,1H),6.41(d ,J=8.6Hz,1H),4.76-4.54(m,3H),4.16(s,2H),3.97(d,J=11.9Hz,1H),3.75(d,J =11.8Hz,1H),3.66-3.42(m,2H),2.62-2.38(m,2H),1.20(dd,J=6.8,1.4Hz,6H).

[0803] 6. Separation of compound 373 enantiomers

[0804]

[0805] The racemic compound 6-[(4-chlorophenyl)methyl]-9-(propan-2-yl)-2-(pyridin-2-yl)-2,6,9-triazaspiro[4.5]decane-7,10-dione (80 mg, 0.19 mmol, 1.0 equivalent) was separated by chiral HPLC using the following conditions (Prep-HPLC-009): column: Chiralpak IC, 2*25 cm, 5 um; mobile phase A: Hex--HPLC, mobile phase B: EtOH-HPLC; flow rate: 15 mL / min; isocratic elution 21 min; 220 / 254 nm) to obtain 28.7 mg (36%, first elution peak) of enantiomer 373A and 29 mg (second elution peak) of enantiomer 373B as white solids. Chiral analysis data (CHIRALPAK IC-3; 0.46 cm × 5 cm; 3 μm; Hex (0.1% DEA): EtOH = 55:45, 1 ml / min) showed that enantiomer 373A was the first eluting peak (RT 2.2 minutes) and enantiomer 373B was the second eluting peak (RT 3.2 minutes). Enantiomer 373A: LRMS (ES) m / z 413 (M+H). 1H-NMR: (300 MHz, methanol-d4, ppm) δ7.97 (ddd, J = 5.2, 1.9, 0.9 Hz, 1H), 7.50 (ddd, J = 8.8, 7.1, 1.9 Hz, 1H), 7.28-7.18 (m, 2H), 7.10 (d, J = 8.4 Hz, 2H), 6.61 (ddd, J = 7.2, 5.1, 0.9 Hz, 1H), 6.4 1(d,J=8.6Hz,1H),4.86(s,1H),4.76-4.54(m,2H),4.15(s,2H),3.97(d,J=11.8Hz,1H),3 .75(d,J=11.8Hz,1H),3.66-3.42(m,2H),2.62-2.38(m,2H),1.20(dd,J=6.8,1.4Hz,6H).

[0806] Enantiomer 373B: LRMS (ES) m / z 413 (M+H). 1 H NMR: (300MHz, methanol-d4) δ8.01-7.93 (m, 1H), 7.50 (ddd, J = 8.8, 7.2, 1.9Hz, 1H), 7. 28-7.18(m,2H),7.10(d,J=8.3Hz,2H),6.61(dd,J=6.9,5.4Hz,1H),6.41(d,J= 8.5Hz,1H),4.76-4.54(m,2H),4.16(s,2H),3.97(d,J=11.8Hz,1H),3.75(d,J= 11.8Hz,1H),3.66-3.42(m,2H),2.62-2.38(m,2H),1.20(dd,J=6.9,1.4Hz,6H).

[0807] The following compounds were prepared by methods analogous to those described for compound 373:

[0808] HPLC separation conditions

[0809]

[0810]

[0811] Example 5: Synthesis of Compound 108

[0812] 1. Synthesis of intermediate 5-2

[0813]

[0814] To a solution of 3-amino-1-(tert-butoxycarbonyl)pyrrolidine-3-carboxylic acid (7.0 g, 30.4 mmol, 1.0 equiv) in MeOH (80 mL) was added 4-(trifluoromethyl)benzaldehyde (5.6 g, 31.9 mmol, 1.05 equiv). The mixture was stirred at room temperature for 1 hour, and NaCNBH (2.9 g, 45.6 mmol, 1.5 equiv) and AcOH (0.5 mL) were added and stirred for 2 hours. The mixture containing 1-(tert-butoxycarbonyl)-3-((4-(trifluoromethyl)benzyl)amino)pyrrolidine-3-carboxylic acid was used directly in the next step. LRMS (ES) m / z 389.2 (M+H).

[0815] 2. Synthesis of Intermediate 5-3

[0816]

[0817] To a solution containing 1-(tert-butoxycarbonyl)-3-((4-(trifluoromethyl)benzyl)amino)pyrrolidine-3-carboxylic acid (30.4 mmol, 1.0 equiv) from the previous reaction was added DCM (100 mL) and (trimethylsilyl)diazomethane (2M in hexanes, 45.6 mL, 91.1 mmol, 3.0 equiv). The mixture was stirred at room temperature for 3 h, AcOH (5.0 g) was added, concentrated onto silica (30 g), and purified by silica gel chromatography (120 g, 0-100% EtOAc / hexanes) to afford 7.4 g (61% over multiple steps) of 1-(tert-butyl)3-methyl 3-((4-(trifluoromethyl)benzyl)amino)pyrrolidine-1,3-dicarboxylate as a white solid. LRMS (ES) m / z 403.2 (M+H).

[0818] 3. Synthesis of Intermediate 5-4

[0819]

[0820] To a solution of 1-(tert-butyl)3-methyl 3-((4-(trifluoromethyl)benzyl)amino)pyrrolidine-1,3-dicarboxylate (7.4 g, 18.4 mmol, 1.0 equiv) in DCM (50 mL) cooled to 0° C. was added TEA (7.7 mL, 84.9 mmol, 3.0 equiv) and chloroacetyl chloride (2.9 mL, 36.8 mmol, 2.0 equiv). The ice bath was removed and the mixture was stirred at room temperature for 3 hours, then poured into saturated aqueous NH4Cl solution (200 mL). The aqueous layer was extracted three times with DCM (100 mL). The combined organic layers were dried over MgSO4 and concentrated to give the intermediate product, 1-(tert-butyl)3-methyl 3-(2-chloro-N-(4-(trifluoromethyl)benzyl)acetylamino)pyrrolidine-1,3-dicarboxylate. LRMS (ES) m / z 379.1 (M+H-Boc).

[0821] 4. Synthesis of intermediate 5-5

[0822]

[0823] To a solution of 1-(tert-butyl)pyrrolidine-1,3-dicarboxylate 3-methyl 3-(2-chloro-N-(4-(trifluoromethyl)benzyl)acetamido)pyrrolidine-1,3-dicarboxylate (18.4 mmol, 1.0 equiv, assuming 100% yield) in ACN (300 mL) was added isopropylamine (4.7 mL, 55.1 mmol, 3.0 equiv) and TEA (7.7 mL, 55.1 mmol, 3.0 equiv). The mixture was heated at 80° C. for 15 h, concentrated, and purified by silica gel chromatography (80 g, 0-100% EtOAc / hexanes) to give an intermediate mixture containing tert-butyl 9-isopropyl-7,10-dioxo-6-(4-(trifluoromethyl)benzyl)-2,6,9-triazaspiro[4.5]decane-2-carboxylate. LRMS (ES) m / z 414.2 (M+H- t Bu).

[0824] 5. Synthesis of Intermediates 5-6

[0825]

[0826] To a solution of tert-butyl 9-isopropyl-7,10-dioxo-6-(4-(trifluoromethyl)benzyl)-2,6,9-triazaspiro[4.5]decane-2-carboxylate (18.4 mmol, 1.0 equiv) in DCM (40 mL) was added TFA (20 mL). The mixture was stirred at room temperature for 1 hour, concentrated, diluted with saturated aqueous NaHCO (200 mL), and extracted three times with DCM. The combined organic layers were dried over MgSO, filtered, concentrated, and purified by silica gel chromatography (40 g column, 0-50% MeOH / DCM + 1% TEA) to afford 2.8 g (41% over 3 steps) of 9-isopropyl-6-(4-(trifluoromethyl)benzyl)-2,6,9-triazaspiro[4.5]decane-7,10-dione as a solid. LRMS (ES) m / z 370.2 (M+H). 1 H-NMR (dichloromethane-d2, 400 MHz, ppm) δ 7.65-7.60 (m, 2H), 7.39-7.33 (m, 2H), 4.93-4.65 (m, 3H), 4.02 (s, 2H), 3.46-3.40 (m, 1H), 3.16 (ddd, J = 11.3, 8.2, 5.3 Hz, 1H), 3.00 (ddd, J = 11.3, 8.1, 6.7 Hz, 1H), 2.92 (d, J = 12.1 Hz, 1H), 2.45 (ddd, J = 13.6, 8.3, 6.7 Hz, 1H), 1.98 (ddd, J = 13.5, 8.0, 5.2 Hz, 1H), 1.23 (d, J = 6.8 Hz, 6H).

[0827] 6. Synthesis of Compound 108

[0828]

[0829] To a solution of 9-isopropyl-6-(4-(trifluoromethyl)benzyl)-2,6,9-triazaspiro[4.5]decane-7,10-dione (50 mg, 0.14 mmol, 1.0 equiv) in DCM (2 mL) was added TEA (27 mg, 0.27 mmol, 2.0 equiv) and methyl isocyanate (15 mg, 0.27 mmol, 2.0 equiv). The mixture was stirred at room temperature for 30 minutes, concentrated, and purified by reverse phase HPLC (Phenomenex, Gemini 5μ C18 150×21.2 mm, 10-100% acetonitrile / water (both containing 0.1% formic acid) gradient over 40 minutes) to afford 49 mg (85%) of 9-isopropyl-N-methyl-7,10-dioxo-6-(4-(trifluoromethyl)benzyl)-2,6,9-triazaspiro[4.5]decane-2-carboxamide as a white foamy solid. LRMS (ES) m / z 327.2 (M+H). 1 H-NMR (methanol-d4, 400MHz, ppm) δ7.67-7.62(m,2H),7.43-7.36(m,2H),4.95(d,J=17.0Hz,1H),4.79-4.65(m,2H),4.18(d,J=2.1Hz,2H ), 3.95 (d, J = 11.7Hz, 1H), 3.59 (d, J = 11.7Hz, 1H), 3.52-3.43 (m, 2H), 2.69 (s, 3H), 2.49-2.33 (m, 2H), 1.24 (dd, J = 6.8, 1.3Hz, 6H).

[0830] The following compounds were prepared by methods analogous to those described for compound 108:

[0831]

[0832]

[0833] Example 6: Synthesis of Compound 76

[0834] 1. Synthesis of intermediate 6-2

[0835]

[0836] To a solution of 3-amino-1-(tert-butoxycarbonyl)pyrrolidine-3-carboxylic acid (7.0 g, 30.4 mmol, 1.0 equiv) in MeOH (80 mL) was added 4-(trifluoromethyl)benzaldehyde (5.6 g, 31.9 mmol, 1.05 equiv), and the mixture was stirred at room temperature for 1 hour. To this mixture was added NaCNBH (2.9 g, 45.6 mmol, 1.5 equiv) and AcOH (0.5 mL). The mixture was stirred at room temperature for 2 hours to give a solution containing 1-(tert-butoxycarbonyl)-3-((4-(trifluoromethyl)benzyl)amino)pyrrolidine-3-carboxylic acid, which was used in the next reaction without further treatment. LRMS (ES) m / z 389.2 (M+H).

[0837] 2. Synthesis of Intermediate 6-3

[0838]

[0839] To the solution containing 1-(tert-butoxycarbonyl)-3-((4-(trifluoromethyl)benzyl)amino)pyrrolidine-3-carboxylic acid (30.4 mmol, 1.0 equiv) from the previous step was added DCM (100 mL) and (trimethylsilyl)diazomethane (2M in hexanes, 45.6 mL, 91.1 mmol, 3.0 equiv). The mixture was stirred at room temperature for 3 h, quenched with AcOH (5 g), concentrated onto 30 g SiO, and purified by silica gel chromatography (120 g, 0-100% EtOAc / hexanes) to afford 7.4 g (61% over 2 steps) of 1-(tert-butyl)3-methyl 3-((4-(trifluoromethyl)benzyl)amino)pyrrolidine-1,3-dicarboxylate as a white solid. LRMS (ES) m / z 403.15 (M+H).

[0840] 3. Synthesis of Intermediate 6-4

[0841]

[0842] To a solution of 1-(tert-butyl)pyrrolidine-1,3-dicarboxylic acid 3-methyl ester (7.4 g, 18.4 mmol, 1.0 equiv) in DCM (50 mL) at 0°C was added TEA (7.7 mL, 84.9 mmol, 3.0 equiv) and chloroacetyl chloride (2.9 mL, 36.8 mmol, 2.0 equiv). The ice bath was removed and the mixture was stirred at room temperature for 3 hours. The reaction was poured into saturated aqueous NH4Cl (200 mL) and the layers were separated. The aqueous layer was extracted three times with DCM (100 mL). The combined organic layers were dried over MgSO4 and concentrated to give the intermediate product, 1-(tert-butyl)pyrrolidine-1,3-dicarboxylic acid 3-methyl ester. LRMS (ES) m / z 379.1 (M+H-Boc).

[0843] 4. Synthesis of Intermediate 6-5

[0844]

[0845] To a solution of 1-(tert-butyl)pyrrolidine-1,3-dicarboxylate 3-methyl 3-(2-chloro-N-(4-(trifluoromethyl)benzyl)acetamido)pyrrolidine-1,3-dicarboxylate (18.4 mmol, 1.0 equiv, assuming 100% yield) in ACN (300 mL) was added isopropylamine (4.7 mL, 55.1 mmol, 3.0 equiv) and TEA (7.7 mL, 55.1 mmol, 3.0 equiv). The mixture was heated at 80° C. for 15 h, concentrated, and purified by silica gel chromatography (80 g, 0-100% EtOAc / hexanes) to give the intermediate product, tert-butyl 9-isopropyl-7,10-dioxo-6-(4-(trifluoromethyl)benzyl)-2,6,9-triazaspiro[4.5]decane-2-carboxylate, as a colored solid. LRMS(ES)m / z 414.15(M+H- t Bu).

[0846] 5. Synthesis of Intermediate 6-6

[0847]

[0848] To a solution of tert-butyl 9-isopropyl-7,10-dioxo-6-(4-(trifluoromethyl)benzyl)-2,6,9-triazaspiro[4.5]decane-2-carboxylate (18.4 mmol, 1.0 equiv) from the previous step in DCM (40 mL) was added TFA (20 mL). The mixture was stirred at room temperature for 1 hour, concentrated, diluted with saturated NaHCO (200 mL), and extracted three times with DCM. The combined organic layers were dried over MgSO, filtered, concentrated, and purified by silica gel chromatography (40 g column, 0-50% MeOH / DCM + 1% TEA) to afford 2.8 g (41% over 3 steps) of 9-isopropyl-6-(4-(trifluoromethyl)benzyl)-2,6,9-triazaspiro[4.5]decane-7,10-dione as a dark, sticky solid. LRMS (ES) m / z 370.2 (M+H). 1 H-NMR (dichloromethane-d2, 400 MHz, ppm) δ 7.65-7.60 (m, 2H), 7.39-7.33 (m, 2H), 4.93-4.65 (m, 3H), 4.02 (s, 2H), 3.46-3.40 (m, 1H), 3.16 (ddd, J = 11.3, 8.2, 5.3 Hz, 1H), 3.00 (ddd, J = 11.3, 8.1, 6.7 Hz, 1H), 2.92 (d, J = 12.1 Hz, 1H), 2.45 (ddd, J = 13.6, 8.3, 6.7 Hz, 1H), 1.98 (ddd, J = 13.5, 8.0, 5.2 Hz, 1H), 1.23 (d, J = 6.8 Hz, 6H).

[0849] 6. Synthesis of Compound 76

[0850]

[0851] To a mixture of 9-isopropyl-6-(4-(trifluoromethyl)benzyl)-2,6,9-triazaspiro[4.5]decane-7,10-dione (50 mg, 0.14 mmol, 1.0 equiv), potassium tert-butoxide (61 mg, 0.54 mmol, 4.0 equiv), Pd2(dba)3 (12 mg, 0.014 mmol, 0.1 equiv) and xantphos (16 mg, 0.027 mmol, 0.2 equiv) combined in a 5 mL microwave vial (5 mL) was added 4-bromopyridin-2(1H)-one (47 mg, 0.27 mmol, 2.0 equiv) and dioxane (2 mL). The mixture was sealed and heated in a microwave reactor at 150° C. for 30 minutes, filtered, and purified by reverse phase HPLC (Phenomenex, Gemini 5 μm C18 150×21.2 mm, 10-100% acetonitrile / water (both containing 0.1% formic acid) gradient over 40 minutes) to afford 4.8 mg (8%) of 9-isopropyl-2-(2-oxo-1,2-dihydropyridin-4-yl)-6-(4-(trifluoromethyl)benzyl)-2,6,9-triazaspiro[4.5]decane-7,10-dione as a foaming solid. LRMS (ES) m / z 463.2 (M+H). 1 H-NMR (methanol-d4, 400MHz, ppm) δ8.18 (s, 1H), 7.62 (d, J = 8.1 Hz, 2H), 7.41-7.36 (m, 2H), 7.20 (d, J = 7.4 Hz, 1H), 5.88 (dd, J = 7.4, 2.4 Hz, 1H), 5.30 (d, J = 2.4 Hz, 1H), 4.99 (d, J=16.9Hz,1H),4.79-4.68(m,2H),4.23(d,J=2.0Hz,2H),3.88(d,J=11.8Hz,1H),3 .66(d,J=11.7Hz,1H),3.57-3.49(m,2H),2.67-2.46(m,2H),1.26(d,J=6.8Hz,6H).

[0852] The following compounds were prepared by methods analogous to those described for compound 76:

[0853]

[0854]

[0855] Example 7: Synthesis of Compound 491. Synthesis of Intermediate 7-2

[0856]

[0857] To a solution of 3-methyl-3-aminoazetidine-1,3-dicarboxylic acid 1-(tert-butyl) ester (5.0 g, 21.7 mmol, 1.0 equivalent) in MeOH (50 mL) was added 4-chlorobenzaldehyde (4.5 g, 32.6 mmol, 1.5 equivalents). The mixture was stirred at room temperature for 1 hour. NaCNBH (1.4 g, 21.7 mmol, 1.0 equivalents) and AcOH (1 mL) were added to the mixture. The mixture was stirred for 4 hours, concentrated under reduced pressure, and distributed between DCM (60 mL) and saturated sodium bicarbonate (60 mL). The layers were separated, and the aqueous phase was extracted with DCM (25 mL). The combined organic layers were dried over sodium sulfate, filtered through celite, concentrated under reduced pressure, and purified by silica gel chromatography (80 g column, 0-100% EtOAc / hexanes) to afford 6.0 g (78%) of 3-methyl 1-(tert-butyl) 3-methyl 3-((4-chlorobenzyl)amino)azetidine-1,3-dicarboxylate. LRMS (ES) m / z 355.2 (M+H). 1 H-NMR (dichloromethane-d2, 400 MHz, ppm) δ7.35 (s, 4H), 4.19 (d, J = 8.8 Hz, 2H), 3.86 (d, J = 8.8 Hz, 2H), 3.82 (s, 3H), 3.68 (s, 2H), 1.46 (s, 9H).

[0858] 2. Synthesis of Intermediate 7-3

[0859]

[0860] To a solution of 3-((4-chlorobenzyl)amino)azetidine-1,3-dicarboxylic acid 1-(tert-butyl) 3-methyl ester (6.0 g, 16.9 mmol, 1.0 equiv) in DCM (50 mL) cooled to 0° C. was added TEA (7.1 mL, 50.7 mmol, 3.0 equiv) and chloroacetyl chloride (2.7 mL, 33.8 mmol, 2.0 equiv). The mixture was stirred at room temperature for 3 hours and poured into saturated aqueous NH4Cl solution (200 mL). The aqueous layer was extracted three times with DCM (100 mL). The combined organic layers were dried over MgSO4 and concentrated to give the intermediate product, 3-(tert-butyl) 3-methyl 3-(2-chloro-N-(4-chlorobenzyl)acetamido)azetidine-1,3-dicarboxylate. LRMS (ES) m / z 431.1 (M+H).

[0861] 3. Synthesis of Intermediate 7-4

[0862]

[0863] To a solution of 1-(tert-butyl)3-methyl 3-(2-chloro-N-(4-chlorobenzyl)acetamido)azetidine-1,3-dicarboxylate (16.9 mmol, 1.0 equiv) in ACN (300 mL) was added isopropylamine (2.9 mL, 33.9 mmol, 2.0 equiv) and TEA (7.1 mL, 50.8 mmol, 3.0 equiv). The mixture was heated at 80° C. for 15 h, cooled to room temperature, concentrated, and purified by silica gel chromatography (80 g, 0-100% EtOAc / hexanes) to give 6.5 g (91%) of tert-butyl 5-(4-chlorobenzyl)-8-isopropyl-6,9-dioxo-2,5,8-triazaspiro[3.5]nonane-2-carboxylate as a colored solid. LRMS (ES) m / z 366.1 (M+H- t Bu).

[0864] 4. Synthesis of Intermediate 7-5

[0865]

[0866] To a solution of tert-butyl 5-(4-chlorobenzyl)-8-isopropyl-6,9-dioxo-2,5,8-triazaspiro[3.5]nonane-2-carboxylate (6.5 g, 15.4 mmol, 1.0 equiv) in DCM (40 mL) was added TFA (12 mL). The mixture was stirred at room temperature for 1 hour, concentrated, diluted with saturated NaHCO (200 mL), and extracted three times with DCM. The combined organic washes were dried over MgSO, filtered, concentrated, and purified by silica gel chromatography (40 g column, 0-50% MeOH / DCM) to afford 4.1 g (83%) of 5-(4-chlorobenzyl)-8-isopropyl-2,5,8-triazaspiro[3.5]nonane-6,9-dione as an off-white solid. LRMS (ES) m / z 322.1 (M+H). 1 H-NMR (dichloromethane-d2, 400 MHz, ppm) δ7.36-7.32 (m, 2H), 7.28-7.24 (m, 2H), 5.16 (s, 2H), 4.85 (p, J = 6.9 Hz, 1H), 4.30-4.19 (m, 4H), 4.00 (s, 2H), 1.24 (d, J = 6.8 Hz, 6H).

[0867] 5. Synthesis of Compound 49

[0868]

[0869] To a mixture of 5-(4-chlorobenzyl)-8-isopropyl-2,5,8-triazaspiro[3.5]nonane-6,9-dione (50 mg, 0.16 mmol, 1.0 equiv), potassium tert-butoxide (70 mg, 0.62 mmol, 4.0 equiv), Pd2(dba)3 (7 mg, 0.008 mmol, 0.05 equiv) and xantphos (9 mg, 0.016 mmol, 0.1 equiv) combined in a microwave vial (5 mL) was added 4-bromo-2,6-dimethylpyridine (58 mg, 0.31 mmol, 2.0 equiv) and dioxane (2 mL). The mixture was sealed, heated in a microwave reactor at 150° C. for 10 minutes, filtered, and purified by reverse phase HPLC (Phenomenex, Gemini 5 μm C18 150×21.2 mm, 10-100% acetonitrile / water (both containing 0.1% formic acid) gradient over 40 minutes) to afford 7.1 mg (10%) of 5-(4-chlorobenzyl)-2-(2,6-dimethylpyridin-4-yl)-8-isopropyl-2,5,8-triazaspiro[3.5]nonane-6,9-dione as a white foamy solid. LRMS (ES) m / z 427.15 (M+H). 1 H-NMR (dichloromethane-d2, 400 MHz, ppm) δ7.42-7.33 (m, 2H), 7.24-7.17 (m, 2H), 6.07 (s, 2H), 4.95 (s, 2H), 4.84 (p, J = 6.9 Hz, 1H), 4.62 (dd, J = 9.5, 1.1 Hz, 2H), 4.25 (dd, J = 9.5, 1.1 Hz, 2H), 4.06 (s, 2H), 2.57 (s, 6H), 1.25 (d, J = 6.8 Hz, 6H).

[0870] The following compounds were prepared by methods analogous to those described for compound 49:

[0871]

[0872]

[0873] Example 8: Synthesis of Compound 142

[0874] 1. Synthesis of intermediate 8-2

[0875]

[0876] A mixture of azetidin-3-ol hydrochloride (1.3 g, 11.9 mmol, 1.0 eq), L(-)-proline (0.55 g, 4.8 mmol, 0.4 eq), copper (I) iodide (0.45 g, 2.4 mmol, 0.2 eq) and cesium carbonate (9.7 g, 29.7 mmol, 2.5 eq) combined in a flask with a septum was vacuum-purged with nitrogen three times. Iodobenzene (2.0 mL, 18 mmol, 1.5 eq) and anhydrous DMSO (30 mL) were added to the vessel. The mixture was heated at 90° C. for 15 hours, diluted with water, and extracted three times with EA. The combined organic layers were dried over magnesium sulfate, filtered, evaporated, and purified by silica gel chromatography (40 g, 605 μm, 0-100% ethyl acetate / hexanes gradient over 14 minutes) to afford 1.6 g (90%) of 1-phenylazetidin-3-ol as a clear, colorless oil. LRMS (ES) m / z 150 (M+H). 1 H NMR (400 MHz, dichloromethane-d2) δ 7.27-7.20 (m, 2H), 6.81-6.74 (m, 1H), 6.55-6.49 (m, 2H), 4.80-4.72 (m, 1H), 4.23-4.16 (m, 2H), 3.71-3.65 (m, 2H).

[0877] 2. Synthesis of Intermediate 8-3

[0878]

[0879] To a solution of oxalyl chloride (1.5 mL, 17 mmol, 1.7 equiv) in anhydrous DCM (15 mL) was added DMSO (2.4 mL, 34 mmol, 3.3 equiv) dropwise at -78°C. The mixture was stirred at -78°C for 10 minutes, followed by the addition of 1-phenylazetidin-3-ol (1.5 g, 10.3 mmol, 1.0 equiv) in anhydrous DCM (15 mL) dropwise and stirred for 1 hour. To this mixture was added TEA (10.0 mL, 71.9 mmol, 7.0 equiv) at -78°C. The mixture was stirred for an additional 1 hour at -78°C, diluted with saturated sodium bicarbonate, and extracted three times with DCM. The combined organic extracts were washed with brine, dried over magnesium sulfate, filtered, evaporated, and purified by silica gel chromatography (40 g, 60 μm, 0-10% ethyl acetate / hexanes gradient over 28 minutes) to afford 0.96 g (63%) of 1-phenylazetidin-3-one as a clear yellow oil. LRMS (ES) m / z 148 (M+H). 1HNMR (400 MHz, dichloromethane-d2) δ 7.36-7.29 (m, 2H), 6.92-6.87 (m, 1H), 6.69-6.63 (m, 2H), 4.70 (s, 4H).

[0880] 3. Synthesis of Intermediate 8-4

[0881]

[0882] 1-Phenylazetidin-3-one (0.31 g, 2.1 mmol, 1.0 eq) and (1S)-1-[4-(trifluoromethyl)phenyl]ethan-1-amine (0.44 g, 2.3 mmol, 1.1 eq) were combined in anhydrous MeOH (3 mL) and the mixture was heated at 60° C. for 1 hour. To this mixture, which was cooled to 0° C., acetic acid (0.13 mL, 2.3 mmol, 1.1 eq) and sodium cyanide (0.11 g, 2.3 mmol, 1.1 eq) were added sequentially. The mixture was heated at 60° C. for 15 hours, diluted with water, and extracted three times with EA. The combined organic washes were dried over magnesium sulfate, filtered, evaporated, and purified by silica gel chromatography (12 g, 60 μm, 0-20% ethyl acetate / hexanes gradient over 22 minutes) to afford 0.46 g (62%) of (S)-1-phenyl-3-((1-(4-(trifluoromethyl)phenyl)ethyl)amino)azetidine-3-carbonitrile as a clear, colorless oil. LRMS (ES) m / z 346 (M+H). 1 H NMR (400 MHz, dichloromethane-d2) δ 7.69-7.65 (m, 2H), 7.64-7.59 (m, 2H), 7.26-7.19 (m, 2H), 6.85-6.79 (m, 1H), 6.42-6.38 (m, 2H), 4.38-4.35 (m, 1H), 4.26 (q, J = 6.6 Hz, 1H), 3.92-3.88 (m, 1H), 3.83-3.79 (m, 1H), 3.38-3.34 (m, 1H), 1.48 (d, J = 6.6 Hz, 3H).

[0883] 4. Synthesis of Intermediate 8-5

[0884]

[0885] To a solution of (S)-1-phenyl-3-((1-(4-(trifluoromethyl)phenyl)ethyl)amino)azetidine-3-carbonitrile (0.20 g, 0.58 mmol, 1.0 equiv) in anhydrous MeOH (2 mL) was added aqueous sodium hydroxide (1 N, 1.2 mL, 1.2 mmol, 2.0 equiv). The mixture was heated at 100° C. for 15 h, cooled to room temperature, neutralized with HCl (1 M, 1.2 mL, 1.2 mmol, 2.0 equiv) and extracted twice with EA. The combined organic washes were dried over magnesium sulfate, filtered, and concentrated under reduced pressure to afford 89 mg (42%) of (S)-1-phenyl-3-((1-(4-(trifluoromethyl)phenyl)ethyl)amino)azetidine-3-carboxylic acid as a light yellow solid.

[0886] 5. Synthesis of Intermediate 8-6

[0887]

[0888] To a solution of (S)-1-phenyl-3-((1-(4-(trifluoromethyl)phenyl)ethyl)amino)azetidine-3-carboxylic acid (89 mg, 0.24 mmol, 1.0 equiv) in a mixture of DCM (1 mL) and methanol (1 mL) was added (trimethylsilyl)diazomethane in hexanes (2 M, 0.37 mL, 0.74 mmol, 3.0 equiv) dropwise. The mixture was stirred at room temperature for 2 h, concentrated, and purified by silica gel chromatography (12 g, 60μ, 0-30% ethyl acetate / hexanes gradient over 22 min) to afford 79 mg (86%) of (S)-methyl 1-phenyl-3-((1-(4-(trifluoromethyl)phenyl)ethyl)amino)azetidine-3-carboxylate as a clear, colorless oil. LRMS (ES) m / z 379 (M+H).

[0889] 6. Synthesis of Intermediate 8-7

[0890]

[0891] To a solution of (S)-1-phenyl-3-((1-(4-(trifluoromethyl)phenyl)ethyl)amino)azetidine-3-methyl carboxylate (79 mg, 0.21 mmol, 1.0 equiv) in DCM (10 mL) was added dropwise TEA (0.18 mL, 1.2 mmol, 6.0 equiv) and chloroacetyl chloride (0.067 mL, 0.84 mmol, 4.0 equiv). The mixture was stirred at room temperature for 30 minutes, diluted with saturated sodium bicarbonate, and extracted with DCM. The organic layer was dried over magnesium sulfate, filtered and concentrated to give 140 mg of (S)-3-(2-chloro-N-(1-(4-(trifluoromethyl)phenyl)ethyl)acetamido)-1-phenylazetidine-3-methyl carboxylate as a red oil. LRMS(ES)m / z455(M+H).

[0892] 7. Synthesis of Compound 142

[0893]

[0894] To a solution of (S)-methyl 3-(2-chloro-N-(1-(4-(trifluoromethyl)phenyl)ethyl)acetamido)-1-phenylazetidine-3-carboxylate (0.21 mmol, 1.0 equiv) in anhydrous ACN (7.5 mL) was added triethylamine (0.13 mL, 0.94 mmol, 4.5 equiv) and isopropylamine (0.053 mL, 0.62 mmol, 3.0 equiv). The mixture was heated at 80° C. for 15 h, concentrated, and purified by reverse phase HPLC (Phenomenex, Gemini 5u C18 150×21.2 mm, 10-100% acetonitrile / water (both containing 0.1% formic acid) gradient over 25 min) to afford 19 mg (20% over 2 steps) of (S)-8-isopropyl-2-phenyl-5-(1-(4-(trifluoromethyl)phenyl)ethyl)-2,5,8-triazaspiro[3.5]nonane-6,9-dione as a white foamy solid. LRMS (ES) m / z 446 (M+H). 1H NMR (400MHz, methanol-d4) δ7.67-7.62(m,2H),7.60-7.55(m,2H),7.22-7.16(m,2 H),6.79-6.73(m,1H),6.49-6.44(m,2H),5.74-5.65(m,1H),4.73(hept,J=6 .8Hz,1H),4.46-4.41(m,1H),4.37-4.32(m,1H),4.27-4.21(m,1H),4.13-4 .09(m,1H),4.07-3.96(m,2H),2.01(d,J=7.0Hz,3H),1.23(d,J=6.8Hz,6H).

[0895] The following compounds were prepared by methods analogous to those described for compound 142:

[0896] Compound number LRMS(ES)m / z 138 M+H=447.2 139 M+H=427.2 140 M+H=446.2 141 M+H=446.2

[0897] Example 9: Synthesis of Compound 327

[0898] 1. Synthesis of intermediate 9-2

[0899]

[0900] To a solution of 1-phenyl-2-oxo-3-pyrrolidinecarboxylic acid (0.95 g, 4.6 mmol, 1.0 equiv) in a mixture of DCM (10 mL) and MeOH (10 mL) cooled to 0° C. was added (trimethylsilyl)diazomethane in hexanes (2 M, 7.0 mL, 14 mmol, 3.0 equiv) dropwise. The mixture was stirred at room temperature for 30 minutes, concentrated, and purified by silica gel chromatography (24 g, 0-10% ethyl acetate / hexanes gradient over 11.5 minutes) to afford 1.02 g (100%) of methyl 2-oxo-1-phenylpyrrolidine-3-carboxylate as a white solid. LRMS (ES) m / z 220 (M+H). 1 H NMR (400 MHz, dichloromethane-d2) δ 7.66-7.61 (m, 2H), 7.45-7.38 (m, 2H), 7.25-7.19 (m, 1H), 4.02-3.95 (m, 1H), 3.91-3.84 (m, 1H), 3.81 (s, 3H), 3.68-3.63 (m, 1H), 2.59-2.50 (m, 1H), 2.48-2.38 (m, 1H).

[0901] 2. Synthesis of Intermediate 9-3

[0902]

[0903] To a mixture of methyl 2-oxo-1-phenylpyrrolidine-3-carboxylate (0.30 g, 1.4 mmol, 1.0 equiv) and ytterbium(III) trifluoromethanesulfonate (0.255 g, 0.41 mmol, 0.30 equiv) in EA (9 mL) was added NBS (0.244 g, 1.4 mmol, 1.0 equiv). The mixture was stirred at room temperature for 30 minutes, concentrated, and purified by silica gel chromatography (24 g, 0-30% ethyl acetate / hexanes gradient over 11.5 minutes) to afford 408 mg (100%) of 3-bromo-2-oxo-1-phenylpyrrolidine-3-carboxylate as a white solid. LRMS (ES) m / z 298 (M+H). 1 HNMR (400 MHz, dichloromethane-d2) δ 7.68-7.62 (m, 2H), 7.48-7.42 (m, 2H), 7.30-7.24 (m, 1H), 4.04-3.97 (m, 1H), 3.94-3.88 (m, 4H), 3.19-3.10 (m, 1H), 2.72-2.64 (m, 1H).

[0904] 3. Synthesis of Intermediate 9-4

[0905]

[0906] To a solution of 3-bromo-2-oxo-1-phenylpyrrolidine-3-carboxylate (0.113 g, 0.38 mmol, 1.0 eq) in DMF (1 mL) was added TEA (0.21 mL, 1.5 mmol, 4.0 eq) and 4-(trifluoromethyl)benzylamine (0.11 mL, 0.76 mmol, 2.0 eq). The mixture was stirred at room temperature for 15 min, heated at 50° C. for 1 h, diluted with water, and extracted three times with EA. The combined organic extracts were washed once with brine, dried over magnesium sulfate, filtered, concentrated, and purified by silica gel chromatography (12 g, 60 μm, 0-40% ethyl acetate / hexanes gradient over 22 minutes) and again by silica gel chromatography (12 g, 60 μm, 0-30% ethyl acetate / hexanes gradient over 22 minutes) to afford 24 mg (16%) of methyl 2-oxo-1-phenyl-3-((4-(trifluoromethyl)benzyl)amino)pyrrolidine-3-carboxylate as a clear, colorless oil. LRMS (ES) m / z 393 (M+H). 1H NMR (400 MHz, dichloromethane-d2) δ 7.59-7.54 (m, 2H), 7.54-7.49 (m, 2H), 7.49-7.44 (m, 2H), 7.35-7.29 (m, 2H), 7.15-7.09 (m, 1H), 3.95-3.84 (m, 2H), 3.81-3.69 (m, 5H), 2.68-2.61 (m, 1H), 2.24-2.14 (m, 1H).

[0907] 4. Synthesis of Intermediate 9-5

[0908]

[0909] To a solution of methyl 2-oxo-1-phenyl-3-((4-(trifluoromethyl)benzyl)amino)pyrrolidine-3-carboxylate (0.024 g, 0.061 mmol, 1.0 equiv) in DCM (1 mL) was added TEA (0.051 mL, 0.36 mmol, 6.0 equiv) and chloroacetyl chloride (0.022 mL, 0.24 mmol, 4.0 equiv). The mixture was stirred for 15 minutes. To this mixture was added two more times of TEA (0.051 mL, 0.36 mmol, 6.0 equiv) and chloroacetyl chloride (0.022 mL, 0.24 mmol, 4.0 equiv). The mixture was stirred for 15 minutes, diluted with dichloroethane (2 mL), heated at 83°C overnight, cooled to room temperature, diluted with saturated sodium bicarbonate, and extracted three times with DCM. The combined organic extracts were then washed once with brine, dried over magnesium sulfate, filtered, and concentrated to afford 29 mg (quantitative) of methyl 3-(2-chloro-N-(4-(trifluoromethyl)benzyl)acetamido)-2-oxo-1-phenylpyrrolidine-3-carboxylate as a brown solid. LRMS (ES) m / z 469 (M+H).

[0910] 5. Synthesis of Compound 327

[0911]

[0912] To a solution of methyl 3-(2-chloro-N-(4-(trifluoromethyl)benzyl)acetamido)-2-oxo-1-phenylpyrrolidine-3-carboxylate (29 mg, 0.079 mmol, 1.0 equiv) in ACN (4 mL) was added TEA (0.067 mL, 0.48 mmol, 7.8 equiv) and isopropylamine (0.027 mL, 0.32 mmol, 6.3 equiv). The mixture was heated at 80°C for 1 hour, concentrated, and purified by reverse phase HPLC (Phenomenex, Gemini 5u C18 150 x 21.2 mm, 10-100% acetonitrile / water (both containing 0.1% formic acid) gradient over 25 minutes) to afford 15 mg (20%) of 9-isopropyl-2-phenyl-6-(4-(trifluoromethyl)benzyl)-2,6,9-triazaspiro[4.5]decane-1,7,10-trione as a clear, colorless oil. LRMS (ES) m / z 460 (M+H). 1 HNMR (400MHz, methanol-d4) δ7.64-7.59(m,2H),7.57-7.53(m,2H),7.53-7.49(m,2H),7.42-7.36(m,2H),7.27-7.21(m,1H),4.99-4.92(m,1H) ),4.76-4.67(m,2H),4.33-4.16(m,2H),4.16-4.08(m,1H),3.87-3.78(m,1H),2.86-2.77(m,1H),2.59-2.48(m,1H),1.28-1.20(m,6H).

[0913] Example 10: Synthesis of Compound 328

[0914] 1. Synthesis of intermediate 10-2

[0915]

[0916] Azetidin-3-ol hydrochloride (1.3 g, 11.9 mmol, 1.0 eq), L(-)-proline (0.55 g, 4.8 mmol, 0.4 eq), copper (I) iodide (0.45 g, 2.4 mmol, 0.2 eq) and cesium carbonate (9.7 g, 29.7 mmol, 2.5 eq) were combined in a flask with a septum and then vacuum-nitrogen purged three times. Iodobenzene (2.0 mL, 18 mmol, 1.5 eq) and anhydrous dimethyl sulfoxide (30 mL) were added to the vessel. The mixture was heated at 90° C. for 15 hours, diluted with water, and extracted three times with EA. The combined organic layers were dried over magnesium sulfate, filtered, evaporated, and purified by silica gel chromatography (40 g, 60 μm, 0-100% ethyl acetate / hexanes gradient, 14 minutes) to afford 1.6 g (90%) of 1-phenylazetidin-3-ol as a clear, colorless oil. LRMS (ES) m / z 150 (M+H). 1 H NMR (400 MHz, dichloromethane-d2) δ 7.27-7.20 (m, 2H), 6.81-6.74 (m, 1H), 6.55-6.49 (m, 2H), 4.80-4.72 (m, 1H), 4.23-4.16 (m, 2H), 3.71-3.65 (m, 2H).

[0917] 2. Synthesis of Intermediate 10-3

[0918]

[0919] To a solution of oxalyl chloride (1.5 mL, 17 mmol, 1.7 eq) in anhydrous DCM (15 mL) was added DMSO (2.4 mL, 34 mmol, 3.3 eq) dropwise at -78° C. The mixture was stirred at -78° C. for 10 min and 1-phenylazetidin-3-ol (1.5 g, 10.3 mmol, 1.0 eq) in anhydrous DCM (15 mL) was added dropwise, stirred for 1 h, TEA (10.0 mL, 71.9 mmol, 7.0 eq) was added, stirring was continued for 1 h at -78° C., diluted with saturated sodium bicarbonate, and extracted three times with DCM. The combined organic extracts were washed with brine, dried over magnesium sulfate, filtered, evaporated, and purified by silica gel chromatography (40 g, 60 μm, 0-10% ethyl acetate / hexanes gradient over 28 minutes) to afford 0.96 g (63%) of 1-phenylazetidin-3-one as a clear yellow oil. LRMS (ES) m / z 148 (M+H). 1 HNMR (400 MHz, dichloromethane-d2) δ 7.36-7.29 (m, 2H), 6.92-6.87 (m, 1H), 6.69-6.63 (m, 2H), 4.70 (s, 4H).

[0920] 3. Synthesis of Intermediate 10-4

[0921]

[0922] 1-Phenylazetidin-3-one (0.31 g, 2.1 mmol, 1.0 eq) and (1S)-1-[4-(trifluoromethyl)phenyl]ethan-1-amine (0.44 g, 2.3 mmol, 1.1 eq) were combined in anhydrous MeOH (3 mL) and the mixture was heated at 60° C. for 1 hour. To this mixture, which was cooled to 0° C., acetic acid (0.13 mL, 2.3 mmol, 1.1 eq) and sodium cyanide (0.11 g, 2.3 mmol, 1.1 eq) were added sequentially. The mixture was heated at 60° C. for 15 hours, diluted with water, and extracted three times with EA. The combined organic washes were dried over magnesium sulfate, filtered, evaporated, and purified by silica gel chromatography (12 g, 60 μm, 0-20% ethyl acetate / hexanes gradient over 22 minutes) to afford 0.46 g (62%) of (S)-1-phenyl-3-((1-(4-(trifluoromethyl)phenyl)ethyl)amino)azetidine-3-carbonitrile as a clear, colorless oil. LRMS (ES) m / z 346 (M+H). 1 H NMR (400 MHz, dichloromethane-d2) δ 7.69-7.65 (m, 2H), 7.64-7.59 (m, 2H), 7.26-7.19 (m, 2H), 6.85-6.79 (m, 1H), 6.42-6.38 (m, 2H), 4.38-4.35 (m, 1H), 4.26 (q, J = 6.6 Hz, 1H), 3.92-3.88 (m, 1H), 3.83-3.79 (m, 1H), 3.38-3.34 (m, 1H), 1.48 (d, J = 6.6 Hz, 3H).

[0923] 4. Synthesis of Intermediate 10-5

[0924]

[0925] To a solution of (S)-1-phenyl-3-((1-(4-(trifluoromethyl)phenyl)ethyl)amino)azetidine-3-carbonitrile (0.272 g, 0.787 mmol, 1.0 equiv) in DCM (3 mL) was added TEA (0.33 mL, 2.4 mmol, 3.0 equiv) and chloroacetyl chloride (0.12 mL, 1.6 mmol, 2.0 equiv) dropwise. The mixture was stirred for 15 minutes. To this mixture was added TEA (0.33 mL, 2.4 mmol, 3.0 equiv) and chloroacetyl chloride (0.12 mL, 1.6 mmol, 2.0 equiv). The mixture was stirred for 30 minutes, diluted with saturated sodium bicarbonate, and extracted twice with DCM. The combined extracts were dried over magnesium sulfate, filtered, and concentrated to afford 332 mg (100%) of (S)-2-chloro-N-(3-cyano-1-phenylazetidin-3-yl)-N-(1-(4-(trifluoromethyl)phenyl)ethyl)acetamide as a red oil. LRMS (ES) m / z 422 (M+H). 1 H NMR (400 MHz, dichloromethane-d2) δ 7.72-7.67 (m, 2H), 7.59-7.54 (m, 2H), 7.28-7.21 (m, 2H), 6.89-6.84 (m, 1H), 6.45-6.41 (m, 2H), 5.19-5.11 (m, 1H), 4.49-4.45 (m, 1H), 4.42-4.39 (m, 1H), 4.07-3.94 (m, 3H), 3.83-3.79 (m, 1H), 1.96 (d, J = 7.1 Hz, 3H).

[0926] 5. Synthesis of Intermediate 10-6

[0927]

[0928] To a solution of (S)-2-chloro-N-(3-cyano-1-phenylazetidin-3-yl)-N-(1-(4-(trifluoromethyl)phenyl)ethyl)acetamide (0.332 g, 0.787 mmol, 1.0 equiv) in anhydrous DCM (3 mL) was added isopropylamine (3.4 mL, 39 mmol, 50 equiv). The mixture was stirred at room temperature for 3 days, concentrated, and purified by silica gel chromatography (12 g, 60 μm, 0-10% methanol / dichloromethane gradient over 22 minutes) to afford 314 mg (90%) of (S)-N-(3-cyano-1-phenylazetidin-3-yl)-2-(isopropylamino)-N-(1-(4-(trifluoromethyl)phenyl)ethyl)acetamide as a clear, light yellow oil. LRMS (ES) m / z 445 (M+H). 1H NMR (400 MHz, dichloromethane-d2) δ 7.64-7.60 (m, 2H), 7.43-7.38 (m, 2H), 7.24-7.18 (m, 2H), 6.82-6.77 (m, 1H), 6.43-6.39 (m, 2H), 5.90-5.80 (m, 1H), 4.60-4.46 (m, 1H), 4.41-4.35 (m, 1H), 4.30-4.21 (m, 1H), 4.07-3.99 (m, 2H), 3.90-3.83 (m, 1H), 3.79-3.73 (m, 1H), 1.87 (d, J = 7.2 Hz, 3H), 1.28-1.21 (m, 6H).

[0929] 6. Synthesis of Compound 328

[0930]

[0931] A solution of (S)-N-(3-cyano-1-phenylazetidin-3-yl)-2-(isopropylamino)-N-(1-(4-(trifluoromethyl)phenyl)ethyl)acetamide (54 mg, 0.12 mmol, 1.0 equiv) in anhydrous toluene (0.5 mL) was heated to 150° C. for 30 minutes in a microwave reactor. The mixture was concentrated and purified by reverse phase HPLC (Phenomenex, Gemini 5uC18 150×21.2 mm, 10-100% acetonitrile / water (both containing 0.1% formic acid) gradient over 25 minutes) to afford 28 mg (52%) of (S)-9-imino-8-isopropyl-2-phenyl-5-(1-(4-(trifluoromethyl)phenyl)ethyl)-2,5,8-triazaspiro[3.5]nonan-6-one as a clear, colorless oil. LRMS (ES) m / z 445 (M+H). 1 H NMR (400 MHz, methanol-d4) δ 8.38 (s, 1H), 7.69-7.63 (m, 2H), 7.56-7.50 (m, 2H), 7.25-7.19 (m, 2H), 6.89-6.82 (m, 1H), 6.56-6.48 (m, 2H), 5.73-5.61 (m, 1H), 4.54-4.45 (m, 2H), 4.32-4.14 (m, 5H), 1.86 (d, J = 7.1 Hz, 3H), 1.46-1.39 (m, 6H).

[0932] Example 11: Synthesis of Compound 332

[0933] 1. Synthesis of intermediate 11-2

[0934]

[0935] To a solution of racemic 3-amino-1-(tert-butoxycarbonyl)pyrrolidine-3-carboxylic acid (2.00 g, 8.69 mmol) in NaOH (1 M, 15 mL) was added di-tert-butyl dicarbonate (3.79 g, 17.37 mmol, 2.0 equiv) in 1,4-dioxane (15 mL). The resulting mixture was stirred at room temperature for 18 hours. The pH was adjusted to 3 using 3M aqueous HCl, and the resulting mixture was extracted twice with EA (total volume = 125 mL). The organic extracts were combined, washed with brine, dried over sodium sulfate, and concentrated under reduced pressure to afford 1-(tert-butoxycarbonyl)-3-((tert-butoxycarbonyl)amino)pyrrolidine-3-carboxylic acid (2.93 g, 7.98 mmol, 92% yield) as a viscous foam, which was used in the following step without further purification. LRMS (APCI) m / z 329.1 (MH). 1 H NMR(400MHz,DMSO-d6)δ12.68(s,1H),7.54(s,1H),3.74-3.66(m,1H),3.51( dd,J=20.3,11.4Hz,1H),3.34-3.26(m,2H),2.21-2.04(m,2H),1.39(s,18H).

[0936] 2. Synthesis of Intermediate 11-3

[0937]

[0938] To a solution of 1-(tert-butoxycarbonyl)-3-((tert-butoxycarbonyl)amino)pyrrolidine-3-carboxylic acid (2.93 g, 7.98 mmol) in a mixture of DCM (40 mL) and MeOH (20 mL) was added portionwise (diazomethyl)trimethylsilane (11.97 mL, 2.0 M solution in hexane, 23.95 mmol, 3.0 equivalents). The resulting solution was stirred at room temperature for 30 minutes, quenched with glacial acetic acid (10 mL) until gas evolution stopped, and concentrated under reduced pressure. The remaining residue was dissolved in DCM (100 mL) and washed with a 2M KCO aqueous solution (25 mL). The organic phase was dried over sodium sulfate, concentrated, and purified on silica gel using 30% EA / Hex to afford 2.12 g (77%) of 3-methyl 1-(tert-butyl) 3-((tert-butoxycarbonyl)amino)pyrrolidine-1,3-dicarboxylate as a colorless, sticky solid. LRMS (APCI) m / z 245.2 (M+H) (Boc loss). 1H NMR (400 MHz, methanol-d4) δ 3.84-3.75 (m, 1H), 3.64 (s, 3H), 3.57-3.44 (m, 1H), 3.43-3.30 (m, 2H), 2.24-2.13 (m, 1H), 2.12-2.02 (m, 1H), 1.41-1.32 (m, 18H).

[0939] 3. Synthesis of Intermediates 11-4A and 11-4B

[0940]

[0941] This step follows the disclosed method in Chem.Pharm.Bull.42(8)1302-1306,1995. To a round-bottomed flask (250 mL) containing a mixture of hydrated ruthenium oxide (386 mg, 2.90 mmol, 0.5 equivalent) and sodium periodate (6.21 g, 29.04 mmol, 5.0 equivalents) was added water (25 mL) and EA (25 mL) containing 3-((tert-butyloxycarbonyl)amino)pyrrolidine-1,3-dicarboxylic acid 1-(tert-butyl) ester 3-methyl ester (2.00 g, 5.81 mmol, 1.0 equivalents). The gained two-phase mixture was vigorously stirred for 3 hours, diluted with additional EA (50 mL), and filtered through diatomaceous earth. The layers were separated, and the aqueous phase was extracted once with EA (50 mL). The organic phase was merged and diluted with MeOH (5 mL). At room temperature gained black solution was stirred 30 minutes and again filtered through diatomite.Solvent was evaporated in a vacuum, and 30% EA / Hex was used to purify the remaining solid residue with silica gel, obtain 1.44g (69%) 3-((tert-butoxycarbonyl) amino)-5-oxo-pyrrolidine-1,3-dicarboxylic acid 1-(tert-butyl) ester 3-methyl esters (11-4A) and 437mg (21%) 3-((tert-butoxycarbonyl) amino)-2-oxo-pyrrolidine-1,3-dicarboxylic acid 1-(tert-butyl) ester 3-methyl esters (11-4B), utilize KMnO on TLC Dyeing observation the two.

[0942] Characterization of intermediate 11-4A: LRMS (APCI) m / z 203.1 (M+H) (loss of Boc and loss of tert-butyl). 1 HNMR (400 MHz, methanol-d4) δ 4.21 (d, J = 11.5 Hz, 1H), 3.95 (d, J = 11.5 Hz, 1H), 3.78 (s, 3H), 3.13 (d, J = 17.5 Hz, 1H), 2.80 (dd, J = 17.5, 0.8 Hz, 1H), 1.55 (s, 9H), 1.46 (s, 9H).

[0943] Characterization of intermediate 11-4B: LRMS (APCI) m / z 203.1 (M+H) (loss of Boc and loss of tert-butyl). 1 HNMR (400 MHz, methanol-d4) δ 3.94-3.74 (m, 5H), 2.63 (ddd, J = 13.4, 7.9, 2.2 Hz, 1H), 2.42 (dt, J = 13.5, 9.2 Hz, 1H), 1.56 (s, 9H), 1.46 (s, 9H).

[0944] 4. Synthesis of Intermediate 11-5

[0945]

[0946] To a solution of 3-methyl 1-(tert-butyl)-5-oxopyrrolidine-1,3-dicarboxylate (916 mg, 2.56 mmol) in DCM (5 mL) was added TFA (5 mL). The resulting mixture was stirred at room temperature for 30 minutes. The solvent was removed under reduced pressure and dried under high vacuum to give 692 mg (quantitative yield) of methyl 3-amino-5-oxopyrrolidine-3-carboxylate as a TFA salt without further purification. LRMS (APCI) m / z 159.1 (M+H).

[0947] 5. Synthesis of Intermediate 11-6

[0948]

[0949] To the mixture of THF (30mL) and ethylene dichloride (10mL) containing the mixture of 3-amino-5-oxopyrrolidine-3-methyl formates TFA salt (692mg, 2.55mmol) and p-chlorobenzaldehyde (1.07g, 7.63mmol, 3.0 equivalents) stirred for 15 minutes, add NaBH (OAc) (2.69g, 12.71mmol, 5.0 equivalents). At room temperature, the gained mixture was stirred for 1 hour, and a homogeneous solution was observed during this period. The solvent was evaporated under reduced pressure and the remaining residue was distributed between DCM (60mL) and saturated NaHCO between the aqueous solution (60mL). The aqueous phase was extracted with DCM (25mL). Merge organic phase, dried over sodium sulfate, filtered through diatomite and concentrated under reduced pressure. The remaining residue was purified on silica gel using a 0%-100% EA / Hex gradient as eluent to give 548 mg (76%) of methyl 3-((4-chlorobenzyl)amino)-5-oxopyrrolidine-3-carboxylate. LRMS (APCI) m / z 159.1 (M+H).

[0950] 6. Synthesis of Intermediate 11-7

[0951]

[0952] To a mixture of CuI (25 mg, 0.13 mmol, 0.5 eq) and KCO (143 mg, 1.03 mmol, 4.0 eq) was added methyl 3-((4-chlorobenzyl)amino)-5-oxopyrrolidine-3-carboxylate (73 mg, 0.26 mmol, 1.0 eq) in anhydrous 1,4-dioxane (2 mL), 2-iodopyridine (41 μL, 0.39 mmol, 1.5 eq) and N,N-dimethylethylenediamine (13 μL, 0.13 mmol, 0.5 eq). The resulting mixture was flushed with nitrogen, sealed and heated in an oil bath at 115° C. for 18 hours. The reaction was filtered through a syringe filter, concentrated under reduced pressure, and purified by reverse phase HPLC using 10%-100% ACN / water (all containing 0.1% formic acid; Phenomenex Gemini C18 5μ column) to provide 59 mg (62%) of methyl 3-((4-chlorobenzyl)amino)-5-oxo-1-(pyridin-2-yl)pyrrolidine-3-carboxylate. LRMS (APCI) m / z 360.1 (M+H). 1 H NMR (400 MHz, methanol-d4) δ 8.40-8.23 (m, 2H), 7.79 (ddd, J = 8.3, 7.3, 2.1 Hz, 1H), 7.33 (d, 2H), 7.26 (d, 2H), 7.14 (ddd, J = 7.3, 4.8, 1.1 Hz, 1H), 4.37 (d, J = 11.8 Hz, 1H), 4.19 (dd, J = 11.7, 0.7 Hz, 1H), 3.81 (s, 3H), 3.73 (d, J = 2.1 Hz, 2H), 3.22 (d, J = 17.1 Hz, 1H), 2.80 (dd, J = 17.2, 0.7 Hz, 1H).

[0953] 7. Synthesis of compound 332

[0954]

[0955] To a solution of methyl 3-((4-chlorobenzyl)amino)-5-oxo-1-(pyridin-2-yl)pyrrolidine-3-carboxylate (59 mg, 0.16 mmol) in DCM (3 mL) was added EtN (229 μL, 1.64 mmol, 10.0 equiv). Chloroacetyl chloride (131 μL, 1.64 mmol, 10.0 equiv) was added dropwise to the resulting solution cooled to 0°C with an ice bath. The ice bath was removed and the resulting mixture was stirred at room temperature for 30 minutes, diluted with DCM (20 mL), washed with saturated aqueous NaHCO (15 mL), dried over sodium sulfate, and concentrated in vacuo. To the remaining residue dissolved in ACN (3 mL) was added EtN (229 μL, 1.64 mmol, 10.0 equiv) and isopropylamine (140 μL, 1.64 mmol, 10.0 equiv). The resulting solution was heated in a sealed tube in a 100° C. oil bath for 45 minutes, cooled to room temperature, concentrated under reduced pressure, and purified by reverse phase HPLC using 10%-100% ACN / water (all containing 0.1% formic acid; Phenomenex Gemini C18 5μ column) and on silica gel using 50% EA / Hex as eluent to afford 32 mg (46%) of 6-(4-chlorobenzyl)-9-isopropyl-2-(pyridin-2-yl)-2,6,9-triazaspiro[4.5]decane-3,7,10-trione as a white solid. LRMS (APCI) m / z 427.2 (M+H). 1 HNMR(400MHz, methanol-d4)δ8.31-8.22(m,2H),7.78(ddd,J=8.5,7.3,2.0Hz,1H ),7.20(s,4H),7.13(ddd,J=7.3,4.9,1.0Hz,1H),4.98-4.89(m,1H),4.80 -4.68(m,2H),4.46(d,J=12.4Hz,1H),4.33-4.25(m,2H),4.18(d,J=17.8H z, 1H), 3.40 (d, J = 17.8Hz, 1H), 3.11 (d, J = 17.8Hz, 1H), 1.30-1.22 (m, 6H).

[0956] Example 12: Synthesis of Compound 331

[0957]

[0958] A procedure similar to Example 11 was used, but iodobenzene was used in place of 2-iodopyridine in Step 6.

[0959] Example 13: Synthesis of Compound 330

[0960] 1. Synthesis of Intermediate 13-1

[0961]

[0962] To a solution of 3-methyl 1-(tert-butyl)-2-oxopyrrolidine-1,3-dicarboxylate (437 mg, 1.22 mmol) in DCM (5 mL) was added TFA (5 mL). The resulting mixture was stirred at room temperature for 30 minutes, dried under reduced pressure, and concentrated to afford 330 mg (quantitative yield) of methyl 3-amino-2-oxopyrrolidine-3-carboxylate as a TFA salt. LRMS (APCI) m / z 159.1 (M+H).

[0963] 2. Synthesis of Intermediate 13-2

[0964]

[0965] To a mixture of methyl 3-amino-2-oxopyrrolidine-3-carboxylate TFA salt (330 mg, 1.22 mmol) and p-chlorobenzaldehyde (513 mg, 3.65 mmol, 3.0 equiv) in dichloroethane (5 mL) and MeOH (5 mL) stirred at room temperature for 15 minutes was added NaBH3CN (229 mg, 3.65 mmol, 3.0 equiv). The resulting mixture was stirred at room temperature for 18 hours. Additional p-chlorobenzaldehyde (513 mg, 3.65 mmol, 3.0 equiv) and NaBH3CN (229 mg, 3.65 mmol, 3.0 equiv) were added to the mixture. The mixture was heated in a 65°C oil bath for 2 hours, evaporated in vacuo, and partitioned between EA (40 mL) and saturated NaHCO3 aqueous solution (40 mL). The layers were separated, and the aqueous phase was extracted once with additional EA (30 mL). The combined organic phases were dried over sodium sulfate, concentrated under reduced pressure, and purified by silica gel chromatography using EA / Hex (0-100%) to give 258 mg (75%) of methyl 3-((4-chlorobenzyl)amino)-2-oxopyrrolidine-3-carboxylate. LRMS (APCI) m / z 283.1 (M+H). 1 H NMR (400 MHz, methanol-d4) δ 7.37-7.15 (m, 4H), 3.74 (d, J = 12.4 Hz, 1H), 3.59 (d, J = 12.4 Hz, 1H), 3.47-3.33 (m, 2H), 2.59 (ddd, J = 13.4, 7.3, 3.6 Hz, 1H), 2.23 (ddd, J = 13.4, 8.7, 7.5 Hz, 1H).

[0966] 3. Synthesis of Intermediate 13-3

[0967]

[0968] To a mixture of CuI (6 mg, 0.033 mmol, 0.2 equiv), 4-iodo-1-methyl-1H-pyrazole (41 mg, 0.195 mmol, 1.2 equiv) and KCO (90 mg, 0.651 mmol, 4.0 equiv) was added methyl 3-((4-chlorobenzyl)amino)-2-oxopyrrolidine-3-carboxylate (46 mg, 0.163 mmol, 1.0 equiv) in anhydrous 1,4-dioxane (2 mL) and N,N-dimethylethylenediamine (4 μL, 0.033 mmol, 0.2 equiv). The resulting mixture was flushed with nitrogen, sealed, heated in a 115° C. oil bath for 18 hours, cooled to room temperature, filtered through a syringe filter, and purified by reverse phase HPLC using 10%-100% ACN / water (all containing 0.1% formic acid; Phenomenex Gemini C18 5μ column) to provide 8 mg (14%) of methyl 3-((4-chlorobenzyl)amino)-1-(1-methyl-1H-pyrazol-4-yl)-2-oxopyrrolidine-3-carboxylate. LRMS (APCI) m / z 363.2 (M+H).

[0969] 4. Synthesis of Compound 330

[0970]

[0971] To a solution of methyl 3-((4-chlorobenzyl)amino)-1-(1-methyl-1H-pyrazol-4-yl)-2-oxopyrrolidine-3-carboxylate (8 mg, 0.022 mmol) in DCM (1 mL) was added Et3N (31 μL, 0.22 mmol, 10.0 equiv). Chloroacetyl chloride (18 μL, 0.22 mmol, 10.0 equiv) was added dropwise to the resulting solution cooled to 0°C in an ice bath, and the ice bath was removed after the addition was complete. The resulting mixture was stirred at room temperature for 30 minutes, diluted with DCM (10 mL), washed once with saturated aqueous NaHCO3 (10 mL), dried over sodium sulfate, and concentrated in vacuo. The remaining residue was dissolved in ACN (10 mL). To the mixture was added Et3N (62 μL, 0.44 mmol, 20.0 equiv) and isopropylamine (38 μL, 0.44 mmol, 20.0 equiv). The resulting solution was heated in a sealed tube in a 100°C oil bath for 45 minutes, cooled to room temperature, evaporated under reduced pressure, and purified by reverse phase HPLC using 10%-100% ACN / water (all containing 0.1% formic acid; Phenomenex Gemini C18 5μ column) to afford 5 mg (53%) of 6-(4-chlorobenzyl)-9-isopropyl-2-(1-methyl-1H-pyrazol-4-yl)-2,6,9-triazaspiro[4.5]decane-1,7,10-trione. LRMS (APCI) m / z 430.2 (M+H). 1 H NMR (400MHz, methanol-d4) δ7.91 (s, 1H), 7.64 (s, 1H), 7.34-7.23 (m, 4H), 4.84 (d, J = 1 6.1Hz,1H),4.68(p,J=6.9Hz,1H),4.55(d,J=16.1Hz,1H),4.27(d,J=17.7Hz,1H ),4.17(d,J=17.7Hz,1H),3.93-3.83(m,4H),3.70(td,J=9.4,2.6Hz,1H),2.82 (ddd,J=14.0,8.4,2.6Hz,1H),2.57-2.45(m,1H),1.23(dd,J=10.0,6.8Hz,6H).

[0972] Example 14: Synthesis of Compound 333

[0973]

[0974] A procedure similar to Example 13 was used, except that 4-iodo-2-methylpyridine was used in place of 4-iodo-1-methyl-1H-pyrazole in Step 4.

[0975] Example 15: Synthesis of Compound 389

[0976] 1. Synthesis of intermediate 15-2

[0977]

[0978] To a solution of (S)-1-(4-chlorophenyl)ethan-1-amine (2.4 mL, 16.7 mmol, 1.0 equiv) and tert-butyl 3-oxopyrrolidine-1-carboxylate (3.1 g, 16.7 mmol, 1.0 equiv) in MeOH (16 mL) was added 2-isocyanopropane (1.6 mL, 16.7 mmol, 1.0 equiv) and chloroacetic acid (1.6 g, 16.7 mmol, 1.0 equiv). The mixture was stirred for 30 minutes, concentrated, and purified by silica gel chromatography to give 3.2 g (39%) of tert-butyl 3-(2-chloro-N-((S)-1-(4-chlorophenyl)ethyl)acetamido)-3-(isopropylcarbamoyl)pyrrolidine-1-carboxylate as a mixture of diastereomers. LRMS (ES) m / z 486.2 (M+H).

[0979] 2. Synthesis of Intermediate 15-3

[0980]

[0981] To a solution of tert-butyl 3-(2-chloro-N-((S)-1-(4-chlorophenyl)ethyl)acetamido)-3-(isopropylcarbamoyl)pyrrolidine-1-carboxylate (3.2 g, 6.6 mmol, 1.0 equiv) in ACN (20 mL) was added potassium carbonate (0.9 g, 6.6 mmol, 2.0 equiv). The mixture was heated to 80° C. for 2 h, filtered, concentrated, and purified by silica gel chromatography (80 g, 0-100% EtOAc / hexanes) to afford 1.0 g (34%) of tert-butyl 6-((S)-1-(4-chlorophenyl)ethyl)-9-isopropyl-7,10-dioxo-2,6,9-triazaspiro[4.5]decane-2-carboxylate as a mixture of diastereomers. LRMS (ES) m / z 394.15 (M+H- t Bu).

[0982] 3. Synthesis of Intermediate 15-4

[0983]

[0984] To a solution of tert-butyl 6-((S)-1-(4-chlorophenyl)ethyl)-9-isopropyl-7,10-dioxo-2,6,9-triazaspiro[4.5]decane-2-carboxylate (1.0 g, 2.2 mmol, 1.0 equiv) in DCM (5.0 mL) was added TFA (5 mL). The mixture was stirred for 20 minutes, concentrated, diluted with saturated NaHCO aqueous solution (200 mL), and the layers were separated. The aqueous layer was extracted three times with DCM. The combined organic washes were dried over MgSO, filtered, concentrated, and purified by silica gel chromatography (24 g column, 0-40% MeOH / DCM) to afford 380 mg (49%) of 6-((S)-1-(4-chlorophenyl)ethyl)-9-isopropyl-2,6,9-triazaspiro[4.5]decane-7,10-dione as a mixture of diastereomers. LRMS (ES) m / z 350.2 (M+H).

[0985] 4. Synthesis of Compound 389 (Diastereomer 389A...

Claims

1. A compound of formula (I): or a pharmaceutically acceptable salt thereof, wherein: R 1 selected from the group consisting of substituted or unsubstituted phenyl and substituted or unsubstituted pyridyl; R 2A , R 2B and R 3 Defined by any of (i) to (iii): (i)R 2A is H or substituted or unsubstituted alkyl; R 2B is selected from the group consisting of H, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted cycloalkenyl, substituted or unsubstituted cycloalkynyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl, and substituted or unsubstituted heteroaryl; and R 3 is substituted or unsubstituted phenyl or substituted or unsubstituted pyridyl; or (ii) R 2A is H or substituted or unsubstituted alkyl; R 2B is substituted or unsubstituted phenyl or substituted or unsubstituted pyridyl; and R 3 is a substituted or unsubstituted alkyl group; or (iii) R 2A and R 2B Together with the carbon atom to which they are attached, they form G 1 , where G 1 is a substituted or unsubstituted cycloalkyl, substituted or unsubstituted cycloalkenyl, substituted or unsubstituted cycloalkynyl, or substituted or unsubstituted heterocyclyl ring, each of which is optionally fused to a phenyl ring; and R 3 Selected from the group consisting of substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted cycloalkenyl, substituted or unsubstituted cycloalkynyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl and substituted or unsubstituted heteroaryl; R 4 is H or substituted or unsubstituted alkyl; and R 5 is H or substituted or unsubstituted alkyl; Where one or more of the provisions (a) to (c) apply, then R 1 is substituted or unsubstituted pyridyl or phenyl substituted with at least one substituent other than methyl or methoxy: (a)R 2A and R 2B As defined in (i), and R 3 is a substituted or unsubstituted phenyl group; (b)R 2A and R 3 As defined in (ii), and R 2B is 4-methoxyphenyl; (c)R 2A and R 2B As defined in (iii), and R 3 It is 4-methoxyphenylmethyl.

2. The compound according to claim 1, or a pharmaceutically acceptable salt thereof, wherein R 2A is H or substituted or unsubstituted alkyl; R 2B is selected from the group consisting of H, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted cycloalkenyl, substituted or unsubstituted cycloalkynyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl, and substituted or unsubstituted heteroaryl; and R 3 is substituted or unsubstituted phenyl or substituted or unsubstituted pyridyl.

3. The compound according to claim 2, or a pharmaceutically acceptable salt thereof, wherein R 3 is a substituted or unsubstituted phenyl group.

4. The compound according to claim 2, or a pharmaceutically acceptable salt thereof, wherein R 3 is a substituted or unsubstituted pyridyl group.

5. The compound according to any one of claims 2 to 4, or a pharmaceutically acceptable salt thereof, wherein R 3is phenyl substituted with one or more halo substituents selected from the group consisting of F and Cl.

6. The compound according to claim 5, or a pharmaceutically acceptable salt thereof, wherein R 3 It is also substituted with one, two or three -CN substituents.

7. A compound as claimed in any one of claims 2 to 6, or a pharmaceutically acceptable salt thereof, wherein R 2A is a substituted or unsubstituted alkyl group.

8. A compound as claimed in any one of claims 2 to 6, or a pharmaceutically acceptable salt thereof, wherein R 2A It's H.

9. The compound according to any one of claims 2 to 8, or a pharmaceutically acceptable salt thereof, wherein R 2B is a substituted or unsubstituted alkyl group.

10. The compound according to any one of claims 2 to 9, or a pharmaceutically acceptable salt thereof, wherein R 2B Selected from the group consisting of methyl, hydroxymethyl and isopropyl.